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Abstract
Developing optical probes that can monitor voltage signaling events on the sub-microsecond timescale
and can be targeted to specific cells and membranes is crucial to advance our understanding of the
communication between neurons. Organic voltage sensitive dyes can report changes in membrane
potential on appropriate timescales with high sensitivity; however, they cannot be genetically targeted to
specific cell types. This lack of targetability is solved by using genetically encoded voltage indicators
(GEVIs). GEVIs are typically constructed from the voltage-sensing domain of natural proteins, but they
tend to be dimmer and slower than organic voltage sensitive dyes. Here, we present our progress on the
development and characterization of a new family of genetically encoded voltage indicators called THOR
(Transmembrane Hemoprotein Optical Reporter), a fusion protein of a de novo designed transmembrane
4-α-helical protein and a fluorescent optical reporter. THORs bind heme in the core of the 4-α-helical
bundle, and the heme oxidation states change as a function of the transmembrane electric field. The
oxidation state of one of the heme cofactors is then reported via FRET by an attached fluorescent protein.
The speed of THORs is dependent on electron transfer between the cofactors, and therefore, tunable by
their distance. Based on the Moser-Dutton Ruler of electron transfer, we can achieve electron transfer
rates on the µs timescale between heme cofactors. Water-soluble prototypes of THOR expressed in E.
coli revealed an 18% fluorescent quenching of mOrange2 and a 57% fluorescent quenching of Sirius upon
heme reduction. Several different variants of THOR were designed with two different lengths: one that
closely matches the thickness of the membrane and one that extends into the cytoplasm. THORs have
been expressed in HEK293t cells, rat hippocampal neurons, and mouse primary neurons. The trafficking
of THORs into the plasma membrane was improved with the sequential addition of export tag sequences
from the potassium ion channel, Kir2.1. THORs expressed in neurons exhibit a fluorescence decrease in
response to a potassium ion-induced depolarization. This work presents the development of the first de
novo designed GEVI for improved faster sensing of neuronal electrical events.
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ABSTRACT
THE DEVELOPMENT OF NOVEL GENETICALLY ENCODED VOLTAGE INDICATORS
USING DE NOVO DESIGNED PROTEINS
Martin Joshua Iwanicki
Bohdana M. Discher
Developing optical probes that can monitor voltage signaling events on the submicrosecond timescale and can be targeted to specific cells and membranes is crucial to
advance our understanding of the communication between neurons. Organic voltage
sensitive dyes can report changes in membrane potential on appropriate timescales with
high sensitivity; however, they cannot be genetically targeted to specific cell types. This
lack of targetability is solved by using genetically encoded voltage indicators (GEVIs).
GEVIs are typically constructed from the voltage-sensing domain of natural proteins, but
they tend to be dimmer and slower than organic voltage sensitive dyes. Here, we present
our progress on the development and characterization of a new family of genetically
encoded voltage indicators called THOR (Transmembrane Hemoprotein Optical
Reporter), a fusion protein of a de novo designed transmembrane 4-α-helical protein and
a fluorescent optical reporter. THORs bind heme in the core of the 4-α-helical bundle, and
the heme oxidation states change as a function of the transmembrane electric field. The
oxidation state of one of the heme cofactors is then reported via FRET by an attached
fluorescent protein. The speed of THORs is dependent on electron transfer between the
cofactors, and therefore, tunable by their distance. Based on the Moser-Dutton Ruler of
electron transfer, we can achieve electron transfer rates on the µs timescale between
heme cofactors. Water-soluble prototypes of THOR expressed in E. coli revealed an 18%
vii

fluorescent quenching of mOrange2 and a 57% fluorescent quenching of Sirius upon
heme reduction. Several different variants of THOR were designed with two different
lengths: one that closely matches the thickness of the membrane and one that extends
into the cytoplasm. THORs have been expressed in HEK293t cells, rat hippocampal
neurons, and mouse primary neurons. The trafficking of THORs into the plasma
membrane was improved with the sequential addition of export tag sequences from the
potassium ion channel, Kir2.1. THORs expressed in neurons exhibit a fluorescence
decrease in response to a potassium ion-induced depolarization. This work presents the
development of the first de novo designed GEVI for improved faster sensing of neuronal
electrical events.

viii

TABLE OF CONTENTS

ACKNOWLEDGMENT .........................................................................................IV
ABSTRACT .........................................................................................................VII
LIST OF TABLES AND EQUATIONS ................................................................XII
LIST OF FIGURES .............................................................................................XIII
CHAPTER 1: INTRODUCTION AND THESIS STATEMENT............................... 1
1.1 Understanding Neuronal Communication using Non-Invasive Technologies .................. 1
1.1.1 The basis of electrical signaling between neurons............................................................. 2
1.1.2 Calcium and neurotransmitter imaging .............................................................................. 5
1.1.3 Using organic voltage-sensing dyes for membrane potential measurement ..................... 7
1.1.4 Genetically encoded voltage indicators and their evolution for improved membrane
targeting and voltage-sensing ..................................................................................................... 8
1.2 Introduction to Protein Maquettes....................................................................................... 17
1.2.1 Removing complexity from natural protein design ........................................................... 17
1.2.2 First principles of protein folding for protein maquettes ................................................... 20
1.2.3 Cofactor binding within protein maquettes ....................................................................... 22
1.2.4 The case for protein maquettes for voltage sensing ........................................................ 24

CHAPTER 2: DESIGN PRINCIPLES FOR AN ELECTRON TRANSFER-BASED
DE NOVO DESIGNED GENETICALLY ENCODED VOLTAGE INDICATOR ... 26
2.1 Introduction ........................................................................................................................... 26
2.2 Biological Electron Transfer as a Voltage-Sensing Mechanism in a GEVI ..................... 27
2.3 The Electrostatic Profile of a Plasma Membrane ............................................................... 32
2.4 Electron Transfer Rate Calculations ................................................................................... 38
2.5 Approximate Electron Transfer Rates for Voltage Sensing .............................................. 44
2.6 Discussion and Future Directions ....................................................................................... 51

CHAPTER 3: FLUORESCENT REPORTING OF HEME REDOX STATE BY
WATER-SOLUBLE MAQUETTE-BASED GEVI PROTOTYPES ....................... 56
3.1 Introduction ........................................................................................................................... 56
3.2 Fluorescent proteins for heme redox state indicating ...................................................... 57

ix

3.3 mOrange2 as a reporter for heme redox state ................................................................... 61
3.3.1 Indication of redox state sensing of mOrange2................................................................ 61
3.3.2 Heme midpoint potential determination using spectroelectrochemistry ........................... 63
3.3.3 Reversibility of mOrange2 fluorescence using chronoamperometry................................ 64
3.3.4 Spectroscopic and electrochemical characteristics due to heme ligation site changes ... 66
3.3.5 Considerations for additional spectral and redox variations............................................. 75
3.4 Sirius as a reporter for heme redox state ........................................................................... 76
3.4.1 Indication of redox state sensing of Sirius........................................................................ 76
3.4.2 Heme midpoint potential determination using spectroelectrochemistry ........................... 77
3.4.3 Reversibility of Sirius fluorescence using chronoamperometry........................................ 78
3.5 mTFP1 as a potential reporter of heme redox state .......................................................... 79
3.5.1 Indication of redox state sensing of mTFP1 ..................................................................... 79
3.6 Intermission ........................................................................................................................... 80
3.7 FJORD, a de novo designed Genetically Encoded Redox Indicator (GERI).................... 81
3.7.1 Expression in HEK293T cells ........................................................................................... 83
3.7.2 Expression in rat hippocampal neurons ........................................................................... 84
3.8 Discussion and Future Work ............................................................................................... 85

CHAPTER 4: THE DESIGN, EXPRESSION, AND VOLTAGE SENSITIVITY OF
THE DE NOVO GENETICALLY ENCODED VOLTAGE INDICATOR, THOR ... 90
4.1 Introduction ........................................................................................................................... 90
4.2 The Design and Mechanism of THOR ................................................................................. 91
4.2.1 Repurposing (MZH3) into a transmembrane protein for voltage sensing ........................ 92
4.2.2 Various methods for constructing a transmembrane domain........................................... 93
4.2.3 Hydropathy of transmembrane domains .......................................................................... 99
4.2.4 Two-heme variations of THOR....................................................................................... 103
4.2.5 Attachment of a fluorescent protein reporter .................................................................. 105
4.2.6 Export and trafficking signals ......................................................................................... 107
4.2.7 Choosing an initial vector for mammalian expression .................................................... 108
4.3 Expression and Voltage Sensitivity of THOR in HEK Cells ............................................ 109
4.3.1 Combinatorial approach for improved expression of THOR in HEK293T Cells ............. 109
4.3.2 Voltage sensitivity in HEK Cells ..................................................................................... 111
4.4 Expression and voltage sensitivity of THOR in rat and mouse neurons....................... 113
4.4.1 Imaging membrane trafficking of THOR......................................................................... 114
4.4.2 Voltage sensitivity of THOR ........................................................................................... 118
4.5 Summary and Future Directions........................................................................................ 120

CHAPTER 5: CONCLUSIONS ......................................................................... 125
x

APPENDIX A1: EXPERIMENTAL METHODS ................................................. 129
A1.1 Cloning and Molecular Biology Techniques .................................................................. 129
A1.1.1 Gene construction of FJORD....................................................................................... 129
A1.1.2 Vector Map of FJORD ................................................................................................. 132
A1.1.3 Gene construction of THOR ........................................................................................ 133
A1.1.4 Vector Map of THOR ................................................................................................... 134
A1.1.5 List of Primers .............................................................................................................. 135
A1.2 Protein expression and purification of FJORD.............................................................. 135
A1.3 Heme binding .................................................................................................................... 136
A1.4 Spectroscopic and biophysical characterizations ........................................................ 137
A1.4.1 Spectroscopic characterization .................................................................................... 137
A1.4.2 Redox Titration ............................................................................................................ 137
A1.4.3 Spectroelectrochemistry .............................................................................................. 138
A1.4.4 Spectrofluoroelectrochemistry ..................................................................................... 139
A1.4.5 Chronoamperometry .................................................................................................... 140
A1.4.6 Pyocyanine Preparation............................................................................................... 141
A1.5 Protein Sequences and Localization Tags..................................................................... 141
A1.6 Mammalian Cell Techniques and Imaging ..................................................................... 144
A1.6.1 HEK Cell Methods ....................................................................................................... 144
A1.6.2 Cultured Primary Neuron Methods .............................................................................. 144
A1.6.3 Potassium depolarization assay .................................................................................. 146
A1.7 Dictionary .......................................................................................................................... 146

BIBLIOGRAPHY ............................................................................................... 147

xi

LIST OF TABLES AND EQUATIONS
Equation 1.1: The general Goldman-Hodgkin-Katz (GHK) equation .............................................. 2
Equation 1.2: GHK equation for a typical neuron ............................................................................ 3
Table 1.1: Voltage-sensing domains and reporters of GEVIs ......................................................... 9
Equation 2.1: Marcus Theory activation energy ............................................................................ 28
Equation 2.2: Semi-classical approximation of electron transfer rate ........................................... 29
Equation 2.3: Distance dependent rate of electron transfer .......................................................... 29
Equation 2.4: Moser-Dutton Ruler ................................................................................................ 30
Equation 2.5: Simplified Moser-Dutton Ruler ................................................................................ 30
Equation 2.6: Canonical membrane potential formulation ............................................................ 32
Equation 2.7: Intracellular surface potential .................................................................................. 33
Equation 2.8: Extracellular surface potential ................................................................................. 33
Equation 2.9: Internal membrane potential difference .................................................................. 33
Equation 2.10: Gibbs free energy change for electron transfer between two hemes ................... 38
Equation 2.11: Dielectric distance between two hemes ................................................................ 38
Equation 2.12: Gibbs free energy change in terms of midpoint potential ..................................... 39
Equation 2.13: Gibbs free energy change in terms of effective midpoint potential ....................... 39
Equation 2.14: Nernst equation .................................................................................................... 45
Equation 2.15: Fraction of reduced species .................................................................................. 45
Equation 2.16: Electric field-induced redox potential shift ............................................................ 45
Equation 2.17: Fraction of reduced species due to an electric field .............................................. 46
Table 2.1: Fraction of reduced heme in heme-binding constructs ................................................ 51
Table 3.1: Spectroscopic properties of heme-binding maquettes ................................................. 58
Equation 3.1: Nernst equation ...................................................................................................... 63
Table 4.1: Calculated hydropathies of THOR ............................................................................. 101
Table 4.2: Common vectors used for GEVIs .............................................................................. 108
Table A1.1: List of primers .......................................................................................................... 135
Equation A1.1: Nernst equation .................................................................................................. 139
Equation A1.2: Integrated density ............................................................................................... 146

xii

LIST OF FIGURES
Figure 1.1: A typical action potential ............................................................................................... 3
Figure 1.2: Generation of an action potential at the membrane ...................................................... 4
Figure 1.3: Stark Effect dyes ........................................................................................................... 8
Figure 1.4: Schematic of voltage-sensitive phosphatase-based GEVIs ....................................... 13
Figure 1.5: Schematic of rhodopsin-based GEVIs ........................................................................ 14
Figure 1.6: Phylogenetic tree of current GEVIs ............................................................................ 15
Figure 1.7: Muller’s ratchet ........................................................................................................... 18
Figure 1.8: Heptad repeat and topology of maquettes .................................................................. 20
Figure 1.9: The versatility of the maquette platform ...................................................................... 22
Figure 1.10: Goal of thesis ............................................................................................................ 25
Figure 2.1: Marcus Theory diagram .............................................................................................. 28
Figure 2.2: Characteristic electron tunneling rates ....................................................................... 31
Figure 2.3: Electrostatic profile of a membrane ............................................................................ 34
Figure 2.4: Simulation of an electron transfer-based maquette GEVI .......................................... 36
Figure 2.5: Gibbs free energy for electron transfer due to dielectric distance .............................. 40
Figure 2.6: Ideal midpoint potential difference for optimal change in Gibbs free energy .............. 41
Figure 2.7: Electron tunneling speeds for hemes separated by 11 Å ........................................... 43
Figure 2.8: Electron tunneling rates and speeds at varying distances .......................................... 44
Figure 2.9: Electric field induced shift in midpoint potential .......................................................... 46
Figure 2.10: Fraction of reduced heme 2D plots ........................................................................... 47
Figure 2.11: Heterogeneity in heme redox states at equilibrium ................................................... 49
Figure 3.1: Absorbance spectra of oxidized and reduced heme ................................................... 57
Figure 3.2: Diagrams and spectra of different FRET-probes ........................................................ 59
Figure 3.3: Crystal structure of MZH3 ........................................................................................... 60
Figure 3.4: Heme binding capability of MZH3-mOrange2 ............................................................. 61
Figure 3.5: Reduction assay via sodium dithionite of MZH3-mOrange2 ....................................... 62
Figure 3.6: Spectrofluoroelectrochemical redox titration of MZH3-mOrange2 .............................. 64
Figure 3.7: Chronoamperometry of MZH3-mOrange2 .................................................................. 65
Figure 3.8: Heme binding of MZH3-mOrange2 H110M ................................................................ 67
Figure 3.9: Spectroelectrochemistry and chronoamperometry of H110M .................................... 68
Figure 3.10: Fluorescence heme titration of H110M ..................................................................... 69
Figure 3.11: Spectroelectrochemical redox titration of H110K ...................................................... 70
Figure 3.12: Spectroelectrochemical redox titration of H110C ..................................................... 71
Figure 3.13: Spectrofluoroelecrochemistry of H110M and H110C ............................................... 72
Figure 3.14: Chronoamperometry of H110C ................................................................................. 73
Figure 3.15: Carboxy state of MZH3-mOrange2 variants ............................................................. 74
Figure 3.16: Redox range caused by mutations of non-ligating residues ..................................... 75
Figure 3.17: Heme binding capability of MZH3-Sirius ................................................................... 77
Figure 3.18: Spectrofluoroelectrochemical redox titration of MZH3-Sirius .................................... 77
Figure 3.19: Chronoamperometry of MZH3-Sirius ........................................................................ 78
Figure 3.20: Reduction assay via sodium dithionite of MZH3-mTFP1 .......................................... 80
Figure 3.21: Schematic of FJORD ................................................................................................ 83
Figure 3.22: FJORD expressed in rat hippocampal neurons ........................................................ 85
Figure 4.1: Voltage sensing mechanism of THOR ........................................................................ 91
Figure 4.2: Snake diagram of MZH3 and THOR template ............................................................ 93
Figure 4.3: Bioinformatic scan of cytochrome b domains ............................................................. 94
Figure 4.4: Snake diagrams of bioinformatic inspired THORs ...................................................... 95
Figure 4.5: Snake diagrams of conserved core THORs ............................................................... 97
Figure 4.6: THORH and THORI snake diagrams ........................................................................... 98

xiii

Figure 4.7: Hydropathy indices of amino acid residues .............................................................. 100
Figure 4.8: Snake diagrams of mini-THORC and mini-THORG ................................................... 104
Figure 4.9: Schematic diagram of Type I, II, and III THORs ....................................................... 105
Figure 4.10: HEK cell expression of THOR ................................................................................ 110
Figure 4.11: Whole cell patch clamp of THOR ............................................................................ 111
Figure 4.12: Whole cell patch clamp of QuasAr2-mOrange2 ..................................................... 112
Figure 4.13: Expression of THOR in rat hippocampal neuron DIV7 ........................................... 114
Figure 4.14: Expression and trafficking of THOR from DIV8 to DIV14 ....................................... 116
Figure 4.15: THOR gene structure .............................................................................................. 117
Figure 4.16: THORG-ST expressed in mouse primary neurons .................................................. 118
Figure 4.17: Potassium depolarization of THORG ....................................................................... 119
Figure 4.18: Potassium depolarization of THORG-ST ................................................................. 120
Figure A1.1: FJORD plasmid map for mammalian expression ................................................... 132
Figure A1.2: THOR plasmid map ................................................................................................ 134
Figure A1.3: Spectral properties of mOrange2, Sirius, and mTFP1 ........................................... 137
Figure A1.4: Spectrofluoroelectrochemical setup ....................................................................... 140
Figure A1.5: THOR supplementation with 5-aminolevulinic acid ................................................ 144
Figure A1.6: THORG-ST stained in mouse hippocampal neurons .............................................. 145

xiv

Chapter 1: Introduction and Thesis Statement

“One never notices what has been done; one can only see what remains to be
done.”
-Maria Składowska-Curie

1.1 Understanding
Technologies

Neuronal

Communication

using

Non-Invasive

One of the most important goals in neuroscience is to understand the
structure-function relationship of the nervous system. In 1791, Italian physician
Luigi Galvani published De viribus electricitatis in motu musculari commentarius
(On the Effects of Electricity on Muscular Motion), documenting the experiments
where he and his wife, Lucia, had noticed that dead frogs’ muscles twitch when
they came into contact with either an electric spark or two different metals1. These
experiments sparked the idea that electricity played a central role in nerve and
muscle function.
In 1906, Camillo Golgi and Santiago Ramón y Cajal were awarded the
Nobel Prize in Physiology or Medicine for their work on the structure of the nervous
system. This work was crucial in understanding that neurons are the fundamental
unit of the nervous system, responsible for all aspects of human behavior. From
their illustrations, it became easier to visualize that neurons were discrete units2,3.
The soma, the central region of the neuron, contains the genetic and protein
1

synthesis machinery for the cell, such as the nucleus, endoplasmic reticulum, and
mitochondria. Dendrites and axons are the two types of processes that extend from
the soma, where dendrites are responsible for receiving incoming signals from
other neurons, and axons are responsible for propagating electrical signals, called
action potentials, down its length. The ability to visualize and comprehend how
interneuronal interactions generate network dynamics would lead to developments
in better understanding processes such as learning, memory, sensory, motor
integration, and perception. Thus, development of probes is needed to capture the
voltage signaling between neurons.

1.1.1 The basis of electrical signaling between neurons
At the membrane of a neuron, a slight excess of ions forms the membrane
potential. The Goldman-Hodgkin-Katz (GHK) equation calculates the resting
membrane potential of a neuron based on the concentration and permeability of
the ions. The general GHK equation for A monovalent positive ions and B negative
ions across the neuronal membrane is expressed as:
Eqn. 1.1
where Vm is the membrane potential, Pion is the relative permeability coefficient for
each ion, R is the ideal gas constant, T is temperature, and F is Faraday’s constant.
When determining the resting membrane potential of a neuron using potassium,
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sodium, and chloride ions at physiological temperature, the GHK equation can be
rewritten as:
.

Eqn. 1.2

In most neurons, the values for each ion’s concentration inside and outside the
membrane and relative permeability to one another result in a resting membrane
potential that can range from -70 mV to -60 mV4. However, it is not uncommon for
certain neurons to have different resting membrane potentials. When a neuron
becomes excited by an external stimulus, the change in ion concentration
generates electrical signals, called action potentials.
The action potential is the electrical signal responsible for neuronal
communication5. For an action potential to be generated, the change in membrane
potential needs to be above a

40 mV

Voltage (mV)

certain threshold. Neurons follow

-60 mV

the “all-or-none” principle, where as
long as the strength of the stimulus
is above a certain threshold, a

Resting State

Hyperpolarization

complete action potential will occur;

Time (ms)

Figure 1.1: The waveform of a typical action
potential. Stimuli that trigger action potentials must
be above a certain threshold potential (not shown).
Subthreshold events cause slight perturbations that
return to the resting state potential.

if the stimulus is below this
threshold, no action potential will
occur. The action potential travels

down the axon by way of sodium and potassium ion channels. When stimulated,
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sodium channels are activated, allowing for extracellular sodium to enter the
neuron, causing the membrane to depolarize. As the membrane depolarizes and
reaches the peak of the action potential,
sodium channels are inactivated while
potassium channels open, prohibiting
sodium ions from entering the neuron
while allowing intracellular potassium to
rush out of the neuron. Once the
membrane is repolarized, potassium
channels close. This process occurs
along the axon until it reaches the
presynaptic terminal. Once stimulated,
synaptic

vesicles

containing

neurotransmitters are released into the
synaptic

cleft,

postsynaptic

docking

terminals

of

onto

the

dendrites

nearby, allowing the signal caused by the

Figure 1.2: The generation of action
potentials at the cellular level. (Top panel)
When stimulated, sodium ion channels
(green) open, creating an inward current of
sodium ions to depolarize the membrane.
Sodium ions flow down the axon, triggering
more sodium ion channels downstream to
open (middle panel). When the membrane
depolarizes, sodium ion channels inactivate
and potassium ion channels (purple) open,
creating an outward current of potassium
ions to repolarize the original segment of the
membrane. This process continues (bottom
panel) through the axon until it reaches the
axon terminals.

initial stimulus to proliferate throughout a network of neurons. This combination of
electrical signals and chemical signals is the foundation of neuronal
communication6,7. Capturing the dynamics of action potential across an entire
network of neurons would enable for a better understanding of the mechanisms
that underlie neural activity8.
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Alan Hodgkin and Andrew Huxley were the first to report an intracellular
recording of an action potential by inserting electrodes within the giant axon of
Loligo forbesii, the veined squid9. Voltage clamp, current clamp, and patch-clamp
recordings are examples of intracellular recording techniques commonly used
today5,10–12. While intracellular and extracellular electrodes have been valuable in
neuroscience research, they have disadvantages, including being an invasive
method for recording and not being able to record a large area of neurons
simultaneously. The development of non-invasive, molecular, optical probes that
can image changes in membrane potential with high spatial and temporal
resolution would alleviate limitations caused by electrode recordings13.

1.1.2 Calcium and neurotransmitter imaging
A popular method for imaging neuronal activity is by imaging calcium
dynamics within a neuron. During the depolarization phase of an action potential,
calcium channels activate, allowing a calcium influx into the neuron14–16. Calcium
imaging has been fruitful in detecting electrical events by monitoring the calcium
dynamics within a population of neurons, as well as at presynaptic terminals and
dendritic spines in a single neuron. Organic calcium indicator dyes are popular for
use in calcium imaging, where original dyes were based on metallochromic
indicators, BAPTA, rhodamine, and fluorescein molecules17–19. While these dyes
are bright, they are not targetable to specific cellular compartments. Another early
alternative was the use of the calcium-activated hydrozoan photoprotein, aequorin,
5

where bioluminescence from its luciferase, coelenterazine, is activated upon
calcium binding20,21. While aequorin can be targeted easily to membranes,
coelenterazine needs to be supplemented to cells and has a weak luminescence.
Genetically encoded calcium indicators (GECIs) based on calmodulin were
engineered to be bright, targetable probes. The first GECI, cameleon, was a
chimera of calmodulin, the calmodulin-binding peptide M13, and two green
fluorescent-protein (GFP) mutants, who form a Förster resonance energy transfer
(FRET) pair22. The GECIs camgaroo and pericam were later engineered by fusing
a single GFP mutant to calmodulin23,24. The most prolific family of GECIs is the
GCaMP family, where circularly permutated EGFP (cpEGFP) is attached to
calmodulin and M13. Through site-directed mutagenesis and library screenings,
the GCaMP family has resulted in GECIs with bright fluorescence, fast dynamics,
red-shifted probes, and the ability to image neuronal calcium activity in various
animal models25–31. While synthetic calcium indicator dyes and GECIs are
prevalent in neuroscience research, calcium is an echo of neuronal membrane
activity, so calcium imaging is an indirect method of measuring membrane
potential changes.
Neurotransmitter imaging is an alternative method of imaging neuronal
activity. Several genetically encoded neurotransmitter indicators (GENIs) have
been developed, such as the dopamine sensors, dLight1, RdLight1, and GRABDA,
the glutamate sensor family iGluSnFr, and the GABA sensor iGABASnFr32–37.
Similar to GECIs, these GENIs are bright, targetable to various cell types, and
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useful in neuroscience research in vitro and in vivo. However, they are secondary
measurements of the electric field changes occurring at the membrane. Voltage
sensing probes that can be inserted into the membrane are necessary to faithfully
capture membrane potential changes.

1.1.3 Using organic voltage-sensing dyes for membrane potential measurement
Organic voltage-sensitive dyes (VSDs) have been commonly used to study
individual cell dynamics in invertebrates and for functional brain mapping in
mammals13,38–40. One phenomenon utilized by organic VSDs is the optical Stark
effect, where chromophores experience electric-field induced changes to their
extinction coefficient41–45. VSDs that exhibit the Stark effect typically have large
differences in the dipole moment of their ground state and electronically excited
states, which are dependent on the magnitude and direction of an electric field.
For Stark dyes, also known as electrochromic dyes, the membrane potential
changes the energies of ground and excited states, leading to a change in the
absorption and emission spectra of these dyes. Stark dyes are typically based on
hemicyanine and styryl dyes and have excellent temporal resolution since the
voltage

sensing

mechanism

only

involves

an

intramolecular

charge

redistribution46–54. The best performing Stark dyes, ANNINE-6 and di-n-ANEPPS,
have relative changes in fluorescence, ∆F/F, of ~25%, and have subnanosecond
voltage response time50–54. While these dyes are both bright and have great
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temporal resolution, Stark dyes lack specificity. Unless injected intracellularly, the
dyes are not able to offer single cell resolution when applied to an entire tissue.
In addition to electrochromic dyes, other organic dyes utilize other voltage
sensing

mechanisms,

such

as

repartitioning,

reorientation,

FRET,

and

aggregation13,55. Notably, organic
molecular wires were developed
whose voltage sensing mechanism
relied on photo-induced electron
transfer, where a fast electron
transfer is able to detect changes in
membrane potential56–58; however,
these

dyes

still

suffer

from

nonspecific background labeling and
lack of specificity. In order to combat
Figure 1.3: Chemical structures of common
and sensitive Stark effect dyes. From Ref. [51].

the lack of specificity, biophysicists
and neuroscientists explored using

proteins as a platform for genetically encoded voltage indicators (GEVIs).

1.1.4 Genetically encoded voltage indicators and their evolution for improved
membrane targeting and voltage-sensing
Genetically encoded voltage indicators (GEVIs) were developed in order to
improve upon the lack of genetic targeting seen in organic voltage-sensing dyes.
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By encoding protein-based probes into DNA, GEVIs can be targeted to specific
membranes and neuron types. There are currently many different geometries and
designs of GEVIs, as seen in Table 1.1. Each GEVI is composed of a sensor and
a reporter. The most common sensors are derived from voltage-sensing
phosphatases or microbial rhodopsins, and the most common reporters are
fluorescent proteins. Combining different sensors and reporters, along with
targeted mutagenesis, have created a wide variety of different GEVIs, each with
its own strengths and pitfalls.

GEVI
FlaSh
SPARC
VSFP1
Pado
VSFP2.1
VSFP2.3
VSFP-Butterfly
nirButterly
Zahra2
Mermaid2
VSFP3.1
ArcLight Q239
Bongwoori
ElectricPk
FlicR1
ASAP1
ASAP2f
PROPS
Arch
Arch D95N
Arch EEQ
QuasAr1
QuasAr2
Archer1
MacQ-mOrange2
Ace2N-mNeon
QuasAr2-mOrange2
VARNAM
Voltron
Positron

Voltage-Sensing
Domain
Voltage-gated K+ Channel
Voltage-gated Na+ Channel
Voltage-gated K+ Channel
Voltage-gated H+ Channel
Ci-VSP
Ci-VSP
Ci-VSP
Ci-VSP
Danio rerio VSP
Ci-VSP
Ci-VSP
Ci-VSP
Ci-VSP/Kv
Ci-VSP
Ci-VSP
Gallus gallus VSP
Gallus gallus VSP
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin
Rhodopsin

Fluorescent
Reporter
GFP
GFP
CFP/YFP
Super ecliptic pHluorinA227D
CFP/YFP
CFP/YFP
mCitrine/mKate2
miRFP670/miRFP720
CFP/YFP
mUKG/mKOK
CFP
Super ecliptic pHluorinA227D
Super ecliptic pHluorinA227D
cpGFP
cpmKate
cpGFP
cpGFP
Proteorhodopsin
Archaerhodopsin
Archaerhodopsin
Archaerhodopsin
Archaerhodopsin
Archaerhodopsin
Archaerhodopsin
mOrange2
mNeon
mOrange2
mRuby3
JaneliaFluor525
JaneliaFluor525

∆F/F (%)
~ -5
-0.5
1.8
-5
8.6
13.3
6
8
1.8
48.5
-0.6
-39
-16
-1.2
6.6
-17.5
-25
N/A
40
60
60
32
90
85
-20
-18
-10
-8
-23
20

Table 1.1 List of GEVIs and their voltage-sensing domain, fluorescent reporter, and ∆F/F
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Initial GEVIs were fusion constructs between fluorescent proteins and
voltage-sensitive

ion

channels,

where

voltage

dependent

structural

rearrangements in the ion channel induced fluorescent changes in the fluorescent
protein. The first GEVI, FlaSh, was a fusion construct of a Shaker K+ channel and
GFP59. A modified GFP was inserted after the sixth transmembrane helix of the
Shaker channel, and a 5% decrease in ∆F/F per 100 mV was seen in Xenopus
oocytes. FlaSh exhibits slow kinetics of fluorescence changes on the millisecond
timescale, and since the kinetics of the fluorescence changes were much slower
than the movement of the gating charge, improvements were necessary for faster
voltage-sensing. FlaSh variants contain additional mutations to either the Shaker
channel, GFP, or by replacing GFP with a different fluorescent protein (CFP and
YFP)60. However, these FlaSh variants have fluorescence time constants on the
millisecond timescale in response to depolarizing steps. Other ion channel GEVIs
were developed to improve the kinetics of the voltage-sensing. Sodium Channel
Protein-Based Activity Reporting Construct (SPARC) was created from a fusion
construct of a rat muscle sodium channel subunit and GFP. Voltage-Sensing
Fluorescent Protein 1 (VSFP1) changed GEVI designs by creating a fusion
construct of a mammalian potassium channel and two fluorescent proteins, CFP
and YFP, that served as a FRET pair. While both show faster kinetics than FlaSh,
both have lower changes in relative fluorescence61,62. Additionally, these ion
channel-based GEVIs suffer poor plasma membrane expression, due to protein
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misfolding or intracellular aggregation, citing the need for different voltage-sensing
scaffolds63.
Through a genomic survey, a novel voltage-sensing domain with homology
to ion channels was discovered in an ascidian phosphatase – the Ciona intestinalis
voltage-sensitive phosphatase (Ci-VSP)64. Here, the voltage-sensing mechanism
is dependent on the vertical movement of the S4 helix as a membrane depolarizes.
To improve plasma membrane expression in VSFP1, the potassium ion channel
of VSFP1 was replaced with the Ci-VSP voltage-sensing domain to create
VSFP2.1. The CFP/YFP FRET pair from VSFP1 was carried over into VSFP2.1.
VSFP2.1 has a greater voltage sensitivity than its predecessor, 8.6% decrease in
∆F/F per 100 mV. Due to the monomeric nature of the Ci-VSP voltage-sensing
domain65, expression also improved, but the dynamics of VSFP2.1 were still slow
upon repolarization of the membrane. By removing five amino acids from the
restriction sites in VSFP2.1, VSFP2.3 had improved expression, faster dynamics,
and greater sensitivity with a ∆F/F of 13.3% per 100 mV66. The VSFP family later
branched into other FRET-based designs, such as Mermaid which used two pHresistant coral-derived fluorescent proteins mUKG/mKOK as a FRET pair67, Zahra2
that incorporated zebrafish-VSP DNA68, VSFP-Butterfly which placed the
fluorescent proteins at the N- and C-termini69, and a near-infrared Butterfly
(nirButterfly) that utilized miRFP for better deep-tissue imaging and two-photon
voltage imaging70. While FRET pairs are useful for ratiometric imaging, two
fluorescent proteins attached to the VSP places a higher demand on cellular
11

protein synthesis machinery, as well as makes it difficult to image with other
sensors.
VSFP3.1 was the first VSP based GEVI with one fluorescent protein, CFP,
as the voltage reporter. Removal of YFP from VSFP2.3 led to improved kinetics in
VSFP3.1. In PC12 cells, VSFP3.1 had activation time constants similar to neuronal
electrical activity66. Red-shifted variants of VSFP3.1 were later developed, with
VSFP3.1_mOrange2 being the most promising spectral variant for reporting
neuronal activity when it was developed71. However, VSFP3.1 and its variants
suffered in its sensitivity. ArcLight Q239 evolved from Mermaid, replacing the coral
FRET pair with a super ecliptic pHluorin. This replacement improved sensitivity,
exhibiting a 35% decrease in ∆F/F per 100 mV in HEK293 cells72, and the addition
of an ER and Golgi export tag, membrane trafficking improved73. ElectricPk was
the first GEVI to contain a circularly permutated fluorescent protein (cpFP),
cpEGFP, at its C-terminus74, followed by FlicR1, which contains cpmApple75. By
using the voltage-sensing domain from the chicken Gallus gallus voltage-sensitive
phosphatase and incorporating a cpGFP in the S3-S4 loop of the VSP, the ASAP1
probe was developed76. The sensitivity of ASAP1 is higher than that of ElectricPk
and FlicR1 and is able to detect action potential waveforms up to 200 Hz. ASAP2f
and ASAP2s, which show much promise for two-photon imaging, were developed
through mutagenesis in the linker region between the S3 helix and the cpGFP and
within the S4 helix, respectively77,78. As the single-FP VSP-based GEVI evolved,
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the kinetics, sensitivity, and subcellular spatial resolution improved. While the VSPbased GEVIs were being developed, another family of GEVIs were being
engineered using another voltage-sensing scaffold.
Microbial rhodopsins are 7-transmembrane helical proteins with a retinal
chromophore embedded in the core. The retinal chromophore is weakly
fluorescent in its protonated state, and the protonation state of the retinal Schiff
base is affected by the membrane potential. By exploiting this property, the first
microbial rhodopsin-based GEVI developed was the Proteorhodopsin Optical
Protein Sensor, PROPS79. While PROPS shows voltage response in bacteria, it
does not traffic to the plasma membrane in eukaryotic cells, even with the help of
targeting sequences. A new microbial rhodopsin-based GEVI, Arch, was shortly
developed by using the Archaerhodopsin-3 from Halorubrum sodomense since it
expresses to neuronal membranes80,81. While it expresses well in neurons, it has
a dim fluorescence, and illumination of Arch slightly perturbs the membrane

Figure 1.4: Architecture of voltage-sensitive phosphatase-based GEVIs. A) Membrane potential
events cause structural rearrangements to occur in the VSP, modulating the fluorescence in a
FRET pair of fluorescent proteins. B) VSP-based GEVIs were engineered to be functional only
with one fluorescent protein. C) Circularly permutated fluorescent proteins inserted into the S3S4 loop undergo fluorescent changes in response to the voltage-dependent movement of the
S4 helix.
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potential82. The Arch D95N mutant removes this perturbation, but slows the
response time83. Through additional mutations to Arch and the attachment of ER
export tags and membrane trafficking tags from the Kir2.1 potassium channel led
to improved trafficking in neurons, faster kinetics, and the removal of the protonpumping photocurrent84,85. While these later Arch-based GEVIs have the ability to
probe the microsecond-timescale dynamics of action potential propagation in
single cells and the network activity of multiple neurons, they are still much dimmer
than fluorescent proteins and require intense laser illumination.
To increase the brightness of the rhodopsin-based GEVIs, electrochromic
FRET (eFRET) GEVIs were developed by using a fluorescent protein as an eFRET
donor to the retinal, which experienced voltage-induced absorption changes.
Various fluorescent proteins, including EGFP, Citrine, mOrange2, and mKate2,
have been shown to report voltage changes when attached to QuasAr286.

Figure 1.5: Architecture of the microbial rhodopsin-based GEVIs. A) Protonation of the retinal
Schiff base results in a dim fluorescence. Due to the dim fluorescence, necessary intense laser
illumination produced cellular and tissue auto-fluorescence. B) An attached fluorescent protein
that forms a FRET pair with the retinal diminishes the need for higher-powered laser illumination.
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However, even the most sensitive QuasAr2-FP, QuasAr2-Citrine, has much lower
sensitivity than QuasAr2, 13% decrease in ∆F/F per 100 mV vs. 90% increase in
∆F/F per 100 mV. The eFRET GEVI, Mac, uses the rhodopsin from Leptosphaeria
maculans as the voltage-sensing domain, and undergoes FRET with both
mOrange2 and mCitrine87. Ace-mNeon indicators incorporate the rhodopsin from
Acetabularia acetabulum with the fluorescent protein, mNeon-Green. These
indicators were the first GEVIs to detect single action potentials in live animals and
could detect subthreshold hyperpolarizations and spike trains in awake mice and
flies88. VARNAM is a red-shifted version of Ace, which contains mRuby3 as the
fluorescent reporter89. Despite the sensitivities of the eFRET GEVIs being lower
than the rhodopsin-based GEVIs, eFRET GEVIs are brighter and provide the
opportunity for multispectral imaging in both mice and flies. Chemigenetic GEVIs
FlaSh

SPARC
VSFP1

VSFP2.1

VSFP-Butterfly

VSFP2.3

nirButterfly

Zahra2

Pado

Mermaid

ArcLight Q239

VSFP3.1

ElectricPk
ASAP1

Bongwoori
FlicR1

ASAP2s
ASAP2f

PROPS

Arch

Arch D95N

Arch EEQ

Archer

QuasAr1/2

QuasAr-FP
MacQ
Ace2N

VARNAM
Voltron

Positron

Figure 1.6: The phylogenetic tree of the two families of GEVIs. Changes in color refer to a major
change from previous generations, such as a change in the voltage sensing domain or
addition/removal of fluorescent proteins. All current GEVIs are descendants from two initial
GEVIs. There is limitation of currently available voltage-sensing proteins in nature.
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have been developed to increase the brightness and photostability of Arch-based
and eFRET GEVIs, by replacing either the retinal with a synthetic chromophore or
by replacing the fluorescent protein with synthetic dyes have been made90–92.
Voltron and Positron show great promise for continuous imaging in in vivo
experiments, but require exogenous, non-genetic material to be introduced to the
system91,92.
While each GEVI expands the toolkit for neuroscientists to image neuronal
activity, no GEVI is ideal for all experiments. In a comparative evaluation of eight
GEVIs (ArcLight Q239, ArcLight-MT, ASAP1, ASAP2f, ASAP2s, Ace2N, QuasAr2,
Archer1), it was seen that the rhodopsin-based sensors perform better in
sensitivity, signal-to-noise ratio (SNR), and in capturing the kinetics in voltage
steps, single action potentials, and spike trains in vitro, with QuasAr2 being
deemed the best performer93. However, in vitro performance does not correlate
with in vivo performance. While QuasAr2 performed the best in vitro, it was too dim
for in vivo experiments (along with Archer1). ArcLight-MT performs the best in vivo
and in one-photon experiments and the ASAP family performs well in two-photon
experiments, although with poor SNR. The perfect GEVI should have high
sensitivity, fast temporal resolution, genetic targeting, a bright and photostable
fluorescent reporter, and a tunable structure for optimization. As the quest for an
ideal GEVI continues, the arc of GEVI development could turn to either new natural
protein chassis or de novo designed protein engineering.
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1.2 Introduction to Protein Maquettes
Protein design and engineering aims to either take existing proteins and
modify the primary structure to alter the protein behavior, or to rationally design
new proteins to better understand natural protein function and to develop novel
functions. In 2018, Frances Arnold was awarded the Nobel Prize in Chemistry for
her work in using directed evolution to develop new enzymes. Arnold harnessed
evolution in the laboratory and was the first to use directed evolution on natural
enzymes. Her work has developed enzymes that can convert renewable biomass
to fuels as well as perform novel chemistries that no natural enzyme could do
previously. Computational methods have also been proven to be powerful in
protein design. The software Rosetta has the ability to take a protein sequence not
seen in nature and compare it against protein sequences from structures in the
Protein Data Bank. The maquette approach to de novo protein design focuses on
using first principles of protein folding to develop simple, artificial proteins to better
study natural protein function.

1.2.1 Removing complexity from natural protein design
Just as species evolve over time due to natural selection, proteins evolve
to better function in changing environments. Proteins can belong to families and
superfamilies that descend from a common ancestor and share similar tertiary
structures, functions, and sequence similarity. For example, the G protein-coupled
receptor (GPCR) superfamily is the largest protein family of eukaryotic cell surface
17

receptors, comprising of various classes, such as rhodopsins, secretin receptors,
fungal mating pheromone receptors, and cyclic AMP receptors94,95. While having
retained their tertiary structure of seven transmembrane helices through its
evolution, GPCR family members bind a range of diverse ligands, such as lightsensitive cofactors, odors, hormones, and neurotransmitters. Single mutations in
GPCRs can lead to changes in cofactor fluorescence or to countless pathologies,
such as vision disorders or cancer96,97. The
altered residue can unexpectedly be located in
a region not associated with the mechanism,
suggesting that through the protein’s natural
evolution

over

the

course

of

time,

interdependencies were formed.
When studying functional properties of
natural proteins, an amino acid or motif can be
found

to

be

complexities

multifunctional

arising

from

the

due

to

protein’s

evolution, a feature of Darwin’s principle of
multiple utility98. If a mutation occurs to a
multifunctional amino acid, such as an amino
acid necessary for electron transfer and the
stability of the protein, both structure and
function

are

affected.

This

complexity
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Figure 1.7: A visual depiction of
Muller’s ratchet that serves as an
analogy for the evolutionary history,
amino acid interdependence, and
irreversible complexity in natural
proteins. (Top) A functional bridge
comprised of three stepping stones.
(Second) A wooden plank added on top
of the stepping stones is non-essential
to the original function of the bridge.
(Third) Removal of a stepping stone
forces to the wooden plank to become
a necessary component of the bridge.
(Bottom) Removal of another stepping
stone
demonstrates
the
interdependence of the parts and
irreversible complexity of the system.

inherent in natural proteins can at times be irreversible, as explained by Muller’s
genetic ratchet99. As a protein evolves and mutations occur, a non-essential amino
acid can be forced to become essential to a protein’s structure or function. Before
this modification, a mutation of the amino acid would have no effect on the protein,
whereas now, a mutation would be deleterious. These complexities found in
natural proteins necessitates a need for simpler, designed protein scaffolds to
study natural proteins that alleviates issues generated from Darwinian and
Mullerian principles.
Protein maquettes are de novo designed proteins which share no sequence
homology to natural proteins and are minimalistic in their design. The word
maquette means a preliminary sketch or model, often used by artists, sculptors,
and engineers. Multiple maquettes can be made throughout design process, where
gradual modifications are added until a satisfactory final product is realized. Protein
maquettes are inspired by natural four-α-helical bundle proteins, yet the
minimalism associated in its design allow them to be subjected to iterative
redesigns without compromising structure100. Maquettes remove constraints
imposed by natural proteins, where a protein engineer can focus on fewer design
aspects, chiefly the folding sequence, conformational stability, membrane or
cytosolic solubility, and cofactor localization, in order to study specific protein
functions101,102. In protein engineering, the maquette approach perhaps best
embodies the essence of Richard Feynman’s celebrated quote, “What I cannot
create, I do not understand.”
19

1.2.2 First principles of protein folding for protein maquettes
Protein maquettes rely on binary patterning of polar and nonpolar amino
acids to produce a robust four-α-helical scaffold that can bind cofactors and can
withstand successive iterations of redesign without a loss of secondary or tertiary
structure. Regan and DeGrado were first to show that a repeating sequence of
seven polar (P) and non-polar, hydrophobic (H) amino acids (HPPHHPP) could
form a tetrameric α-helical bundle
protein103.

This

heptad

repeat

structural motif is based on firstprinciples of protein folding seen in
natural four-α-helical bundles and
leads to two different topologies:
antiparallel and parallel/antiparallel. αhelices in nature typically have a pitch
of 5.4 Å, with 3.6 amino acids per turn,
meaning there is a rise of 1.5 Å per
amino acid. α-helices interacting as
Figure 1.8: (Top) Helical wheel diagram
showing the heptad repeat structural motif
seen in ideal maquettes, where H represents
hydrophobic residues and P represents polar
residues. (Bottom) Helical wheel diagram
representation of two maquettes with different
topologies. Threading of the helices is
controlled by charge patterning and
hydrophobic core packing.
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coiled-coils,

though,

have

a

periodicity of 3.5 amino acids per turn,
meaning the heptad repeat structural
motif repeats itself every two turns.

Using the nomenclature first described by McLachlan and Stewart, the heptad
positions can be lettered from a to g, where a and d in the helix refer to the core
residues, b, c, and f are exterior residues, and e and g are interfacial residues104.
From this patterning, the exterior of a maquette is hydrophilic while the core is
hydrophobic and where cofactors can be attached. In the maquettome, each helix
in the conventional maquette contains four heptad repeats; however, other
maquette designs include ones with shortened or extended helices, as well as 3-,
8-, 12-, and 16-α-helical bundles. Each helix is connected to one another typically
by, but not limited to, glycine-rich loops, where loops can be 4, 5, or 9 amino acids
in length.
Initial maquettes were design to be water-soluble proteins, but by
introducing lipophilic patterning on the exterior of the maquettes, amphiphilic,
transmembrane maquettes were developed that could tetramerically assemble in
lipid bilayers105,106. Eventually, a single-chain transmembrane maquette was
designed, comprised of a major and minor water-soluble domain with a
transmembrane domain in between107. The transmembrane domain is rich in
leucine and alanine residues, due to their α-helical propensities and hydropathy
indices determined from the Wimley-White whole-residue octanol scale108,109. The
two water-soluble domains follow the conventional binary patterning of watersoluble maquettes, and allow for the transmembrane domain to be driven into
helical association110. New minimal de novo membrane proteins are being
engineered by introducing a helix packing motif into the transmembrane domain111.
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1.2.3 Cofactor binding within protein maquettes
Due to the simplicity of the design, maquettes are versatile in their cofactor
binding ability. Maquettes have been shown to bind a variety of redox- and lightactivated natural and synthetic cofactors, which bestow functionality upon the
maquettes107,110,112–114. Heme, the cofactor predominantly featured in this thesis,
was the first cofactor which bound to a maquette precursor, a two-α-helical

Figure 1.9: The versatility of protein maquettes. (Top) The water-soluble four-helical-bundle
maquette frame binds various natural and artificial cofactors (cofactor legend on right side).
Differences in helical threading produce either antiparallel or parallel/antiparallel maquette
topologies. (Bottom, left) Additional helices can be attached to increase the size and number of
cofactors added. (Bottom, middle and right) Maquettes partition into membranes by patterning
the exterior with hydrophobic residues which favor the hydrophobic environment of membranes.
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protein115. Heme b was attached via a bis-His ligation. Heme-binding maquettes
show preferential binding to oxygen over carbon monoxide, a prototype for an
artificial oxygen transporter116. When the CXXCH motif from cytochrome c is
introduced, the cytochrome c maturation machinery in E. coli can incorporate heme
c to the maquette in vivo117. By mutating a single histidine in the bis-His ligation
site, the absorption peaks of the bound heme shift, as well as its midpoint potential,
with reported values spanning from -260 mV to 70 mV118,119. Intra-protein electron
transfer has been demonstrated within water-soluble and transmembrane hemebinding maquettes on the microsecond timescale, as well as inter-protein electron
transfer with cytochrome c and other maquettes107,113,117,120.
In addition to heme, other endogenous cofactors have been incorporated
into the maquette scaffold. When coexpressed with heme oxygenase and bilin
lyase, bilins covalently attach to maquettes via a thioether bond to the cysteine in
the CLRD motif121,122. Through chemical methods, flavins have been shown to
attach to cysteines within maquettes. Other natural cofactors, such as metal ions,
quinones, and chlorophyll, bind to maquettes, as well as synthetic porphyrins and
chlorins110,114. A chimera constructed of a phycobiliprotein and a maquette with
bound chlorin and bacteriochlorin cofactors has been demonstrated to show
excitation energy transfer123. The ability for this minimalistic scaffold to bind various
cofactors showcases the remarkable adaptability of maquettes. Moreover, the
multiple functionalities conferred to maquettes through these cofactors allow
protein engineers to study processes such as biological electron transfer and
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magneto-sensing124–126, as well as develop novel artificial oxygen transports116,
light-harvesting antennae123, and photosynthetic reaction centers118,127 without the
fear of structural loss.

1.2.4 The case for protein maquettes for voltage sensing
In the first half of this introduction, various methods for detecting neuronal
activity were outlined: electrodes, calcium and neurotransmitter imaging, optical
voltage-sensitive dyes, and GEVIs. Each method has benefits and disadvantages.
Through these comparisons, qualities of an ideal optical voltage-sensing probe
can be established. First, a probe must have high sensitivity, measured by their
relative change in fluorescence during an electrical event. A probe also must have
fast temporal resolution, so that not only an action potential can be captured, but
subthreshold events as well. A genetically encodable probe is preferred, since this
allows for genetic targeting to specific cells and membranes. In addition, a bright,
stable fluorophore is desired, as well as a probe having tunable structure for
optimization.
In the second half of this introduction, the maquette approach for de novo
protein design was presented. The goal of this thesis is to design and develop
novel GEVIs using the maquette technology. By virtue of being a protein,
maquettes already have an advantage over organic voltage-sensitive dyes by
being able to be genetically targeted to specific cells and membranes. The
combinatorial nature of the maquette approach allow for a diverse array of possible
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de novo designed GEVIs. Endogenous cofactors,
such as heme and bilins, can be attached in vivo to
maquettes. These cofactors can also participate in
inter-

and

intra-protein

electron

and

energy

transfer107,120,123. By harnessing these mechanisms
and developing them into a voltage-sensitive one, a
maquette-based GEVI could sense electrical events
on the timescale of organic voltage-sensitive dyes.
Fluorescent

proteins,

whose

brightness

and

photostability have improved over generations of
directed evolution, can operate as a bright reporter,
Figure 1.10: A maquette-based
GEVI. Voltage sensing is
carried out using electron
tunneling, and voltage reporting
is carried out using a
fluorescent protein.

in addition to endogenous cofactors128–130. Finally,
since maquettes lack intrinsic Darwinian and
Mullerian complexities that natural proteins inherit

from evolution, their structure can tolerate successive rounds of optimization.
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Chapter 2: Design Principles for an Electron TransferBased de novo Designed Genetically Encoded Voltage
Indicator

“Empiricism may serve to accumulate facts, but it will never build science. The
experimenter who does not know what he is looking for will not understand what
he finds.”
-Claude Bernard

2.1 Introduction
In creating an electron transfer-based de novo designed genetically
encoded voltage indicator (GEVI), the electrostatics across the membrane must
be considered in order to determine such factors as cofactor position and midpoint
potential. In this chapter, a mathematical model will be developed to serve as an
initial framework for understanding the kinetics of a de novo designed GEVIs. The
goal is to determine the parameters needed for a heme-binding transmembrane
maquette which utilizes electron transfer in order to sense changes in an electric
field across a membrane.
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2.2 Biological Electron Transfer as a Voltage-Sensing Mechanism in a GEVI
In designing a GEVI, a sensing mechanism must be established. A fair
amount of GEVIs rely on a combination of protein structural rearrangements and
FRET to sense and report changes in membrane potential. While these GEVIs are
capable of detecting electrical activity in neuronal membranes, their temporal
resolution is much slower than those seen in organic voltage sensitive dyes. A
GEVI that incorporates electron transfer as its voltage sensing mechanism would
improve upon the speed of sensing seen in current GEVIs.
A classical theoretical approach for understanding electron transfer was
developed by Rudolph A. Marcus, now referred to as Marcus theory. Marcus
theory describes electron transfer using one-dimensional surfaces for the potential
energy and reaction coordinates of reactants and products and assumes that
donor and acceptor molecules behave as a collection of harmonic oscillators131.
Similar to other theories of reaction rates, Marcus theory postulates that there
exists a transition state for electron transfer with an accompanying activation
energy needed for electron transfer to occur. For electron transfer to occur in a
solvated system, the solvent needs to be repolarized prior to the charge
distribution. The energy needed to repolarize the solvent is called the outer sphere
reorganization energy, λo. The inner sphere reorganization energy, λi, reflects the
changes in the bond lengths in the reactants. The summation of the outer and inner
sphere reorganization energies is the total reorganization energy, λ, which is the
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energy needed for the geometry of the reactants to be reconfigured to the
geometry of the products before electron transfer occurs132.
Figure 2.1 depicts different energy parabolas, representing non-adiabatic
states for donor-acceptor pairs, with the reaction coordinate on the x-axis and
potential energy on the y-axis133. The
intersection

of

each

parabola

represents the transition state of the
electron transfer, where the total
energy

is

twice

the

electronic

coupling matrix element, HAB. When
this term is large, the probability of
electron

transfer

occurring

approaches unity. However, when

Figure 2.1: Theoretical reaction diagrams from
Marcus Theory. From left to right, the energy
parabolas represent normal, ideal, and inverted
regions. Figure from Ref. [133].

this term is small, such as in longrange electron transfer seen in proteins, it encapsulates the quantum tunneling
necessary to overcome the energy barrier. Marcus theory predicts three distinct
regions: normal, activationless or ideal, and inverted. The activation energy is
given by:
Eqn. 2.1.
Normal exergonic electron transfer is considered when ΔG < 0 and also less than
the reorganization energy. When ΔG = λ, this is referred to as ideal or
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activationless electron transfer, since there is no free energy barrier. At this point,
the electron transfer rate is at a maximum. When the Gibbs free energy associated
with the electron transfer is decreased even further and has a magnitude greater
than λ, Marcus theory predicts an interesting third region referred to as the inverted
region, where despite the increasing exergonicity, the electron transfer rate will
decrease. This can be understood that there is an ideal amount of energy that
electron transfer products can accept before the rate of electron transfer becomes
inhibited. The semi-classical approximation for the electron transfer rate can be
written as:
Eqn. 2.2.
When electron transfer becomes long-ranged as seen in proteins, the electronic
coupling matrix, HAB, becomes the critical component in determining the rate of
non-adiabatic electron transfer, as it represents the overlap of the donor and
acceptor electronic wave functions. The distance dependent rate of electron
transfer can be rewritten as:
Eqn. 2.3
where β, the distance decay constant, describes the strength of the electronic
wave functions between the donor and acceptor molecules, which decreases with
distance. The value of this coefficient in proteins has been subjected to
experimental debates. Beratan and Gray theorized that electron transfer rates
were dependent on the protein medium in their “Pathway Model” through extensive
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experiments on ruthenated proteins, where the value of β changes dependent on
the path of electron transfer, including a-helices and β-sheets134–136.
Dutton and Moser provide an empirical formulation for biological electron
transfer, where exergonic electron transfer is dependent on the distance between
cofactors, β is set to 1.4 Å-1. The Moser-Dutton Ruler was established where:
Eqn. 2.4
where ρ represents the packing fraction and R represents the distance between
cofactors in Å137–139. R has oft been debated whether it is edge-to-edge distance
or center-to-center distance between cofactors – in this thesis, R will be considered
the edge-to-edge distance between cofactors. Dutton and Moser assert that in
nature, the packing fraction between cofactors is not modified in order to enhance
electron transfer, contrasting from the Pathway Model. By setting ρ to 0.75 (which
is the average packing fraction seen between cofactors), the Moser-Dutton Ruler
can be simplified to:
Eqn. 2.5
which comprises several elements of semi-classical electron-transfer theory139,140.
The Eyring rate limit for nuclear vibrations at room temperature is 13, the tunneling
decay constant through protein medium is 0.6, R is the edge-to-edge distance, the
van der Waals contact is represented by 3.6, and Hopfield’s characteristic nuclear
frequency is the 3.1 term. This formulation allows for long-ranged exergonic
electron transfer to be calculated simply and accurately141.
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Stemming from the Moser-Dutton Ruler, we can fundamentally consider
biological electron tunneling being dependent on the edge-to-edge distance, R,
and the difference in redox midpoint potential between cofactors in an electron
transfer chain, where this process can occur on the picosecond to millisecond
timescales137,139. Figure 2.2 shows how within a maquette, electron tunneling rates
can be modulated simply by placing cofactors at different locations on the helical
frame. Electron transfer within heme-binding maquettes has been shown in both
water-soluble
constructs

and
on

transmembrane

the

timescale107,113,117.
Takamiya

and

microsecond
Additionally,

Dutton

show

that

membrane potentials can shift the
midpoint potentials of cofactors. Due
the presence of the electric field, redoxsensitive cofactors, such as a heme,
experience a redox shift in their

Figure 2.2: For every ~5Å between cofactors,
or roughly one helical turn on the maquette,
the electron tunneling rate increases by 3
orders of magnitude. This kET dependence on
distance (R) allows us to modulate intraprotein electron tunneling rate by changing
the distance between cofactors.

midpoint potential, Em142. All of this
together suggests that electric field
induced

electron

transfer

within

membranes can be developed through careful positioning of heme cofactors within
a maquette and appropriately poising their midpoint potentials. To engineer an
ideal GEVI using heme cofactors, the dynamics of the electric field across the
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membrane during need to be considered before determining inter-heme distances
and midpoint potential differences.

2.3 The Electrostatic Profile of a Plasma Membrane
The plasma membrane is a phospholipid bilayer which separates the cell
from its external environment, contains various types of membrane proteins, and
has its own electrostatic profile. The membrane potential, which is the difference
in the electric potential on the interior and exterior of the cell, is formed by the slight
excess of ions just outside the membrane. Outside the membrane, two phases of
water exist: the bulk and the interface143. At the membrane-water interface, a layer
of polarized water molecules forms due to the negatively charged phospholipid
heads. This region is referred to as the compact layer (CL). The rest of the
interfacial region of water comprises what is referred to as the diffuse layer or the
Gouy-Chapman layer or cloud (GC), where there is a higher concentration of
cations than seen in the bulk solution144.
To better understand the electrostatics across the membrane and interface,
the potential difference across each layer and region must be characterized. The
potential difference between the intracellular and extracellular bulk regions is
considered the overall cell potential:
Eqn. 2.6.
This is the canonical membrane potential established by the different
concentrations of ions on each side of the membrane. At each interface of the
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membrane, the polarized water molecules of the CL produce a potential difference
on the intracellular and extracellular surface, ∆χi and ∆χe, respectively. The GC
layer also produces a potential difference on both the intracellular and extracellular
side of the membrane, φGCi and φGCe, respectively. The intracellular and
extracellular surface potentials are simply the sum of the potential across the entire
CL and GC layers:
Eqn. 2.7
Eqn. 2.8
which represents the potential difference between the membrane surface and the
bulk layers of the intracellular and extracellular sides. This surface potential has a
Debye length of approximately 1 nm, meaning that the electric field no longer
becomes significant 1 nm from the surface of the membrane. Finally, the potential
difference within the membrane, φM, can be derived as:
Eqn. 2.9
where this potential represents the electric field within the membrane that integral
voltage-sensitive proteins sense changes in. Of course, Equation 2.9 creates an
assumption that the electric field within the membrane to be homogenous. This is
untrue, considering the presence of ion channels and other proteins throughout
the membrane would perturb the electric field. Figure 2.3 shows an approximation
of what the electrostatic profile across the membrane is. However, the exact nature
of the profile is still being considered and developed145–147.
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The purpose of the rest of the chapter is to have an understanding of how
an electron transfer-based GEVI using heme cofactors bound to a maquette would
function. The chain of hemes within the GEVI must be able to sense changes in
the electric field, so a mathematical model was developed to aid in the design of a
de novo designed GEVI. For the heme
cofactors, important parameters are
the midpoint potentials and the interheme distances. Since the midpoint
potential is affected by an electric field,
a model for the electric field needs to
be determined. To model the electric
field, a reductionist approach will be
Figure 2.3: The electrostatic profile of a
membrane. Figure from Ref. [143].

taken. The electric potential difference

between the bulk regions will be used as the potential difference between the
membrane. Additionally, the surface potential will continue to have a Debye length
of 1 nm, but rather than modeling the surface potential caused by the CL and GC
layers, the surface potential will be constant. This reductionist approach should not
affect the trends that will be calculated for this proposed sensing mechanism. Many
of the parameters that will be calculated in this chapter are dependent on potential
differences rather than the absolute electric potential value, such as the Gibbs free
energy and the electron transfer rate, so this model should not alter results greatly.
Additionally, much of the theory involved with determining the membrane surface
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potentials are based on treating the membrane as a set of parallel plate capacitors.
However, the membrane is dynamic and heterogeneous, meaning that even the
previous interpretation of the membrane is not complete. Finally, the effect of the
membrane potential on the heme midpoint potential will be calculated as if the
electric field acts on the center of the heme molecule; of course, this is simply an
approximation, since heme cofactors are ~10 Å in length. Another caveat is that
these heme cofactors are also protected by a protein environment, so any heme
that is outside the membrane must be within the Debye length to sense the electric
field change, allowing the assertion that the surface potential can be considered
constant for this model without creating incredulous results.
For the rest of this chapter, the initial maquette-based GEVI design
considers three hemes embedded within a maquette: two within the membrane
dielectric and one embedded in the water-soluble cap in the intracellular side of
the membrane (Figure 4A). The heme embedded in the water-soluble cap will be
referred to as heme 1, and the two in the membrane will be hemes 2 and 3. As
mentioned earlier, the distance between hemes will be represented by edge-toedge distance opposed to center-to-center distance.
In a simulation performed by Christopher Moser, heme redox states within
a transmembrane maquette can switch during a typical neuronal action potential
[personal communication].

For a three-heme maquette with edge-to-edge

distances of 13 Å between hemes and no difference in midpoint potential, heme 3
has the highest probability of being reduced at resting membrane potential, here
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given as -70 mV (Figure 4B). Over the course of an action potential, the redox
states of the hemes switch. At the peak of an action potential, heme 1 has the
highest probability of being reduced. The electron tunnels within the chain of
hemes as the action potential occurs. When the membrane repolarizes, the
electron would return to heme 3. This is an improvement upon current GEVIs,

Figure 2.4: A membrane maquette with three hemes attached will experience changes in their
redox state during a membrane potential change. (A) During a typical action potential, the redox
states of each of the hemes will change in response to the change in membrane potential. (B))
Schematic representation of the electron transfer occurring during a typical action potential.
Heme 3 (green) has a higher probability of being reduced at resting membrane potential,
whereas Heme 1 (blue) has a higher probability of being more reduced at the peak of an action
potential. (C) Sensitivity to electric field changes diminish upon increasing inter-heme distance.
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since the structural rearrangements cause a short refractory period where changes
in membrane potential can not be sensed148. In an electron transfer-based GEVI,
the heme cofactors would act as a wire, allowing electron transfer to occur in
response to a changing electric field.
Figure 4C shows the effect distance has on the sensing fidelity of a
maquette-based voltage sensor. At an edge-to-edge distance of 13 Å, the heme
chain is poised to respond to changes in membrane potential fast enough. At
further distances, electron transfer will not respond fast enough to millisecond
changes in action potential. It is then crucial to have edge-to-edge distances
between heme cofactors of 13 Å or less in order to have faster temporal resolution
than current GEVIs.
Maquette topology affects heme ligation positions and patterning within
maquettes102,119,149. A common approach for antiparallel maquette topologies is to
place heme attachment sites 14 amino acids away from each other. This interheme distance is often seen due to the heptad repeat motif inherent to maquettes,
where a-d residues are core residues; the 14 amino acid distance represents two
full heptad repeats of the maquette, where the bis-His heme attachment site occurs
at the same “letter” within the motif on the same helix (ai to ai+2 or di to di+2)104. The
edge-to-edge distance for heme cofactors separated by 14 amino acids is 11 Å.
Since the a and d positions are core residues, cofactor attachment can also occur
11 amino acids from each other (ai to di+1, di to ai+2). In parallel/antiparallel
topologies, heme attachment could also occur at interfacial residues, where hemes
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ligate between adjacent helices, such as in Protein 2 in Goparaju et al., where bisHis ligation sites are either 12 or 13 amino acids from each other107. Due to the
flexibility in heme ligation patterns, calculations will consider and include a range
of dielectric distances between hemes and a range of inter-heme distances to
account for possible heme-binding maquette geometries.

2.4 Electron Transfer Rate Calculations
To calculate the expected electron transfer rates between heme cofactors
in maquette-based GEVIs, the Gibbs free energy must first be calculated. Using
Equation 1 from Kim et al., the Gibbs free energy change for electron transfer
between two hemes is given by:
Eqn. 2.10
where ΔΨ is the membrane potential, Em represents the midpoint potential of each
heme, and:
Eqn. 2.11
where βji represents the fraction of the insulating phase within the dielectric
between two hemes, i and j (j > i) (Note: βji is not related to the coefficient seen in
Equation 2.3)150. The total dielectric diameter is d, and r represents the dielectric
distance the center of each heme is from the exterior membrane, where r = 0
represents the exterior membrane surface. For this thesis, d = 30 Å151. Any heme
positioned outside the membrane on the interior of the cell would have an r equal
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to the full dielectric distance in this model. By substituting Equation 2.11 into
Equation 2.10, the Gibbs free energy can be rewritten in terms of the midpoint
potential shift further discussed in Equation 2.16:
Eqn. 2.12.
By combining the midpoint potentials of each heme with their respective electricfield induced shifts, Equation 2.12 can be rewritten in terms of the effective
midpoint potentials due to an electric field:
Eqn. 2.13.
Using these equations, the Gibbs free energy for electron transfer from heme i to
heme j can be determined. In this discussion, the change in Gibbs free energy is
regarded as the change in the “favorability” or the “directionality” of electron
transfer during a change in membrane potential event as a function of membrane
potential and midpoint potential difference. Figure 2.5 shows 2D plots for the Gibbs
free energy in mV for electron transfer in Equation 2.10 between two hemes over
membrane potentials that correspond to a typical action potential, where the x-axis
shows the difference in the midpoint potentials of the two hemes, and the y-axis
shows the membrane potential, over various values of βji. Here, the direction of the
electron transfer is from the heme closer to the interior of the membrane (i) to the
heme closer to the exterior of the membrane (j). For each dielectric distance
calculated, the Gibbs free energy increases in value as the membrane potential is
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depolarized, regardless of the difference in midpoint potential between the two
hemes.
βji = (1/6)

βji = (1/3)

βji = (1/2)

βji = (2/3)

βji = (5/6)

βji = 1

Figure 2.5: Gibbs free energy for electron transfer as a function of dielectric distance. Values
of Gibbs free energy were determined across membrane potential differences seen in typical
action potentials using a dielectric distance of 30 Å.
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In designing an ideal electron transfer-based GEVI, this favorability should
switch directions, meaning that at a typical resting membrane potential, the
favorable direction of electron transfer should be from heme i to heme j, and by
peak action potential, this direction should switch, where the favorability goes from
heme j to heme i. This “Goldilocks Zone” exists for each dielectric distance, βji.
Figure 6 depicts how the rate of the Gibbs free energy of electron transfer
increases over a typical membrane potential change as the dielectric distance
increases at varying midpoint potential differences. As the dielectric distance
increases, the rate of Gibbs free energy of electron transfer increases uniformly.
As the dielectric distance increases between hemes, the Goldilocks Zone for ideal
Gibbs free energy change also increases.

Figure 2.6: Gibbs free energy change as a function of dielectric distance and midpoint potential
difference between two hemes. The rate of change in Gibbs free energy increases as dielectric
distance is increased. A wider favorable zone for electron transfer exists due to this.
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For an antiparallel maquette whose hemes are separated by 11 Å, heme 1
and heme 2 would have a dielectric distance separation of 5 Å, and heme 2 and 3
would have a dielectric distance separation of 20 Å. At 5 Å, an ideal difference of
midpoint potential between heme 1 and 2 would be {-6.66,10} mV to observe a
favorable change of Gibbs free energy of electron transfer. As this distance
increases to the full dielectric distance, this Goldilocks Zone would be a difference
in midpoint potential in the range of {-60,40} mV. While the Gibbs free energy does
increase as the dielectric distance increases, however, the rate at which electron
transfer would occur diminishes.
Biological electron transfer rates within maquettes can be determined by
using the Moser-Dutton Ruler, described earlier in Section 2.2. For these
equations, the reorganization energy, λ, is set to 0.7. Initial calculations use an
edge-to-edge distance between each heme cofactor of 11 Å, due to the bis-His
ligation sites each being 14 amino acids apart. Using the Gibbs free energy of
electron transfer determined previously, the electron transfer rates between heme
1 and 2 and heme 2 and 3 all are on the microsecond timescale at resting
membrane potential and at the peak of an action potential, as shown in Figure 2.7.
Electron tunneling occurs the fastest in both directions when the donor heme has
a lower midpoint potential than the acceptor heme. As electron tunneling rates are
not greatly affected by the direction of the electric field, this further suggests the
importance of poising the midpoint potentials of the heme in order for favorable
electron transfer to occur.
42

40 mV

Hemes 2 and 3

Hemes 1 and 2

-60 mV

Figure 2.7: Electron tunneling speeds for two heme cofactors separated by 11 Å at resting
membrane potential and peak action potential. Using heme midpoint potential values from -200
mV to -100 mV, electron tunneling rates occur on the microsecond timescale. 10 mV increments
of heme midpoint potential values were displayed for better visual contrast.

While increasing the distance between cofactors also effects favorability of
electron transfer, electron tunneling rates decrease, as seen in Figure 2.8. As R
approaches 14 Å and 15 Å, electron tunneling occurs on the sub-millisecond and
millisecond timescale, which is comparable to current GEVIs152–156. Edge-to-edge
distances less than 13 Å, which is feasible in maquette designs, would provide fast
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temporal resolution for sensing electrical events within the membrane seen in
voltage-sensitive dyes.
12 Å

13 Å

14 Å

15 Å

kET12

kET23

ET12

ET23

Figure 2.8: (Top Two Rows) Electron tunneling rates for hemes separated by 12-15 Å. (Bottom
Two Rows) Electron tunneling speeds for hemes separated by 12-15 Å. Once hemes are
separated by a distance greater than 13 Å, electron tunneling speeds approach millisecond
timescales in sensing. 10 mV increments of heme midpoint values were displayed for better
visual contrast.

2.5 Approximate Electron Transfer Rates for Voltage Sensing
In the previous section, electron transfer rates on the microsecond
timescale can be achieved through careful positioning and midpoint potentials of
heme cofactors within a maquette. An ideal heme-based maquette voltage sensor,
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when equilibrated with the cell, would have one electron within the system that
would tunnel from heme 3 to heme 1 as a membrane depolarized. However, in a
population of maquettes, the actual distribution of heme redox states would vary,
which could lead to some maquettes having all or no heme cofactors occupied by
an electron. This probability highly depends on the initial midpoint potential of the
hemes and the magnitude and direction of the electric field. Due the presence of
the electric field, redox-sensitive cofactors, such as a heme, experience a redox
shift in their midpoint potential, Em142. To determine the probable redox state of a
heme in an electric field within a membrane, the Nernst equation:
#

𝐸! = 𝐸" + (0.059𝑉)𝑙𝑜𝑔 # !"

Eqn. 2.14

#$%

can be rewritten in terms of the fraction of reduced species:
Eqn. 2.15.
The redox potential shift experienced by a heme can be written as:
Eqn. 2.16
where d represents the width of the membrane and r represents the dielectric
distance at which the heme is located, where the origin point is the extracellular
edge of the membrane. r/d is similar to Equation 2.11, but rather than the fraction
of the insulating phase between two hemes, it represents the fraction of the
insulating phase between a heme and the extracellular edge of the membrane.
This means that hemes furthest away from the extracellular face of the membrane
experience the greatest shift in their redox potential due to the electric field.
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Additionally, it is to be noted that in these calculations, heme cofactors are
considered point masses at their center. Introducing the redox potential shift into
Equation 2.16, the fraction of reduced heme in a population in the presence of an
electric field can be rewritten as:
Eqn. 2.17.
In Figure 2.9, three hemes with a ΔEm of 0 mV across a membrane with no electric
field all continue to have the same effective midpoint potential. At a resting
membrane potential of -60 mV, the effective midpoint potential of hemes across a
membrane becomes more negative. During the depolarization of a membrane, the
effective midpoint of hemes across a membrane is raised. With the assumptions
listed earlier, in both scenarios, the heme furthest from the extracellular membrane
edge feels the perturbation caused by the electric field the most. A maquette
voltage sensor with three embedded hemes placed 11 Å, edge-to-edge, from each
other are affected by the membrane potential differently. Heme 1 experiences the

Figure 2.9: (Left) In the absence of an electric field, three hemes with identical midpoint
potentials experience no shift in midpoint potential. (Middle) At resting membrane potential, the
electric field induces a negative shift in the midpoint potential that is dependent on distance from
the extracellular surface. (Right) At peak action potential, the electric field causes an increase
in the effective midpoint potential.
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full electric-field induced redox shift in its redox potential, since its center is
positioned on the intracellular side of the membrane. The center of heme 2 is
located 25 Å from the extracellular surface of the membrane, and the center of
heme 3 is located 5 Å from the extracellular surface. Figure 2.10A shows contour
plots of how the initial midpoint potential of each heme affects its probability of
being reduced across membrane potentials seen in a typical action potential,
where the considered heme midpoint potential range is from -300 mV to 100 mV.
At resting membrane potential, heme 3 has the highest propensity of being
reduced across this redox potential range and heme 1 has the lowest propensity
for being reduced. Figure 2.10B further shows more generally how the depth of a
heme within a dielectric affects the probability a heme cofactor will be reduced
A

Heme 1

Heme 2

Heme 3

B

Figure 2.10: (A) As hemes are placed at various depths within a dielectric, the probability of a
heme being reduced at resting membrane potential changes. (B) The probability of being a
heme being reduced at resting membrane potential and peak action potential changes based
on the depth within the membrane dielectric.
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during changes in membrane potential. Additionally, it indicates that hemes with
midpoint potentials around -200 mV show the greatest change in redox state,
regardless of dielectric distance.
Heme midpoint potential values seen in natural and designed heme-binding
proteins can be used to see how the electron occupancy of each heme changes
during a typical action potential, where the resting membrane potential is -60 mV
and the peak of the action potential is 40 mV. Protein 2 in Goparaju et al, also
referred to as AM1 (Amphiphilic Maquette 1), bound three heme b cofactors at bisHis ligation sites, where heme 1 and heme 2 are 12 amino acids apart and heme
2 and 3 are 14 amino acids away from each other107. The inter-heme distance
between each heme is approximately 10-11 Å. The midpoint potentials of these
hemes were reported as: -203 mV, -38 mV, and -150 mV (heme 1, heme 2, heme
3, respectively). At resting membrane potential, the fraction of each heme,
respectively, that are reduced are 0.15, 0.99, and 0.91, meaning that averaging
across the population of maquettes, there are 2.04 electrons per maquette. By
using simple independent probability calculations, the number of heme sites
occupied can be determined at resting membrane potential: 8.36% of AM1 would
have one reduced heme, 78% would have two reduced hemes, 13.56% would
have all three hemes reduced, and less than one percent would have no hemes
reduced at resting membrane potential. This means that ~13.7% of AM1 would be
electrically silent or unresponsive to a changing electric field. As peak action
potential is approached, the normalized electron occupancy for each heme is:
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0.64, 0.71, and 0.68, respectively. This supports previous calculations; heme 1
experiences the greatest change in redox state, both due to its dielectric distance
and midpoint potential. Using the Moser-Dutton Ruler, electron transfer between
the hemes occur on the microsecond timescale. AM1 is currently the only threeheme

maquette

whose

midpoint potentials have
been
natural
Figure 2.11: At resting membrane potential, a heterogeneity
in heme redox states exist. Fine tuning of heme midpoint
potentials can aid in resolving this heterogeneity.

determined,

but

cytochrome

proteins offer an insight to
the

possible

redox

potentials that can be seen in a designed heme-binding transmembrane protein.
The midpoint potential range of transmembrane heme-binding proteins is
much greater than those seen in designed proteins. Cytochrome b6, a
transmembrane protein domain of the cytochrome b6f complex, contains two
hemes that are located within the membrane, heme bH and heme bL, whose
respective midpoint potential values are -68 mV and -187 mV, as reported in
Tome-Stangl et al157. The reaction center maquette designed by Nathan Ennist,
known as MZH3, also contains a heme, whose midpoint potential was reported to
be -190 mV118. To form a three-heme transmembrane maquette voltage sensor,
the region of MZH3 that contains the heme-binding site can be stitched onto the
cytochrome b6 protein. Once again, using their respective midpoint potentials (180 mV, -68 mV, -187 mV), the fraction of hemes 1, 2, and 3 being reduced at
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resting membrane potential is 0.31, 0.97, and 0.71. On average, this would mean
there are 1.99 electrons per maquette, and through independent probabilities, the
total electron occupancy at resting membrane potential of a population of
maquettes can be determined: 0.6% of the MZH3-b6 hybrid would have 0 reduced
hemes, 21.1% would have 1 reduced heme, 56.9% would have two reduced
hemes, and 21.3 % would have all hemes reduced. This would mean that ~22%
of a protein with these midpoint potentials would be unresponsive to a changing
electric field. At the peak of an action potential, the population of reduced hemes
change: .69 for heme 1, .71 for heme 2, and .59 for heme 3. Once again, heme 1
exhibits the greatest change in redox state during the course of an action potential,
and electron tunneling kinetics remain in the microsecond timescale.
For both constructs (Table 2.1), heme 1 demonstrated the largest change
in redox state from resting membrane potential to the peak of an action potential;
however, heme 2 and heme 3 had higher probabilities of being reduced at resting
membrane potential. For an ideal maquette-based voltage sensor, the construct
should be optimized so that heme 3 has the highest probability of being reduced
at resting membrane potential and heme 1 has the highest probability of being
reduced at peak action potential, where the largest percentage of the population
of maquette sensors have one reduced heme at resting membrane potential.
Heme midpoint potentials can be tuned via amino acid mutations. In Pintscher et
al., the heme binding sites in the cytochrome bc1 protein was modified by mutating
histidines into lysines, which induced an increase in the midpoint potential without
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loss of protein function158. In a minimal, glycophorin A-inspired transmembrane
heme-binding protein, a 50 mV midpoint change occurs by mutating a glycine to a
phenylalanine159. Through random mutagenesis at three interfacial amino acids in
a heme binding site, Christopher Moser has shown that a distribution of midpoint
potentials is possible in heme-binding maquettes [unpublished work]. These
observed changes indicate that the potentials seen can be tuned in the future to
facilitate better voltage sensing.

Heme midpoint
potentials

Fraction reduced at
RMP and peak AP

-60 mV
fred1 = 0.15
fred2 = 0.99
fred3 = 0.91

AM1

MZH3-b6

Em1 = -203 mV
Em2 = -38 mV
Em3 = -150 mV

Em1 = -180 mV
Em2 = -68 mV
Em3 = -187 mV

40 mV
fred1 = 0.90
fred2 = 0.99
fred3 = 0.95

Normalized
fred1 = 0.64
fred2 = 0.71
fred3 = 0.68

-60 mV
fred1 = 0.31
fred2 = 0.97
fred3 = 0.71

40 mV
fred1 = 0.96
fred2 = 0.99
fred3 = 0.82

Electrons per maquette

2.04

1.99

p(0 electrons)
p(1 electron)
p(2 electrons)
p(3 electrons)

<1%
8.36%
78%
13.56%

0.6%
21.1%
56.9%
21.3%

Normalized
fred1 = 0.69
fred2 = 0.71
fred3 = 0.59

Table 2.1: Initial redox states for heme-binding constructs based on midpoint potential

2.6 Discussion and Future Directions
The calculations performed in this chapter provide an initial framework for
understanding the kinetics of a de novo designed electron-transfer based voltage
sensor based on electron transfer theory. The voltage-sensing domain of current
GEVIs undergo structural rearrangements during membrane potential events. The
S4 helix in ion channel- and voltage-sensitive phosphatase-based GEVIs rotates
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towards the extracellular side of the membrane during depolarization due to
positively charged residues, such as lysine and arginine, with kinetics on the
millisecond timescale, with the ASAP family being the fastest voltage-sensitive
phosphatase GEVIs76,160. Microbial rhodopsin-based GEVIs have kinetics
observed on the submillisecond timescale, where voltage-sensing is carried out by
the bound retinal within the core of the protein82. By using empirically derived
equations seen in biological electron transfer, electron transfer between a chain of
voltage-sensitive hemes within a transmembrane protein, poised and tuned to
proper redox potentials, would have the ability to detect membrane potential
changes on the microsecond timescale. The microsecond temporal resolution
makes it comparable to rates seen in voltage-sensitive dyes. The direction of
electron tunneling would match the change in electric field during membrane
events, similar to how VoltageFluor dyes function, where depolarization
suppresses electron transfer from an electron-rich aniline group56. Whereas in
these dyes, electron transfer is suppressed towards the extracellular membrane,
the direction of electron movement changes during membrane depolarization.
The proposed voltage-sensing mechanism is reliant on a chain of three
hemes spaced across the membrane. A designed diheme membrane protein,
similar to natural membrane cytochrome proteins, could also sense electrical
events in the membrane, but a three heme chain is more advantageous. Three
hemes allow for sensing to occur over the width of the dielectric, whereas electric
field-sensing by two hemes is limited by edge-to-edge distance. In the design
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discussed in this chapter, the edge-to-edge distance between hemes is 11 Å,
where electron tunneling rate is on the microsecond timescale. For two hemes to
span the same fraction of the dielectric, the electron tunneling rate would increase
by orders of magnitude102. Additionally, natural electron-transfer capable proteins
tend to achieve efficient electron transfer using more cofactors spaced closer
together, which implies a de novo designed GEVI would be most sensitive and
efficient with more cofactors.
Transmembrane proteins with characterized heme midpoint potentials allow
for preliminary understanding of kinetics and initial electron occupancies prior to
any additional tuning. The electron transfer in cytochrome b6 is involved in
photosynthesis, and AM1 was designed to better understand the bioenergetics of
transmembrane proteins in photosynthesis. In this theoretical layout, both proteins
are capable of electron transfer rates on the microsecond timescale during a
membrane potential change, which matches kinetics seen in photosynthetic
electron transfer. For both constructs, the membrane hemes tend to have higher
midpoint potentials than the heme in the water-soluble caps, increasing the
probability of being reduced at neuronal resting membrane potentials, which
results in a higher population of three-heme transmembrane proteins having two
hemes reduced at resting membrane potential than just one. The lower midpoint
potential seen in heme 1 creates a greater change in redox state over a population,
meaning that a voltage reporting mechanism would be most effective by tracking
the change in redox state of heme 1. GEVIs often use fluorescent proteins to report
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conformational changes or protonation changes due to a voltage event148,152;
determining the fluorescent reporter for a heme-based GEVI will be the focus of
Chapter 3.
Biologically functional voltage gradients are not limited to just neurons; their
role is critical in various membranes in stem cells, skeletal muscle cells, plant cells,
and mitochondria147,161. Membrane potentials in typical neurons can range from –
70 mV to 40 mV during an action potential. Other cell types that are not as
proliferative, such as skeletal muscle cells and fat cells, also have more
hyperpolarized membrane potentials162,163. Cells with higher proliferation rates,
such as embryonic and adult stem cells and cancer cells, tend to have depolarized
resting membrane potentials (between -30 mV to 0 mV). Various developmental
studies have shown the importance of bioelectric activity in these proliferative cell
types164–166. While current GEVIs are focused on neuronal activity, GEVIs that
exploit redox-based electron transfer could allow for a less invasive approach for
studying the bioelectrical events seen in cells across the various biological
kingdoms of life. Heme cofactors experience a midpoint potentials from -400 mV
to 400 mV, suggesting they can be used for a wide range of redox-potential
sensing167. Earlier, Figure 2.5 shows that Gibbs free energy associated with
electron transfer with heme cofactor midpoint potentials in the range of -200 mV to
-100 mV. By tuning the midpoint potential of the membrane-bound hemes to higher
potentials158, heme-based GEVIs could allow for sensing in the more depolarized
membrane potentials seen in proliferative cells.
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The model introduced in this chapter can be further refined by incorporating
the changes in the electrostatic profile due to the electrical double layer caused by
polarizations of water molecules and the ionic Guoy-Chapman cloud, since these
perturbations can slightly modulate the potential differences across the dielectric
region. However, in the arguments presented earlier, a more sophisticated model
would not be expected to modify the kinetics of electron transfer, greatly. However,
since the nature of the profile is still being developed, in vitro biophysical
characterization of designed constructs would provide an understanding of kinetics
of electron transfer between hemes.
Furthermore, the theoretical calculations presented in this chapter could be
used for any such cofactor that is capable of electron transfer. In addition to heme
molecules, flavin molecules, quinones, nicotinamides, and iron-sulfur clusters all
play role in electron transport redox reactions. Electron transfer in maquettes
containing these redox-active molecules been characterized, which further
increases the viable options for potential voltage-sensitive cofactors in a de novo
designed GEVI.
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Chapter 3: Fluorescent Reporting of Heme Redox State
by Water-Soluble Maquette-Based GEVI Prototypes

“The organism is capable of performing highly specific chemical transformations
which can never be accomplished with customary agents. To equal Nature here,
the same means have to be applied, and I therefore foresee the day when
physiological chemistry will not only make extensive use of the natural enzymes
as agents, but when it will also prepare synthetic ferments for its purposes.”
–Emil Fischer

3.1 Introduction
The goal of this thesis is to construct a functional de novo designed
genetically encoded voltage indicator (GEVI). In Chapter 2, a GEVI which can
sense changes in membrane potential using a chain of redox-poised heme
cofactors was developed based on theories of electron transfer. Although oxidized
and reduced heme produce different absorption spectra, changes in fluorescence
are more detectable in vivo and extensively used in GEVIs to report changes in
membrane potential. In this chapter, water-soluble GEVI prototypes were
engineered by creating fusion constructs of MZH3, a reaction center maquette
designed by Nathan Ennist, and various fluorescent proteins in order to determine
if fluorescent proteins can detect changes in the redox state of heme. The final
portion of the chapter repurposes these proof of principle maquettes as new
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genetically encoded redox indicators (GERIs), named FJORDs (Fluorescent
Jawns of Redox Dynamics).

3.2 Fluorescent proteins for heme redox state indicating
GEVIs depend on spectral changes in a fluorescent cofactor or fluorescent
protein to report changes in membrane potential. GEVIs which report changes in
membrane potential using fluorescent proteins often use Förster Resonance
Energy Transfer (FRET) as a mechanism for voltage-sensing13. In Figures 1.4 and
1.5, the geometries of these GEVIs either include two fluorescent proteins or a
fluorescent protein and a fluorescent cofactor, where a depolarization event alters
either the distance, orientation, or spectra of the fluorophores, which in turn
modulates the FRET efficiency between the fluorophores.
In order to develop a functional de novo designed GEVI, there must be a

Normalized Absorbance

sensing and reporting component. Described in Chapter 2, electron transfer
1.0

Oxidized Heme

between hemes within a

Reduced Heme

maquette-based

GEVI

can be initiated during a

0.5

change in the magnitude
of the membrane electric
0.0
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Figure 3.1: Absorbance spectra of heme at oxidized and
reduced states. The Soret band experiences a redshift and the
Q-bands increase upon reduction.
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field across the maquette.
While the absorbance of
each heme cofactor is

dependent on its redox state, shown in Figure 3.1, detecting these absorbance
changes in vivo would be fruitless, as the total number of reduced and oxidized
hemes do not change during an action potential. Since heme molecules do not
fluoresce, detecting the change in redox state by creating a FRET pair with a heme
cofactor and a fluorescent protein would allow for fluorescence reporting of the
change in redox state, which in turn would report fluctuations in the membrane
electric field.
The first fluorescent protein, GFP, revolutionized imaging in the field of
biology168. Since its isolation, the fluorescent protein toolbox has grown rapidly in
order to respond to the imaging needs of biologists. Through directed evolution,
the emission spectra of fluorescent proteins have expanded to encompass the
entire visual spectrum and have extended into the near-infrared region, allowing
for greater choice in realizing FRET partners129,169,170. Oxidized heme b in various
Ligation
Pattern

Natural Protein

Abs Peaks (nm)

Abs Peaks
Maquette (nm)

His | His

Neuroglobin

413, 529 (ox)
426, 560 (red)

415, 529 (ox)
430, 560 (red)

-260 to -150

His | Cys

Rr-CooA,
Cystathionine b-synthase

360, 424, 535
422, 540, 570

360, 424, 535
421, 540, 570

-290 to -150

His | Met

b562
Cytochrome c

406, 534
430, 562

409, 529
429, 562

70

His | Tyr

Bovine liver catalase

406, 534, 620
436, 558

407, 530, 615
427, 558

-180

His | Lys

Cytochrome f

412
421, 554

414
427, 532, 560

-65

His | Ala

Myoglobin

409, 505, 635
435, 555

416, 531
428, 530, 562

-110

Cys |Ala

P450
NOS

391, 635
410, 551

387, 635
430, 555

-190

Em (mV)

Table 3.1: Spectroscopic and redox properties of heme-binding maquettes.
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maquettes, as shown in Table 3.1, show a strong Soret peak around 412-415 nm.
When reduced, this band redshifts to about 427-430 nm. Additionally, when heme
b enters its reduced state, the Q-band region sees an increase at 564 nm. Three
fluorescent proteins initially show promise as FRET partners with heme b:
mOrange2, Sirius, and mTFP1. mOrange2 is the photostable derivative of
mOrange and serves as a fluorescent reporter for several GEVIs86,129. mOrange2
has a maximum emission wavelength at 565 nm with a molar extinction coefficient
of 58,000 M-1 cm-1, which overlaps with the Q-band spectral region of heme b;
when heme b is reduced, the fluorescence of mOrange2 is expected to be
quenched via FRET.
Sirius is an ultramarine fluorescent protein with a maximum emission at 424
nm with a molar extinction coefficient of 15,000 M-1 cm-1, situated between the

Figure 3.2: Heme absorbance spectra with emission spectra of fluorescent proteins. (Left)
Absorbance of reduced heme has a greater spectral overlap than oxidized heme with
mOrange2. Reduction will cause a decrease in the fluorescence of mOrange2. (Middle) The
redshift of the Soret peak will cause an increase in fluorescence of Sirius at 415 nm and a
decrease in fluorescence at 430 nm. (Right) mTFP1 should undergo an increase in fluorescence
as heme is reduced.
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oxidized and reduced Soret peaks of heme b171. This allows Sirius the opportunity
to report the change in heme redox state at two wavelengths: when heme enters
its reduced state, the fluorescence at 415 nm should increase as the fluorescence
at 430 nm decreases. Another candidate fluorescent protein is mTFP1, a teal
fluorescent protein128. Its emission maximum is at 492 nm with a molar extinction
coefficient of 64,000 M-1 cm-1, and as heme reduces, the spectral overlap between
mTFP1 and heme b also decreases, meaning that the fluorescence of mTFP is
expected to increase.
Before attaching these fluorescent proteins to a transmembrane maquette,
initial experiments were carried out with water-soluble maquettes to validate that a
change in heme redox state could modulate the
fluorescence of the attached fluorescent proteins. A
working water-soluble GEVI prototype could then be
redesigned into a fully realized maquette-based GEVI.
Many previous maquettes have been designed to bind
heme; however, the majority of these maquettes have
two binding sites for heme. The reaction center
maquette, MZH3, has a well characterized heme
Figure 3.3: Crystal structure
of MZH3. MZH3 is designed
with a heme binding site at its
NC terminal cap, which could
allow for a fluorescent protein
to be attached at the Nterminus, C-terminus, or the
loop between helices 2 and
3.

binding site close to its N- and C-termini (Figure
3.3)118. Due to its length, MZH3 can be redesigned into
a transmembrane maquette with three heme binding
sites, capable of sensing a change in the membrane
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electric field. Thus, MZH3 was a perfect candidate maquette for determining if
heme redox state can modulate the fluorescence of an attached fluorescent
protein.
It should be noted that since the heme binding site in MZH3 is located at
the N- and C-terminal cap, a fluorescent protein could be attached at three
positions: the N-terminus, the C-terminus, and within the second loop. While these
different geometries could be explored, attachment at the C-terminus was chosen
as the standard attachment point for minimal threading across the membrane once
the water-soluble prototypes were redesigned into transmembrane proteins.
Additionally, all prototypes contain the P3G mutation in the MZH3 scaffold, which
was done in order to improve the TEV protease cleavage process.

3.3 mOrange2 as a reporter for heme redox state
3.3.1 Indication of redox state sensing of mOrange2
Purified MZH3-mOrange2 shows an absorbance peak at 415 nm, indicating
that MZH3-mOrange2 is able to bind heme in E. coli (Fig. 3.4). Heme titrations
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Figure 3.4: (Left) Heme titration of MZH3-mOrange2. SVD analysis shows kD < 10 nM. (Right)
Absorption spectra of MZH3-mOrange2 after purification shows MZH3-mOrange2 binds heme
in E. coli.
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performed on MZH3-mOrange2 indicate a tight heme binding site with a kD < 10
nM, which is in agreement with the previously measured kD for MZH3118. UV-Vis
absorption spectra of the completely heme-bound MZH3-mOrange2 show a
defined Soret peak at 415 nm. Due to the presence of mOrange2, there are two
additional peaks at 498 and 549 nm, with the latter overlapping with the Q band
region of heme b. Fluorescence emission spectra reveal a maximum emission at
562 nm when mOrange2 is attached at 541 nm excitation.
Initial in vitro experiments were carried out to investigate whether the
fluorescence of MZH3-mOrange2 could be quenched when reduced with sodium
dithionite, a strong reducing agent (Figure 3.5). Molar equivalents of sodium
dithionite produced a ∆F/F of -15.3% with a 95% CI [-18.48,-12.24] in MZH3MZH3-mOrange2 Emission
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Figure 3.5: (Left) Absorbance and emission spectra of MZH3-mOrange3 upon reduction via
sodium dithionite and oxidation via potassium ferricyanide. Blue spectra indicate oxidized
protein, red spectra indicate reduced protein, and yellow spectra indicate reoxidized protein.
(Middle) Sodium dithionite additions do not alter the fluorescence spectra of mOrange2. (Right)
Statistics of trials of dithionite reductions for MZH3-mOrange2. Mean with 95% CI shown.
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mOrange2. The Soret peak of MZH3-mOrange2 redshifts to 430 nm, and the
mOrange2 absorbance/Q-band region has an increase in its absorbance at 557559 nm. Oxidation via exposure to oxygen or addition of potassium ferricyanide
recovered the fluorescence. Sodium dithionite added to a sample of mOrange2
without the maquette revealed a minimal change in fluorescence, implying that a
change in heme redox state can modulate the fluorescence of an attached
fluorescent protein.

3.3.2 Heme midpoint potential determination using spectroelectrochemistry
Redox titrations were performed to determine whether the change in the
fluorescence of mOrange2 could be used to calculate the midpoint potential of the
heme b of MZH3. Using a customized spectrofluoroelectrochemical setup (Figure
A1.3), the fluorescence of MZH3-mOrange2 was monitored as the heme was
reduced. Changes in the fluorescence of MZH3-mOrange2 were fitted to the
Nernst equation for one electron:
𝐸! = 𝐸" +

$.$&'
(

log

[*+]

Eqn. 3.1

[-./]

where Eh is the solution redox potential vs. standard hydrogen electrode, Em is the
midpoint potential of the heme, and [ox]/[red] is the ratio of concentrations of
oxidized to reduced heme. The reducing curves for MZH3-mOrange2 were fitted
with Em = -204 mV vs. SHE, which compares with the midpoint potential of the
heme b previously reported as -190 mV (Figure 3.6).

The ∆F/F of MZH3-

mOrange2 was much larger in the redox titration, measured to be -86%. However,
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the oxidative recovery of the probe’s fluorescence occurs on longer timescales
than the reductive quenching. A control redox titration performed on mOrange2
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Figure 3.6: Spectrofluoroelectrochemical redox titrations. (Top left) Fluorescence of MZH3mOrange2 collected at different redox potentials vs SHE, with excitation at 541 nm. (Top right)
Fitting the change in fluorescence to a Nernst equation for n = 1 electron yields a heme midpoint
potential of -204 mV, which is in range for the midpoint potential previously reported for MZH3
alone. (Bottom) No fluorescence changes are seen in mOrange2 under similar conditions.

3.3.3 Reversibility of mOrange2 fluorescence using chronoamperometry
To determine whether the fluorescence of MZH3-mOrange2 can be
reversible over several cycles, and to better test the kinetics of the fluorescent
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quenching and recovery of the construct, a chronoamperometry approach was
used, seen in Figure 3.7. The fluorescence of MZH3-mOrange2 was collected as
the redox potential oscillated from 0 mV to -500 mV vs. SHE with a period of 400
seconds, with a precedent 300 second quiet period with a potential held at -250
mV vs. SHE. Upon a series of reduction-oxidation cycles electrochemically applied
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Figure 3.7: Chronoamperometry data collected on MZH3-mOrange2 and mOrange2. (Top left)
Fluorescence of MZH3-mOrange2 was collected as a redox potential was changed from 0 mV
to -500 mV over time. (Top right) The relative change in fluorescence in each reduction and
oxidation step was collected across four trials. Mean and 95% CI are shown. (Bottom)
Chronoamperometry performed on mOrange2 shows no dependence of fluorescence changes
on redox potential.
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for the reductive steps and ∆F/F of 20.1% with a 95% CI [17.7,22.5] for the
oxidative steps (n=4 trials, 38 cycles). The time constant for reduction steps
averaged out to be 0.015 s-1 and the time constant for oxidation was 0.011 s-1.
Chronoamperometry performed on mOrange2 shows no modulation of the
fluorescence in response to an oscillating potential.

3.3.4 Spectroscopic and electrochemical characteristics due to heme ligation site
changes
While MZH3 was originally designed with a bis-His heme ligation site,
natural hemoproteins contain numerous ligation partners. Cytochrome c and the
peroxidase N-acetylmicroperoxidase-8 (AcMet) employ His-Met ligation, while
cystathionine b-synthase ligates heme with a His-Cys pair. As shown in Table 3.1,
mutations to the heme binding site in maquettes can alter the spectral and redox
properties of the protein. Since the changes in fluorescence of mOrange2 during
a redox titration can be used to determine the midpoint potential of the bis-His
ligated heme b in MZH3, it was hypothesized that mOrange2 could report different
midpoint potential values when the heme binding site was altered.
According to Table 3.1, a previous maquette with a His-Met binding site had
a reported midpoint potential of 70 mV. A His-Met MZH3-mOrange2 was chosen
in order to increase the midpoint potential of the ligated heme b, where the histidine
on the third helix of MZH3, H110, was altered to a methionine. Unlike wild type
MZH3-mOrange2, H110M was not found to bind heme in E. coli. UV-Vis of
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ApoMZH3-mOrange2 H110M shows three broad peaks at 384 nm, 509 nm, and
548 nm. Completely bound MZH3-mOrange2 H110M shows a strong Soret peak
at 409 nm, as seen in Figure 3.8.
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Figure 3.8: (Left) Heme titration of H110M. (Right) Absorbance spectra of H110M shows no in
vivo binding of heme occurs in E. coli. A shift in the Soret band is seen upon reduction.

Addition of sodium dithionite shows a ∆F/F of -35.6% at 562 nm. Reduced
MZH3-mOrange2 H110M shows a Soret peak at 428 nm. Chronoamperometry
performed on MZH3-mOrange2 H110M shows a ∆F/F of -17.3% with a 95% CI [21.3,-13.2] in the reductive direction and a ∆F/F of 19.5% with a 95% CI [16.0,23]
in the oxidative direction (Figure 3.9). A spectroelectrochemical redox titration of
the H110M variant was performed using a spectroelectrochemical honeycomb cell
(Pine Research Instrumentation). Using SVD analysis and fitting to a Nernst
equation, the midpoint potential of the H110M variant in the reductive direction was
-124 mV and -134 mV in the oxidative direction. However, past redox titrations
performed on MZH3 H110M has exhibited hysteresis and possible loss or
degradation of the heme cofactor118. Additionally, the fluorescence of mOrange2
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Figure 3.9: Spectrofluoroelectrochemistry performed on H110M. (Top) Reductive and oxidative
spectroelectrochemical titrations performed on H110M. Direction of titration is from red curve to
to violet curve. (Middle) Data were analyzed using SVD analysis. Left shows that the ferrous
minus ferric heme redox difference spectrum was the main component of SVD analysis. Right
shows an n=1 Nernst curve (blue) fitted to the SVD component 1 population (green points).
(Botttom) Chronoamperometry performed on H110M shows a decrease in fluorescence in
reduction steps and an increase in fluorescence in oxidizing steps.

increases in the reductive direction and decreases in the oxidative direction, which
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is in disagreement with the chronoamperometry trace.
A fluorescence heme titration of MZH3-mOrange2 H110M confirms that
substoichiometric additions of heme quenches the fluorescence of mOrange2,
since oxidized heme shares a spectral overlap with mOrange2 emission (Figure
Emission at 560 nm

Emission

3.10).

4000000

4000000
3000000

If

heme

were

displaced

or

3500000

degraded during the redox titration, this

3000000

2500000
0

2000000

200

400

600

800

[Heme] (nM)

1000000

could

explain

the

increase

in

fluorescence seen in the reductive

0
550

600

650

700

Wavelength (nm)

Figure 3.10: Fluorescence heme titration
performed
on
H110M
shows
substoichiometric additions of heme quench
the fluorescence of mOrange2. Similar
results were seen in H110.

direction.

The

introduction

of

the

methionine residue as a ligand could
affect the heme binding, where H110M
binding could display weaker binding to

ferrous heme over ferric heme. However, methionine ligands have been shown to
have increased affinity for ferrous heme over ferric heme in cytochrome c and
AcMet172–174, which is due to the high polarizability of sulfur, where thioether sulfur
atoms have low affinity for hard acids and good affinity for soft metal ions175,176.
The ferric ion is considered a hard Lewis acid whereas the ferrous ion is considered
softer.
Two additional mutants were then cloned: H110K and H110C. His-Lys
ligation is seen in cytochrome f, whereas His-Cys ligation can be seen in P450.
H110K was chosen to see the effect of a longer, charged amino residue on MZH3
heme binding. H110C was chosen, since the presence of the thiol group could
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have a comparable effect to that of the thioether sulfur. Similar to H110M, these
variants do not bind heme in E. coli. A shift in the Soret peak from 412 nm to 427
nm occurs upon reduction of MZH3-mOrange2 H110K, along with a broadening of
the Q-band region from 549 nm to 555 nm. Upon reduction, a ∆F/F of -25.5% is
seen at 561 nm. MZH3-mOrange2 H110C exhibits a broad Soret peak upon heme
binding spanning from 410 nm to 428 nm. The broad Soret could be indicative of
a heterogeneous heme-binding conformation or ligation geometry. Reduction of
H110C causes a shift in the Soret peak to 429 nm with a minimal change in the Qband region, resulting in a negligible change in the emission spectra.
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Figure 3.11: Spectroelectrochemical redox titrations performed on H110K. (Top) Reductive and
oxidative redox titrations. Direction is from red curve to violet curve. (Bottom) The primary
component of SVD analysis was the heme redox difference spectrum. An n=1 Nernst curve
(blue line) fitted to the SVD component 1 population (green).
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Figure 3.12: Spectroelectrochemical redox titrations performed on H110C. (Top) Reductive and
oxidative redox titrations. Direction is from red curve to violet curve. (Bottom) The primary
component of SVD analysis was the heme redox difference spectrum. An n=1 Nernst curve
(blue line) fitted to the SVD component 1 population (green).

Spectroelectrochemical redox titrations performed on H110K and H110C
reveal midpoint potentials of -16 ± 9 mV and -170 mV ± 5 mV relative to SHE,
respectively (Figs. 3.11 and 3.12).

The measured midpoint potential of H9K

without mOrange2 was measured to be -65 mV. The increase in midpoint potential
due to the addition of the lysine residue could be due to the lysine interacting with
the heme propionate groups. Pintscher et al. also observed a raise in midpoint
potential through His-Lys mutations158. Chronoamperometry confirms these
mutants are able to show reversible changes in mOrange2 fluorescence as heme
redox state changes, and fluorescent changes are comparable to those seen in
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the wild type and H110M variants in chronoamperometry experiments. The
reductive direction for H110C showed a ∆F/F of -15.4% with a 95% CI [-20.0,-10.8]
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and the oxidative direction showed a ∆F/F of 18.3% with a 95% CI [12.2,24.3].
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Figure 3.13: (Top) Spectrofluoroelectrochemical redox titration performed on H110M reveals
an increase in fluorescence of the mOrange2. (Bottom) Spectrofluoroelectrochemical redox
titration on H110C shows a similar increase in fluorescence as H110M.

Additionally, a spectrofluoroelectrochemical redox titration on H110C in the
reductive direction causes an increase of the fluorescence of mOrange2, similar
to H110M, seen in Figure 3.13. This could be due to heme loss, degradation, or
the thiolate and thioether sulfur participating in a charge transfer with the heme177.
Natural hemoproteins are known to bind to carbon monoxide with various
heme ligation partners. Hemoglobin functions as an oxygen carrier in mammals,
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Figure 3.14: (Left) Chronoamperometry performed on H110C shows fluorescent signal
changes in response to an oscillating potential. (Right) Reductive steps show a decrease in
fluorescence and oxidative steps show an increase in fluorescence. Mean with 95% CI is shown.

yet binds to carbon monoxide more tightly, which can lead to oxygen deprivation
and eventual death178. Previous hemomaquettes that bind CO report a change in
both the Soret peak and the Q-band region of the absorption spectra116. To
determine if the carboxy state can quench the fluorescence via FRET, wild type,
H110M, H110K, and H110C were reduced with sodium dithionite, followed by
mixing with CO gas (Figure 3.15). Quenching of mOrange2 fluorescence is
increased for all variants in their carboxy states. Carboxy wild type MZH3mOrange2 improves quenching, where a ∆F/F of -27.2% is seen at 562 nm. The
efficiency of the quenching improves slightly in the H110M and H110K mutants
(∆F/F of -51.6% and -28.3% at 561 nm, respectively). Though ferrous H110C did
not quench the fluorescence of mOrange2, its transition into the carboxy state
yielded a ∆F/F of -31.2% at 565 nm. It is of note, that the carboxy state caused a
narrowing of the Soret peak, with a peak absorbance at 424 nm.
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Figure 3.15: Changes in absorbance and fluorescence of MZH3-mOrange2 variants due to
ferric, ferrous, and carboxy state of heme.
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3.3.5 Considerations for additional spectral and redox variations
Wild type MZH3-mOrange2 exhibits approximately ~16% quenching in the
fluorescence of mOrange2 upon heme reduction via chemical and electrochemical
methods. The H110M and H110K mutants quench mOrange2 fluorescence more
efficiently upon reduction than wild type,
and H110C was seen not to. Even though
the carboxy state would not be utilized for
a GEVI, this heme state quenched the
fluorescence

of

mOrange2

more

effectively. The range in relative changes
in fluorescence seen in these MZH3mOrange2 mutants is due to the ligation
pair,
Figure 3.16: (Top) Crystal structure of
MZH3 provides structural information of
interacting with the distal heme face.
(Bottom) Mutations on non-ligating,
interactive residues with heme, in addition
to the ligating residues, increases the
redox range of MZH3.

which

generates

different

orientations of the heme within the pocket.
However, the heme binding pocket was
still able to bind heme strongly within the
maquette.

Spectral and redox properties in hemomaquettes can be greatly altered
through introduction of different heme ligation partners. Mutations at non-ligating
residues that interact with the heme in the heme binding pocket also are shown to
increase the range of spectral and redox properties of MZH3. A library of MZH3
mutants were created through random mutagenesis at L88, L95, and H110 by
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Christopher Moser. These variants exhibit a distribution of midpoint potential just
through mutations at one, two, or all three of these amino acids (Fig. 3.16), with
some experiencing heme loss during redox titrations [personal communication].
Additionally, the oxidized and reduced Soret peaks differ, yet the oxidized peaks
cluster between 405 nm to 415 nm and the reduced peaks cluster between 425
nm and 432 nm. By introducing these substitutions into MZH3-mOrange2, one
could expect to see differences in the amplitude of fluorescent quenching, since
the orientation and the environment of the heme is altered.

3.4 Sirius as a reporter for heme redox state
3.4.1 Indication of redox state sensing of Sirius
Purified MZH3-Sirius shows an absorbance peak at 415 nm, indicating that
the construct is able to bind heme in E. coli (Fig. 3.17). Heme titrations performed
on FJORD indicate a tight heme binding site with a kD < 10 nM, which is in
agreement with both MZH3 and the MZH3-mOrange2 construct, signifying that the
addition of a fluorescent protein does not cause a conformational change in the
heme binding site of MZH3. UV-Vis absorption of the completely heme-bound
MZH3-Sirius show a defined Soret peak at 415 nm, with an additional peak at 355
nm, which spectrally confirms the presence of Sirius. Fluorescence emission
spectra reveal a maximum emission at 424 nm when Sirius is attached (at 352
excitation). When investigating the redox properties of MZH3-Sirius, the relative
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changes in fluorescence can be measured at 415 nm and 430 nm, which reflects
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Figure 3.17: (Left) Absorbance spectra of a heme titration performed on MZH3-Sirius. (Right)
MZH3-Sirius binds a small amount of heme when produced in E. coli.

3.4.2 Heme midpoint potential determination using spectroelectrochemistry
Redox titrations were performed on MZH3-Sirius in a similar manner to
which MZH3-mOrange2 were performed, in order to determine if Sirius
fluorescence could be used to report the midpoint potential value of the heme b of
MZH3. Using the customized spectroelectrochemical setup, fluorescence of Sirius
was collected. The changes in the fluorescence at 415 nm and 430 nm were fitted
to the Nernst equation, respectively (Figure 3.18). At 415 nm, the midpoint
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Figure 3.18: Spectrofluoroelectrochemical
redox titration performed on MZH3-Sirius and an
n=1 Nernst curve fitted to the data reveals a
midpoint potential of -216 mV vs. SHE.
Reductive direction is from red to yellow,
oxidative direction is from green to violet.

midpoint potential of heme b was measured to be Em = -217 mV. During heme
reduction, the ∆F/F at 415 nm for the construct exhibited an increase of 78%, while
the ∆F/F at 430 nm exhibited a decrease of 97%.

3.4.3 Reversibility of Sirius fluorescence using chronoamperometry
Chronoamperometry was performed on MZH3-Sirius, and since the
fluorescence overlap of Sirius changes as heme reduces, the relative ∆F/F was
calculated at both 415 nm and 430 nm (Figure 3.19). As heme b is reduced, the
∆F/F at 415 nm was 55% with a 95% CI [50.5,59.9], and the ∆F/F at 430 nm was
-57% with a 95% CI [-59.6,-56.3]. In the oxidative direction, the ∆F/F at 415 nm
was -29.1% with a 95% CI [-30.3,-28.0], and the ∆F/F at 430 nm was 75% with a
95% CI [70.9,79.1] (14 cycles). Each oscillation cycle shows that the fluorescence
at both wavelengths is successively recovered after being quenched. For future
sensing, measurements at 430 nm is more ideal, since the absolute change in
fluorescence is much larger at that wavelength during oscillations than at 415 nm.
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Figure 3.19: Chronoamperometry performed on MZH3-Sirius reveals the fluorescence of Sirius
can be modulated at 415 nm and 430 nm, due to the shifting Soret band.
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When heme b is reduced, the average time constant for the fluorescent
quenching at 430 nm was found to be 20 s, whereas the fluorescent recovery at
415 nm was found to be 62 s. This is in agreement with earlier measurements of
MZH3-mOrange2, where there is a tendency of the fluorescent recovery to occur
on longer time scales than fluorescent quenching.

3.5 mTFP1 as a potential reporter of heme redox state
3.5.1 Indication of redox state sensing of mTFP1
Similar to the previous fusion constructs, purified MZH3-mTFP1 shows an
absorbance peak at 415 nm, indicating that MZH3-mTFP1 binds heme when being
produced in E. coli, and heme titrations performed on MZH3-mTFP1 indicate a
tight heme binding site with a kD < 10 nM. UV-vis absorption of the completely
heme-bound MZH3-mTFP1 show a defined Soret peak at 415 nm, with an
additional peak at 468 nm, confirming the presence of mTFP1 (Figure 3.20).
Fluorescence emission spectra show a peak in MZH3-mTFP1 at 492 nm. Molar
equivalents of dithionite produced an average increase in ∆F/F of 4% in MZH3mTFP1 (n=2). Oxidation via exposure to oxygen recovered the fluorescence. The
fluorescent changes in MZH3-mTFP1 during a redox titration was not able to report
the midpoint potential of the bound heme b.
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However, due to the low change in fluorescence in mTFP1, additional
experiments were not carried out to see whether omTFP1 fluorescence could
determine the midpoint potential of bound heme.
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Figure 3.20: Reduction of MZH3-mTFP1 using sodium dithionite reveals an increase in
fluorescence of MZH3-mTFP1.

3.6 Intermission
The overall goal of this thesis is to develop a de novo designed GEVI using
a heme-bound maquette and an attached fluorescent protein. GEVI prototypes
which contained fluorescent proteins such as mOrange2, Sirius, and mTFP1,
showed that fluorescent proteins can be used to sense a change in heme redox
state. In the next chapter, the focus will be the transition of these water-soluble
GEVI prototypes into GEVIs. However, before we conclude this chapter and
embark on the next, I will take a moment to report on the progress and the
development of these water-soluble GEVI prototypes as probes for cellular redox
sensing.
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3.7 FJORD, a de novo designed Genetically Encoded Redox Indicator
(GERI)
Redox reactions play a crucial role in various cellular processes such as
oxidative phosphorylation and metabolism and have been found to impact
embryogenesis and tissue regeneration179,180. These cellular redox reactions are
highly controlled and regulated, where disruption to the redox homeostasis can
lead to certain pathologies181,182. Due to the high electronegativity of oxygen,
aerobic respiration creates different byproducts, termed reactive oxygen species
(ROS), which play an important role in cell signaling. An imbalance of ROS can
lead to cellular oxidative stress, causing nucleic acid damage, protein oxidation,
aging, apoptosis, and necrosis183–186.
Genetically encoded redox indicators (GERIs) provide a non-invasive
method for imaging redox dynamics within different cellular compartments187–189.
Redox-sensitive fluorescent proteins, such as rxYFP, rxRFP, and roGFP, have
been engineered to report the redox state of glutathione, an important cytosolic
and nuclear redox regulator, by introducing a pair of disulfide bridge forming
cysteines on the beta barrel surface190–195. The chromophore fluorescence is
dependent on the redox state of the thiol group. Changes in the fluorescence
represent the thiol redox state of the cell, which allow for fluorescent imaging of
the cellular glutathione redox ratio. Attachment of these redox-sensitive
fluorescent proteins to glutaredoxin and thioredoxin have been shown to improve
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the sensitivity to thiol redox state changes196,197. Another set of fusion constructs,
the HyPer family of probes, image cellular H2O2 levels189,198–200. HyPer probes
depend on the H2O2-sensitive regulatory domain of the Escherichia coli
transcription factor, OxyR, which modulates the fluorescence of an attached
circularly permutated fluorescent protein. HyPer probes and glutathione redox ratio
indicators have provided insight into the redox dynamics of H2O2 and glutathione
redox ratio during cellular processes in aging, inflammation, and neuronal
regeneration in vivo201–205.
Current probes, however, are still limited in both spectral and redox range.
With the exception of rxRFP, HyPer Red, and the NAD+/NADH sensor Peredox,
most redox probes only fluoresce in the green to yellow-green region of the visible
spectrum, hindering simultaneous imaging of different cellular compartments and
creating a demand for an expanded palette of fluorescent proteins206. Additionally,
redox active molecules and proteins from other metabolic and cell signaling
pathways exist with midpoint potentials outside the redox sensing range of current
probes, such as natural oxidoreductases whose midpoint potential values can
span from -700 mV to 700 mV207. Developing GERIs which can be poised to redox
potentials outside this range will increase the scope of current redox sensing
probes.
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Water-soluble and membrane maquettes have been designed to
incorporate the heme b cofactor, where heme-bound maquettes have reported
midpoint potential values from approximately -300 mV to 100 mV107,119. As shown
above, various fluorescent proteins can be used as reporters of heme redox state,
and their change in fluorescence can be used to report midpoint potentials of
bound heme within a maquette. These water-soluble GEVI prototypes can be used
as the first de novo designed GERI named FJORD (Fluorescent Jawn of Redox
Dynamics). For the purpose of the rest of the chapter/section, MZH3-mOrange2
will be renamed FJORD565.

Figure 3.21: Schematic of FJORD sensing redox dynamics within a cell. Interaction with
redox-active proteins and molecules induces change in heme redox state, modulating the
fluorescence of mOrange2, as demonstrated earlier in this chapter.

3.7.1 Expression in HEK293T cells
To test in mammalian cells, FJORD565 was expressed in HEK293T cells. 24
hours post transfection, cells were imaged. To reduce the fluorescence of
FJORD565 variants, sodium dithionite was initially introduced into the system.
Relative changes in fluorescence for FJORD565 variants were 50%. However, a
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similar relative change in fluorescence was seen for mOrange2 as well. While
minimal fluorescent changes were seen in vitro, this could be because the sodium
dithionite solution and sample were deoxygenated, minimizing byproducts of
sodium dithionite that could affect the fluorescence of mOrange2. As seen in Fan
et al., 10 mM of DTT was used as a reductant; while the fluorescence decreased
by 10%, the addition of DTT was deleterious to cell health197.

3.7.2 Expression in rat hippocampal neurons
FJORD565 was expressed in rat hippocampal neurons. On DIV7, cells were
imaged. Reduction via sodium dithionite yielded a 46.7% decrease in fluorescence
(Figure 3.22); however, this value matches what is seen in HEK23T cells with the
mOrange2 control.
Since large changes in fluorescence were seen using sodium dithionite,
reducing agents that are found in cells were then chosen to reduce heme b.
NADPH, a reducing agent which plays a central role in anabolism, reduces
glutaredoxin and thioredoxin, which are both analytes for current GERIs.
Glutathione, which plays a crucial role in cell regulation events, also participates in
redox reactions within the cell and is a common analyte for GERIs.
mOrange2 expressed in mouse hippocampal neurons showed no
significant changes in fluorescence upon additions of reduced NADPH and
glutathione. Glutathione added to mouse hippocampal neurons expressing
FJORD565 show a variety of spectral responses.
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Figure 3.22: Sodium dithionite reduction in rat hippocampal neurons reveal a decrease in
fluorescence of around 46%. The large fluorescent change is similar to that seen in HEK293T
cells, but most likely is due to interaction with mOrange2.

3.8 Discussion and Future Work
In this chapter, fluorescent proteins attached to hemomaquettes were able
to report the changes in heme redox state in vitro. These signals were shown to
be reversible through in vitro chemical and electrochemical methods. In addition,
the fluorescent changes in FJORD constructs with bis-His ligation could be fitted
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to a Nernst equation and report the midpoint potential of the heme b. While the
intended purpose of these constructs were to serve as proof of principle watersoluble prototypes for GEVIs, this property allows for these fusion constructs to
optimized for redox sensing in mammalian systems.
In vitro characterization of MZH3-mOrange2 (FJORD565) constructs yielded
a range of ∆F/F values through chemical and electrochemical manipulations,
dependent on the heme ligation pair. In the bis-His ligation scheme, the transition
from ferric to ferrous heme resulted in approximately a 16% decrease in
fluorescence. However, a greater fluorescence change was seen in the redox
titration. We suspect that either electron transfer from the heme to mOrange2 or
electrochemical ring opening of the oxazole chromophore of mOrange2 could have
resulted in the increased fluorescent quenching208–210. Redox titrations performed
on mOrange2 alone showed relatively no change in fluorescence when poised
across the same range of potentials, indicating that electrochemical ring cleavage
was not responsible for the increased quenching. Electron transfer from the heme
to the mOrange2 chromophore could also explain the increased oxidative
fluorescent recovery.
Several FJORD565 constructs with different ligation pairs continued to have
fluorescent quenching between 20-30% upon reduction via sodium dithionite,
except for the H110C mutant. Chronoamperometry experiments performed on
these variants demonstrates the reversibility of the fluorescent signal over several
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cycles as heme redox state changes. This reversibility is crucial for long-term
imaging redox and voltage sensing probes.
Despite Sirius exhibiting the largest changes in relative fluorescence as
heme redox states alternated, mOrange2 would be the more optimal choice as a
fluorescent reporter in a GEVI or GERI than Sirius for in vivo imaging. This is due
to the emission of mOrange2 being over 100 nm more redshifted than that of Sirius,
allowing for imaging to occur deeper in tissues. Additionally, the fluorescence of
Sirius overlaps with known cellular autofluorescent cofactors. The maximum
excitation and emission wavelengths of Sirius are 355/424 nm, which overlaps with
the excitation and emission of NADH. This problem could be overcome by
attaching a blue fluorescent protein at the C-terminus of Sirius or the N-terminus
of the maquette which could participate in FRET with Sirius, such as CFP or
mTFP1. This geometry and FRET mechanism is utilized in the VSFP family of
GEVIs; it should be noted though, that CFP is used in tandem with a more
redshifted fluorescent protein, YFP in VSFP designs65,66. While the attachment of
an additional fluorescent protein to Sirius lessens the issues with cellular
autofluorescence, another fluorescent protein would increase the size of a
maquette-based probe by ~50%, and a proper FRET partner would still be
blueshifted compared to the mOrange2 variants.
The conclusion from Chapter 2 specified that the speed of electron transfer
during an electrical event across the membrane is dependent on the inter-heme
distance, while the midpoint potential dictates how many electrons will be in a
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system at equilibrium. Control over the midpoint potential can be reached through
mutagenesis of the heme ligation site and the binding pocket. Mutated residues at
the heme binding pocket increases the redox potential range seen in current
GERIs. Preliminary data on FJORD565 expressed in mammalian cells exhibits
fluorescent changes in response to reducing agents. However, the same reagents
cause a decrease in fluorescence of mOrange2 alone without the heme-bound
maquette.
To improve the sensitivity and targetability of future FJORDs, the frame of
the maquette can be redesigned in order to interact with specific redox-active
proteins. Fry et al. show that introducing charge patterning to the maquette exterior
allows a maquette to interact with cytochrome c and participate in light-activated
reduction120. Attachment of redox-sensitive fluorescent proteins to redox-active
proteins enhanced sensitivity to redox dynamics, such as chimeras of rxRFP1 to
thioredoxin 1 and roGFP2 to glutaredoxin 1, allowing for both thioredoxin and
glutathione levels to be simultaneously monitored196,197. The addition of organellespecific trafficking signals would allow for compartmentalization of the FJORDs to
organelles to observe differences in cellular redox dynamics.
The mechanism in this chapter depended on FRET-mediated quenching
occurring between the fluorescent protein and heme. The heme binding pocket is
located at the NC-terminal cap of MZH3, but the scaffold allows for two more
cofactor binding sites. For increased quenching, the binding sites could be utilized
in a way for multi-step excited energy transfer (EET), similar to the maquette fusion
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construct seen in Mancini et al123. CpcA (C-phycocyanin alpha subunit) was fused
to a maquette with two tetrapyrrole binding sites. Phycocyanobilin fluorescence
was quenched with the addition of either Zn-chlorophyllide (33%) and
bacteriochlorin BC1 (55%). When both sites were occupied, excitation of the bilin
initiated a relay of excitation-energy transfer, where the phycocyanobilin
fluorescence experienced an 82% decrease.
The current design of FJORD565 is functional with a bound heme b within
the MZH3 portion and an attached fluorescent protein. The frame of MZH3 allows
for two more cofactors to be inserted, and it is conceivable that through careful
consideration and placement of cofactors, multi-step EET could be possible in a
future GERI, or any type of biosensor for that matter. While commonly used beta
barrel fluorescent proteins might not provide the proper geometries for multi-step
EET, phycocyanobilin proteins are possible since they are fluorescent in near-IR
region and can be endogenously produced in the cell211.
The goal of this chapter was to use a water-soluble GEVI prototype to
fluorescently report the change in redox state of a bound heme within a maquette.
This reporting mechanism is the basis of the maquette-based GEVI that will be
further explored in Chapter 4.
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Chapter 4: The Design, Expression, and Voltage
Sensitivity of the De Novo Genetically Encoded Voltage
Indicator, THOR

“Man is certainly stark mad; he cannot make a worm, and yet he will be making
gods by dozens.”
-Michel de Montaigne

4.1 Introduction
Initial de novo designed membrane proteins were inspired by ion channels,
followed by transmembrane proteins found in oxidative phosphorylation and
photosynthetic reaction pathways. For a de novo designed GEVI to be functional,
the protein must be able to be successfully trafficked and inserted into the plasma
membrane. The GEVI must have a voltage sensing domain within the
transmembrane domain for enhanced sensitivity and a bright, fluorescent reporter
to report changes in membrane potential. Chapter 2 detailed how the positioning
and redox poise of a chain of heme cofactors allow for voltage-sensitive electron
transfer to occur. In Chapter 3, fluorescent proteins were shown to function as
fluorescent reporters of heme redox state in de novo designed proteins via FRET.
Here, the design, expression, and voltage sensitivity of a novel family of de novo
designed GEVIs named Transmembrane Hemoprotein Optical Reporters
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(THORs) will be outlined, including discussions of the hydrophobicity and the
trafficking of THORs.

4.2 The Design and Mechanism of THOR
The basic design principle of THOR is a fusion construct of a
transmembrane maquette with a fluorescent protein attached at the C-terminus.
The maquette contains a voltage-sensitive chain of hemes, and the fluorescent
protein functions as the reporter of heme closest to the intracellular side of the
membrane. During the course of an action potential, the heme redox states will
switch, modulating the fluorescence of the fluorescent protein via FRET, as seen
in Figure 4.1. Thus, the fluorescent protein will report the change in heme redox
state, reflecting fluctuations in membrane potential.

Figure 4.1: Reporting the heme oxidation state by fluorescence. (Left) Absorption spectra of
reduced (red) and oxidized (blue) heme overlaid with the emission spectrum of mOrange2
(green). The spectral overlap between heme and mOrange2 increases as heme is reduced.
Förster Resonance Energy Transfer (FRET) can be used in order to quench the fluorescence
of mOrange2 upon heme reduction via electron transfer (Right) Through this mechanism, we
can report changes in membrane potential using the change in fluorescence of mOrange2.
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4.2.1 Repurposing (MZH3) into a transmembrane protein for voltage sensing
Protein 2 from Goparaju et al. incorporated a major and minor water-soluble
cap to drive helicity within the membrane107. Similarly, THOR designs include a
major and minor water-soluble cap flanking a transmembrane domain. The
reaction center maquette, better known as MZH3118, was chosen as the initial
scaffold for THOR, due to its known crystal structure, a high melting temperature,
and its capability for binding three cofactors with a tight heme binding site already
designed (kd ~ nM). Additionally, in Chapter 3, MZH3 was used as the scaffold
maquette to demonstrate heme-mediated quenching of fluorescent proteins.
To create a transmembrane domain within MZH3, a 23-amino acid block
was introduced starting at the L19 position, a g residue in the heptad motif. The
length of the block spans the length of a membrane, and the position of the block
allows for a major and minor water-soluble cap to exist on either side. The first bishistidine heme binding site (H9H110) was conserved. A second heme binding site
was introduced at the a-d core position 14 amino acids away from the first heme
binding site at I23, and the third heme binding site was introduced at the a-d core
position fourteen residues away at G37. For each pair of ligating histidines,
glycines were introduced, which are conserved across cytochrome b proteins.
These glycines have been shown to be essential in high-affinity heme binding in
natural proteins212. While the first bis-histidine heme binding site has the histidines
located on helices 1 and 3, the two other bis-histidine heme binding sites are
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located on helices 2 and 4, in order to lower strain and promote flexibility for
improved heme binding.

Figure 4.2: (Top) Snake diagram of MZH3. Green boxes represent positions where one or two
histidine residues exist. (Bottom) Transforming MZH3 into a transmembrane protein involves
inserting a membrane region which spans 23 amino acids flanked by two water-soluble caps.

4.2.2 Various methods for constructing a transmembrane domain
Once the three bis-histidine heme binding sites were determined, different
methods were employed to assign the rest of the residues. Bryan Fry analyzed
natural cytochrome b sequences from the Entrez database in order to determine
conserved residues across species and how these sequences affect electron
transfer within the chain213. Thus, a bioinformatic approach was the first method in
designing the transmembrane block of the THOR prototypes. THORA, the first
designed prototype, was designed by assigning either the first, second, or third
most common residue seen in cytochrome b. While cytochrome b is a four-αhelical chain, it is a subunit of the cytochrome bc1 and b6f complexes. Its
interaction with the rest of the structure could help drive it into the membrane. In
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order to promote hydrophobicity in the region, certain residues, such as leucine,
phenylalanine, and valine, were chosen over more conserved residues such as
serine and threonine. Aside from the histidines and glycines, prominent conserved
residues were preserved. Tryptophan residues at Position 2 on helices 1 and 3
were conserved to form an aromatic belt, a common feature in membrane proteins
to anchor the protein at the interfacial region of the membrane. The phenylalanine
residues on helix 4 also were preserved, for similar reasons to the tryptophan
residues. Arginine residues on helix 2 form salt bridges with heme propionates,
seen

in

cytochrome

b

and

cytochrome b6 proteins214,215. The
design of MZH3 also exploits an
arginine

for

stabilization.

heme

propionate

While

proline

residues are considered helixbreaking
Figure 4.3: Bioinformatic analysis of various
cytochrome b proteins reveal conserved amino
acids as positions on each of the four helices. From
Ref. [213].

residues

and

unconventional in water-soluble αhelical design216, proline is highly

conserved on helix 4 of cytochrome b proteins and was carried over into THORA
and could be more tolerated in a membrane217.
THORB was simpler in its design. Rather than bias the sequence with
nonpolar residues to promote hydrophobicity, the most conserved residue at each
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Figure 4.4: THORA through THORE snake diagrams which were guided by bioinformatic
analysis of cytochrome b proteins.

position was chosen. THORC was designed from THORA. Many polar residues,
such as glutamine, serine, and threonine, were replaced with leucine and alanine
residues to increase hydrophobicity and helicity. Additionally, tryptophan residues
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were introduced at Position 23 on helix 2 and 4 in order to have an aromatic belt
at each interfacial region. THORD is perhaps the most jocular prototype, since it is
almost identical to THORA, but the LASAGNA motif was introduced on helix 2.
THORE, the last prototype designed using the bioinformatic approach, was the
most hydrophobic variant of THORA. Almost all residues in the transmembrane
domain, except for the arginines, tryptophans, phenylalanines, and histidines and
glycines at the heme binding sites, were replaced with leucine, alanine, valine, and
isoleucine residues. While other THOR prototypes could easily be designed using
this bioinformatic approach, five was considered sufficient for the first round of
design.
The bioinformatic approach for designing THOR can be useful in creating
endless prototypes, but this design method strays from the maquette approach.
Another way to design THOR from MZH3 is by retaining much of the original
architecture of this region in the transmembrane domain. MZH3 has a high thermal
stability, which was an important reason why it was chosen as the initial scaffold.
This thermal stability is due to the presence of layers within the hydrophobic core.
Layers are seen in natural four-α-helical proteins, such as the Lac repressor
tetramerization domain, bacterioferritin monomer, and also in cytochrome b, where
bulky hydrophobic residues like phenylalanine, isoleucine, leucine, and tyrosine
help with core packing and stability. This layering has been recapitulated in the
hydrophobic core of MZH3 between cofactor binding sites and other engineered
proteins218–221. Thus, another method for designing THOR prototypes was to retain
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the layered core of MZH3. Residues at the a-d-a-d core positions were conserved
first, with an exception of the EHEG core being replaced with IGAL at Position 16
in order to remove the histidine residue and have nonpolar bulky residues. All
leucine residues at the g-g interface positions were carried over, with tryptophan
residues added at the e positions at Positions 1 and 23 for spectral visibility and
an aromatic belt. To assign residues for the rest of the transmembrane domain,
THORF was designed by adding leucine and alanine residues at the b and c
positions, and the leucine, alanine, valine, and isoleucine were added at f
positions. Residues in the transmembrane domain for THORG were assigned
using the bioinformatic analysis described earlier.

Figure 4.5: THOR designs guided by conserving the layered core seen in MZH3.

The heme binding sites in the previous THOR designs were all 14 amino
acids apart from each other, where the histidine residues within the
transmembrane domain were located on helix two and four. The original MZH3
scaffold contains a histidine on helix 3 (H124) fourteen amino acids away from the
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H9H110 heme binding site, and another histidine on helix 2 (H67) 11 amino acids
away. With this original architecture in mind, THORH is the only design where the
bis-histidine heme binding sites within the transmembrane domain are 11 amino
acids apart where the second and third heme binding site are introduced at
H23H109 (helices 1 and 3) and H52H138 (helices 2 and 4). The transmembrane
domain was introduced at E15, and the minor water-soluble cap of THORH was
shortened. By having the heme binding sites within the transmembrane region
closer, electron transfer rates would decrease, as demonstrated in Chapter 2.
THORI was the final design in the initial set of THOR prototypes. The
transmembrane domain from the cytochrome b of Rhodobacter capsulatus was
recapitulated into the transmembrane domain of THOR.

Figure 4.6: (Top) THORH designed was guided by creating a inter-heme distance of 11 amino
acids due to the histidine residues already present in MZH3. (Bottom) THORI was designed by
transferring the transmembrane domain of cytochrome b of Rhodobacter capsulatus.

The topology of cytochrome b and MZH3 differ. MZH3 has an antiparallel
topology, whereas cytochrome b has a parallel/antiparallel topology. Because of
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the difference in the threading pattern, and the fact that the major and minor watersoluble caps from MZH3 were chosen to help drive the transmembrane domain
into helices, helix 2 and 4 of the transmembrane region were swapped post-design
in order to the preserve the antiparallel topology of MZH3.

4.2.3 Hydropathy of transmembrane domains
To ensure that the THOR prototypes are energetically favored to insert into
a membrane, the hydrophobicity of each prototype was scored using various
hydrophobicity scales, where the hydropathy index of each amino acid indicates
favorable or unfavorable insertion into a membrane. Most hydrophobicity scales
classify the nonpolar amino acids phenylalanine, leucine, isoleucine, valine, and
alanine as amino acids that increase the hydrophobicity of a protein, whereas
amino acids like lysine and arginine increase the energy cost of membrane
insertion. The hydropathy index of each membrane region was determined using
three different hydrophobicity scales: Kyte-Doolittle, Hessa-White-von Heijne, and
the Transmembrane Tendency hydrophobicity scales. The hydropathy index for
each amino acid in the Kyte-Doolittle hydrophobicity scale was determined through
experimental results, where positive values indicate favorable insertion in a
membrane222. The amino acids isoleucine, valine, leucine, phenylalanine,
cysteine, methionine, and alanine have positive hydropathy indices. The HessaWhite-von Heijne hydrophobicity scale is nicknamed the “biological hydrophobicity
scale” since the hydropathy index for each amino acid was determined by a set of
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designed polypeptide segments that were
sent to the endoplasmic reticulum Sec61
translocon223. On this scale, negative values
indicate favorable insertion into membranes.
Alanine was determined to no longer
increase the hydrophobicity of a protein, and
tryptophan and tyrosine residues also
became

less

hydrophilic.

The

Transmembrane-Tendency hydrophobicity
scale was computationally determined from
databases of helical water-soluble and
transmembrane proteins to determine the
hydropathy indices for each amino acid224.
From these databases, it was shown that
proteins can contain sequences that switch
Figure 4.7: Hydropathy index of each
amino acid according to different scales.
(Top) Kyte-Doolittle Scale. (Middle)
Hessa-White-von Heijne Scale, also
referred
to
as
the
Biological
Hydrophobicity
Scale.
(Bottom)
Transmembrane Tendency Scale.

from

transmembrane

and

non-

transmembrane states. For this scale,
positive values indicate favorable insertion
into a membrane, and notably, tryptophan

and tyrosine were found to increase the hydrophobicity of a protein.
For this analysis, upper and lower bounds were selected in order to discern
whether a designed transmembrane region was too hydrophobic or too hydrophilic.
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AM1, published as Protein 2 in Goparaju et al., was deemed a proper candidate
for the hydrophobic upper bound. The transmembrane domain of AM1 contains a
high percentage of leucine and alanine residues (~65% of the domain is leucinerich, with a 15:4 ratio of leucine to alanine), with a few phenylalanine, tryptophan,
and histidine residues. The overall hydropathy index per amino acid calculated for
AM1 indicates favorable insertion into a membrane for each hydrophobicity scale
(Table

4.1).

For

the

lower

bound,

the

four-α-helical

voltage-sensing

transmembrane domain of Ciona intenstinalis, from which ASAP1 was derived,
was chosen due to its diverse sequence64. 50% of the transmembrane domain
contain residues such as leucine, isoleucine, valine, methionine, and
phenylalanine, that lead to favorable insertion into the membrane region across all
three hydrophobicity scales, while there is an increase of polar residues such as
arginine, glutamate, and aspartate. The overall hydropathy index per amino acid
calculated for the ASAP1 predecessor shows favorable insertion using the KyteDoolittle and Transmembrane Tendency hydrophobicity scales, but unfavorable
insertion using the Hessa-White-von Heijne hydrophobicity scale. From these
upper and lower bound limits, THOR prototypes can be distinguished as being
either too hydrophobic or hydrophilic. A THOR prototype with a hydropathy index
higher than that of AM1 could lead to potential aggregation in the membrane or
cytosol, with both conditions being cytotoxic. A THOR prototype with a hydropathy
index lower than that of the ASAP1 predecessor protein could lead to improper or
no membrane insertion.
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The five THOR prototypes designed from the bioinformatic analysis of
cytochrome b proteins each had hydropathy indices that led to favorable insertion
using the Kyte-Doolittle and Transmembrane Tendency hydrophobicity scales.
However, THORA, THORB, and THORD had energetically unfavorable values on
the Hessa-White-von Heijne scale. While these sequences are comprised of
approximately 62-66% membrane-favored hydrophobic residues as determined by
the Hessa-White-von Heijne scale, each prototype carries over many of the original
cytochrome b residues that lend to its increased hydrophilicity, such as arginine,
proline, glutamine, and asparagine. THORC and THORE, however, are comprised
of 66% and 76% membrane-favored hydrophobic residues, with over half of these
residues being leucine. By designing these two prototypes with increased
phenylalanine, leucine, isoleucine, and valine residues and removing much of the
polar residues commonly found in cytochrome b proteins, the hydrophobicity and
favorability for membrane insertion increased according to the Hessa-White-von
Protein

KD Hydropathy Index

HH Hydropathy Index

TT Hydropathy Index

AM1
THORE
THORH
THORC
THORF
THORG
THORA
THORD
THORB
THORI
ASAP1

2.94
2.87
2.71
2.41
2.37
2.24
2.09
2.08
1.92
1.61
1.18

-0.28
-0.19
-0.16
-0.04
-0.08
-0.04
0.07
0.07
0.09
0.18
0.33

1.44
1.34
1.21
1.17
1.07
1.16
1.03
1.01
1.02
0.89
0.45

Table 4.1: The hydropathies of designed THORs were compared to ASAP1 and AM1. Proteins
are ordered from highest to lowest according to the Kyte-Doolittle Scale.
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Heijne scale. All of these THOR prototypes score between the upper and lower
hydropathy bounds as deemed by AM1 and the ASAP1 predecessor.
All the THOR prototypes that were designed primarily by conserving the
core of MZH3 had hydropathy indices that led to energetically favorable insertion
into the membrane. This is unsurprising, considering that these prototypes have
high levels of nonpolar residues and lack the abundance of polar residues found
across the different variants of cytochrome b. THORI, which was designed by
inserting the transmembrane domain found in the cytochrome b from Rhodobacter
capsulatus, is the least hydrophobic THOR variant. While it shows favorable
insertion according to the Kyte-Doolittle and Transmembrane Tendency scales, it
shows unfavorable insertion on the Hessa-White-von Heijne scale, since only 53%
of its residues have hydropathy indices that lead to favorable insertion into the
membrane. However, its overall hydropathy index per amino acid is still within the
bound limits set by AM1 and the ASAP1 predecessor.

4.2.4 Two-heme variations of THOR
From Chapter 2, it was determined that the temporal response of THOR
was optimal when there were three hemes embedded within the core, with two
hemes embedded within the membrane region and one heme in the intracellular
water-soluble cap. While three hemes were optimal to create a voltage-sensitive
chain of hemes, two hemes can suffice. Taking this into consideration, two other
types of THOR can be designed that only use two hemes to sense changes in
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membrane potential. One type of THOR removes the heme binding site closest to
the extracellular side of the membrane and replaces the histidine residues with a
phenylalanine and alanine. The removal of the heme leads to a decrease in the
sensitivity of the sensor, but also removes the possibility of a capacitance leak of
the membrane. Calculations carried out in Section 2.5 show that midpoint
potentials seen in heme 2 of AM1 and b6 have high probabilities that approach
unity of being reduced at resting membrane potential. This ensures that a greater
percentage of maquettes would have only one electron in the system, rather than
the heterogeneous distribution seen in three-heme THORs.

Figure 4.8: Snake diagrams of mini THORC and THORG
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The other type of THOR
removes the architecture for the
heme

binding

site

in

the

intracellular water-soluble cap.
While this architecture could
help drive the transmembrane
domain into helicity, these mini
THORs allow for a smaller
payload

on

the

protein

production machinery on the cell
(Figure 4.8). The helix swap
mentioned in 4.2.2 does not

Figure 4.9: Three different types of THORs were
designed for membrane insertion. (Left) Type I: a THOR
with three heme binding pockets: two within the
hydrophobic domain and one inside the intracellular
hydrophilic cap. (Middle) Type II: a THOR with two
hemes: one within the hydrophobic domain and one
inside the intracellular hydrophilic cap. (Right) Type III: a
mini-THOR, whose hydrophobic domain contains two
heme binding pockets, and there is no intracellular
hydrophilic cap.

apply to the mini THORs, since the major and minor caps were much smaller.

4.2.5 Attachment of a fluorescent protein reporter
Linker regions between the voltage-sensing domain and fluorescent protein
are important in the functionality of GEVIs. The length and composition of linker
regions can can alter the performance of a GEVI. Mac and Ace both have a two
amino acid linker region of SG, whereas its next evolution, VARNAM, increased
the length of its linker to WRSG after an assay scanning linker variants determined
that the additional tryptophan and arginine created a more responsive GEVI
without altering the brightness of fluorescent protein, mRuby387–89. In the process
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of transforming QuasAr into an eFRET GEVI by attaching mOrange2 to its Cterminus, different linker truncations were explored86. The longest truncations of
31 and 32 amino acids from the C-terminus of QuasAr and the N-terminus of
mOrange2 yielded the highest voltage sensitivity, but the brightness suffered. The
24 amino acid truncation was deemed the optimal truncation length for
performance and brightness.
For THOR, the initial fluorescent protein chosen was mOrange2. While
Sirius had greater sensitivity, detecting its fluorescence could pose imaging
challenges due to competing cellular autofluorescence. mOrange2 also is the most
red-shifted FRET pair with heme, lending itself to be more useful in deep tissue
imaging. The C-terminus of THOR ends with –LG or –KG for mini THORs. The Nterminus of mOrange2 begins with VSK. The initial linker region was chosen to be
ASG. SG is a common linker between proteins and fluorescent proteins. By adding
an alanine residue before the SG, the NheI restriction site (G^CTAGC) can be
inserted between THOR and mOrange2, allowing for the replacement of the
maquette voltage sensor or the fluorescent protein to be carried out through
restriction enzyme cloning methods. Since the fluorescent reporting of THOR is
FRET based, increasing the size of the linker could be detrimental to the FRET
efficiency.
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4.2.6 Export and trafficking signals
Often in natural membrane proteins, peptide motifs instruct the cell the
destination of a protein225,226. The Kir2.1 inward rectifier potassium channel has
several different export and trafficking signals, such as the ER export signal, the
Golgi export signal, and the membrane trafficking signal. Signal peptides that
ensure membrane insertion can be found in opsins such as channelrhodopsin-2.
Many GEVIs have included export and trafficking signal, primarily the ER export
signal and the membrane trafficking signal from the Kir2.1 potassium channel.
More recent GEVIs, like Voltron and Positron, have created versions that include
the soma trafficking signal from Kir2.1, that only traffic to the soma and not to the
dendrities and axons of neurons91,92.
Different combinations of export and trafficking signals were considered.
Initial designs included the ER export signal from Kir2.1, which was inserted at the
C-terminus of THOR prototypes in order to decrease stress in the endoplasmic
reticulum by helping prevent aggregation. Another design featured the ER export
signal along with the Golgi export signal (GS) added at the N-terminus of THOR
prototypes and the membrane trafficking signal before the ER export signal. The
Golgi export signal helps prevent aggregation in the Golgi apparatus, while the
membrane trafficking signal (TS) helps ensure proteins reach the cell surface.
Finally, the soma trafficking signal (ST) was inserted after the ER export signal for
improved neuronal expression.

107

4.2.7 Choosing an initial vector for mammalian expression
When expressing and testing voltage sensitivity of GEVIs in different cell
types, the choice of vector and promoter is important in the expression rate and
cell type. In Table 4.2, GEVIs utilize various vectors and promoters; some vectors
can express across different cell types, whereas other vectors are optimal for only
a specific cell line. Promoters also have an effect on the level of expression in cells.
For THOR, the initial vector-promoter pair that was chosen was pcDNA3.1(+) with
Cell Types
(original paper)

GEVI

Vector (original paper)

Promoter

VSFP2.1

pcDNA3.1(–)

CMV

VSFP2.3
VSFP3.1
VSFP3.1_FP
VSFP-Butterfly

pcDNA3.1(–)
pcDNA3.1(–)
pEF1-Myc-HisA
pCAG

CMV
CMV
EF-1a
CAG

ArcLight Q239

pcDNA3.1/Puro-CAG*

CAG

Mermaid2

pEB6SRmcs
pCS2
pcDNA3.1(+)
pcDNA3.1/Puro-CAG

SRa
Simian CMV IE94
CMV
CAG

ASAP2s

pcDNA3.1/Puro-CAG
pJFRC7-20XUAS

CAG
---

FlicR1

pcDNA3.1(+)**
AAV2

CMV
CaMKIIa

PC12, HEK293,
primary hippocampal
neurons
PC12
PC12
PC12
PC12, hippocampal
neurons
HEK293, hippocampal
neurons
Mammalian cells
mammalian cells
HEK293
HEK293, hippocampal
neurons
In vitro, neuronal
cultures
Drosophila
HEK293
neuronal cultures

Archer

pLenti-CamkIIa

CaMKIIa

Hippocampal neurons

Mac

pLenti-CamkIIa

CAMKIIa

Hippocampal neurons

QuasAr

FCK(1.3)

CaMKIIa

VARNAM

pCAGGS
pAAV-hSyn

Simian CMV IE94
hsyn

Voltron

pcDNA3.1-CAG
pTol2-HuC
pT2-Tbait-UAS
p10XUAS-IVS-Syn21-p10
pAAV-hsyn-flex

CAG
HuC
--hsp70
hsyn

HEK293, hippocampal
neurons
HEK293, primary
neurons
Mouse brain (Credependent)
Primary neuron cultures
Zebrafish (panneuronal)
Zebrafish (GaI4dependent)
Drosophila
Mouse brain (Credependent)

Zahra2
ASAP1

Table 4.2: Vectors used for various GEVIs.

*original paper had a different vector than listed, but this vector is often used in other publications
**created a new vector from pcDNA3.1 named pcDuEx0.5 for prokaryotic expression
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a CMV promoter. pcDNA3.1(+) is a standard vector, where the CMV is a strong
promoter for high-level expression of recombinant protein in mammalian cells,
such as HEK293T cells and neurons.

4.3 Expression and Voltage Sensitivity of THOR in HEK Cells
4.3.1 Combinatorial approach for improved expression of THOR in HEK293T
Cells
Two THOR prototypes, THORC and THORG, were initially chosen to be
expressed in HEK293T cells. THORC and THORG are from two different design
approaches (bioinformatics and conserved-core, respectively), and their
calculated hydrophobicity score on each scale predicted that they would each
favorably insert into a membrane. When compared to the other designs, their
hydropathy indices are closer to the median value. For the initial expression, each
THOR construct had an ER export signal attached to its C-terminus. Images
collected 24 hours after transfection show that all constructs with the ER export
signal show a range of different expression patterns (Figure 4.10). Bright spots
within the cell body indicate aggregation in the ER. Other cells exhibit speckling,
which is indicative of aggregation in the Golgi apparatus. Expression remained
similar 48 and 72 hours after transfection.
Type II versions of THORC and THORG were engineered by replacing the
H75H172 positions with F75A172. By removing the third heme binding site, the
probability of a capacitance leak in the membrane is significantly decreased, as
the chain of hemes could act as a channel for electrons to leave the cell. In case
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a capacitance leak was occurring, we believed that expression of these variants
would produce a lower rate of cell mortality. Compared to Type I THOR prototypes,
Type II does not visibly show a difference in cell mortality.
Type III versions of THORC and THORG, affectionately referred to as mini
THORs, were designed to be smaller constructs in order to decrease the workload
on the protein production machinery in the cell. Expression of these mini THOR
variants with the ER export tag also showed similar mixed expression patterns,
with a combination of healthy cells with aggregation in different cellular
compartments and unhealthy cells.

Figure 4.10: THORs of different types were transfected into HEK293T cells for cell health,
expression levels, and voltage sensitivity measurements. All THORs contained the export tags
in A in Fig. 4.15. Type I (left) and Type III (right) expressed in HEK293t cells. Both images show
a mixture of healthy cells, and cells that either experience aggregation in the endoplasmic
reticulum or Golgi complex. Scale bar: 50 μm.

To improve the membrane targeting and expression of THORC and THORG,
additional export signals were cloned into the construct as mentioned before in
Section 4.2.6. Type I variants of THORC and THORG did not show a stark
110

improvement in expression patterns. In addition to the ER export tag, THORG
variants were expressed with either the Golgi export signal, the membrane
trafficking signal, or both. However, no combination seemed to improve the
membrane trafficking in HEK293T cells. Type II and Type III THORs also showed
no significant improvement in membrane trafficking.

4.3.2 Voltage sensitivity in HEK Cells
While membrane expression in HEK293T cells varied in a cell culture,
voltage-sensing properties of THOR can be determined from a single, isolated cell
with healthy membrane expression. To determine if early THOR prototypes
showed voltage sensitivity, whole cell patch-clamp experiments were performed

Voltage (mV)

Fluorescence

on the Type I variant of THORG with the ER, Golgi, and membrane export and

Time (ms)
Fluorescence

Voltage

Figure 4.11: Whole cell patch-clamp performed on THORG shows no fluorescent dependence
to voltage steps.
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trafficking signals. Isolated cells were patched 24 hours post transfection, with the
resting potential being set at -40 mV. Figure 4.11 shows the fluorescence of
THORG responding to voltage steps. Over the course of a 200 mV voltage change
(-100 mV to 100 mV), no significant sensitivity was detected. During the course of
the patching, the fluorescence decreases due to photobleaching. However,
subtraction of the photobleaching curve yields no significant voltage sensitivity,
except for a small perturbation that occurs as the voltage is raised to 100 mV.
As a comparison, whole cell patch-clamp experiments were performed on
QuasAr2-mOrange2, a rhodopsin-based GEVI86. As mentioned in Chapter 1,
QuasAr2 is an eFRET GEVI, where the retinal cofactor can report a ∆F/F of 90%

Voltage%(mV)

Fluorescence

per 100 mV. Retinal is dimmer than fluorescent proteins used in other GEVIS, so

Time%(ms)
Fluorescence

Voltage

Figure 4.12: Whole cell patch-clamp performed on QuasAr2-mOrange2 shows fluorescent
dependence to voltage steps.
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various QuasAr2-FPs were designed as chimeric constructs to improve the
brightness of the probe. One QuasAr2-FP, QuasAr2-mOrange2, had a reported
∆F/F of 10% per 100 mV, lower than QuasAr2 alone. Since QuasAr2-mOrange2
was still able to report changes in membrane potential, this allowed QuasAr2mOrange2 to being an ideal positive control in voltage sensitivity measurements.
Figure 4.12 shows the voltage response of QuasAr2-mOrange2 to voltage steps
from -100 mV to 100 mV. By removing the photobleaching curve, the voltage
sensitivity of QuasAr2-mOrange2 was determined to be ∆F/F of ~1.5% per 100
mV. Due to the reduced sensitivity in QuasAr2-mOrange2, there exists a small
possibility that the sensitivity of THORG was unable to be detected.

4.4 Expression and voltage sensitivity of THOR in rat and mouse neurons
A working GEVI, or any voltage-sensing probe in general, should be able to
sense and faithfully report action potentials and other voltage signaling events in
a neuron. While HEK293T cells provide a platform to screen constructs at a greater
rate, they are not considered adequate model cells for basic neuroscience
research, where any results or findings should be validated in primary neuronal
cultures. As demonstrated in Bando et al., constructs that perform well in HEK293T
cells do not always perform better in neuronal cultures or in vivo93.
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4.4.1 Imaging membrane trafficking of THOR
Type I variants of THORC
and THORG with the ER
export signal, Golgi export
signal,

and

trafficking

signal

expressed

in

hippocampal
Compared
Figure 4.13: Type I THORG expressed in rat
hippocampal neurons. While less aggregation occurred
in the neurons, membrane trafficking was still not optimal.
Scale bar: 50 μm.

membrane
were

the

rat

neurons.
to

HEK293T

expression, both prototypes
seem to have a lower rate of
cell mortality. When imaged at

7 days in vitro (DIV), THORG is expressed throughout the cell body and processes.
Though it is of note, that the expression is not localized solely to the membrane,
but throughout the cytoplasm. In Figure 4.13, the brighter spots indicate either
localization to lysosomes or puncta formation throughout the neuron. However,
THOR expression at DIV7 shows that neurons are healthy and do not promote cell
death, as seen in HEK293T cells. To determine whether THOR probes eventually
localize solely to the membrane and that cell health is maintained, images were
collected at later DIV and compared to QuasAr2-mOrange2.
THORC, THORG, and QuasAr2-mOrange2 were simultaneously expressed
and imaged at DIV8, DIV10, and DIV14. The left column of Figure 4.14 shows rat
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hippocampal neurons imaged at DIV8. THORC shows localization throughout the
cytoplasm, with localization to the lysosomes/puncta formation. While somatic
expression occurs through all transfected neurons, not all neurons have
expression within their processes. THORG also exhibits somatic expression and
has increased expression within neurites when compared to THORC expression.
While the majority of aggregates were observed in the soma for THORC, THORG
lysosome localization and puncta formation is also observed in the dendrites.
Images collected of QuasAr2-mOrange2 at DIV8 show membrane localization,
diminished somatic cytoplasmic accumulation, and increased localization in the
dendritic branches.
THORC imaged on DIV10 shows increased localization in the dendritic
architecture of the neuron, but continued localization to the lysosomes. In Figure
4.14, the cytoplasm of the soma still has high level of THORC expression, inhibiting
the ability to detect whether the protein is associating to the membrane. THORG
shows similar expression patterns as well at DIV10. QuasAr2-mOrange2 imaged
at DIV10 shows improved membrane trafficking and localization. Except for
lysosomal localization, the bulk of the somatic cytoplasm is much dimmer
compared to the membrane, indicating successful membrane trafficking. THORC
and THORG imaged on DIV14 show similar expression to DIV10 imaging. No
improvement is seen in the membrane trafficking, where somatic cytosolic
accumulation is evident.
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DIV 10

DIV 14

QuasAr2-mOrange2

THORG

THORC

DIV 8

Figure 4.14: Expression and trafficking of THOR was monitored over several days with the
export tag combinations in B in Fig. 4.15. Aggregates and puncta still occur, as well as high
cytosolic expression of THOR. Scale bar: 50 μm.

The attachment of the ER export signal, Golgi export signal, and the
membrane trafficking signal did not improve the localization of THOR. While THOR
may be localized to the membrane, high levels of cytosolic localization impedes
assessment.

A recent trend in GEVI development is introducing the soma
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trafficking tag from Kir2.1 at the C-terminus to improve localization solely within the
soma, as well as to clear any aggregation within the cytosol. The soma trafficking
A

HT

Maquette

mOrange2

ER

B

GS HT

Maquette

mOrange2

TS ER

C

GS HT

Maquette

mOrange2

TS ER ST

tag

was

cloned

from

Positron and inserted into
THORG after the ER export

Figure 4.15: Gene structure of THOR. (A) His-Tag (HT) for
purification purposes and Endoplasmic reticulum (ER) export
sequence were originally added to the probe. (B) To decrease
Golgi aggregation, the Golgi export signal (GS) was added,
and to improve membrane expression, the membrane
trafficking signal (TS) was added. (C) to improve targeting
within neurons, soma tag (ST) was cloned into THOR. All tags
are originally from Kir2.1.

signal and the membrane
trafficking signal at the Cterminus

to

engineer

THORG-ST.

THORG-ST was expressed in rat hippocampal neurons and mouse
hippocampal and cortical neurons and imaged on DIV10. In rat hippocampal
neurons, there was a vast reduction of THORG-ST expressing in neurites, but
cytosolic aggregation in the soma still occurred.
Membrane localization of THORG-ST improved in mouse hippocampal
neurons at DIV10. Expression and localization seemed to be heterogeneous
across various cell types, but expression was limited to the soma (Figure 4.16).
Fixing the neurons and staining for microtubules further show only somatic
expression in mouse neurons (Figure A1.6). Expression in both mouse
hippocampal and cortical neurons also show that THOR is transferrable between
different primary neurons, showing the versatility of THOR for future purposes.
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4.4.2 Voltage sensitivity of THOR
Initial testing for THOR neuronal voltage sensitivity was carried out by
Mouse Hippocampal Neurons

Mouse Cortical Neurons

increasing the extracellular
potassium

ion

concentration to depolarize
the

membrane.

hippocampal

Rat

neurons

expressing THORG were
imaged in Hank’s Buffered
Salt Solution (HBSS) buffer
containing 4 mM K+. After
50 seconds, the buffer was
replaced
Figure 4.16: THORG-ST expressed in mouse primary
neurons and imaged at DIV10. A decrease in puncta and
aggregate formation occurred and an observed increase of
membrane localization was seen.

containing

with
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a

buffer

mM

K+,

increasing the total [K+] to

69 mM. Upon potassium depolarization, the fluorescence of THORG rapidly
decreased, with a total ∆F/F of 60% for the neuron, the membrane, and processes.
In the positive control with QuasAr2-mOrange2, the total ∆F/F was 27%, shown in
Figure 4.17. However, when depolarizing a membrane with potassium,
acidification can occur in the cell, which can modulate the fluorescence of
mOrange2. Additionally, these experiments provide no information on the
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timescale at which reporting can occur. To do so, whole cell patch-clamp is the
optimal choice, but no neurons were able to be patched.
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Figure 4.17: Potassium depolarization assay of THORG and QuasAr2-mOrange2. (Left) THORG
expressed in rat hippocampal neurons and imaged on DIV10 were subjected to a potassium
depolarization by introducing a high potassium buffer. The change in fluorescence was much
greater than that seen in QuasAr2-mOrange2 (left), which was used as a positive control.

After attaching the soma tag to THORG, further potassium depolarization
experiments were carried out on THORG-ST. In these experiments, successive
titrations of 20 mM K+ were introduced. In Figure 4.18, a rat hippocampal neuron
expressing THORG-ST is subjected to 20 mM K+ additions. Upon each successive
addition, the fluorescence initially decreases, followed by fluorescent recovery.
The frames shown in Figure 4.18 are hypothesized to initially show the dome of
the neuron, where more THORG-ST would be localized. Upon depolarization, the
fluorescence decreases. Comparison of the fluorescent changes to the soma
shows similar pattern of fluorescent changes. Additionally, similar potassium
titrations performed on mOrange2 did not show any fluorescent response.
However, as mentioned previously, these assays do not provide any information
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on the temporal response of the probes and might present problems to the health
of the neurons.
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Figure 4.18: Potassium depolarization titration of THORG-ST. (Left) Frames of THORG-ST
expressed in rat hippocampal neurons and imaged on DIV10 were subjected to a potassium
depolarization through titrations of potassium chloride. The frames selected show the dome of
the neuron undergoing fluorescent changes. (Right) Integrated density plotted across time
shows the change in fluorescence due to increases in potassium ion concentration.

4.5 Summary and Future Directions
THOR prototypes were designed using the scaffold of the reaction center
maquette, MZH3. A portion of MZH3 was redesigned by incorporating conserved
lipophilic sequences seen in cytochrome b proteins in order to simultaneously
accommodate two heme bis-His binding sites and to allow insertion into a plasma
membrane. These lipophilic sequences can be scored against various hydropathy
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scales, where each amino acid has an index value that represents its favorability
for membrane insertion. All THOR prototypes had transmembrane domain regions
that favored for insertion according to each of the hydropathy scales.
While THOR is a de novo designed protein, certain motifs from the
potassium ion channel Kir2.1 were added to the N- and C-termini for membrane
trafficking and localization. This is a common approach seen in other GEVIs, aiding
the improvement of membrane targeting. However, upon initial expression in
HEK293T cells, THOR prototypes have variable expression patterns. Even with
export signals from organelles, accumulation of THOR in the endoplasmic
reticulum and Golgi apparatus continues, affecting the long-term viability of the
cell. However, early GEVIs, too, suffered poor membrane expression and
associated with other membrane proteins, decreasing the voltage sensing and
reporting capability. In rat hippocampal neurons, expression of THOR did not affect
overall neuron health, but localization was not solely at the membrane; there was
cytosolic expression and lysosomal localization as well. This lysosomal localization
was seen in QuasAr2-mOrange2 as well, but QuasAr2-mOrange2 yielded much
more targeted membrane localization and insertion. In mouse primary neurons,
the addition of the soma tag cleared up aggregation and allowed for more targeted
localization at the membrane. This shows promise for the future of THORs to be
used across various cell types and species.
THOR was not able to report voltage steps via whole cell patch-clamp in
HEK293T cells. However, in rat hippocampal neurons, THOR was more
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responsive to potassium depolarization of the neuron than QuasAr2-mOrange2.
While promising, responsiveness to potassium depolarization is not a great
determinant for voltage sensitivity, since it induces a decrease in cellular pH which
can also affect the fluorescence of mOrange2. Additionally, potassium
depolarization does not provide temporal information, as the goal of THOR is to
have sensing capabilities on timescales seen in voltage sensitive dyes.
There is still room for improvement in the design of THOR. Initial GEVIs
exhibited poor membrane expression and voltage reporting, which improved
through successive optimizations59. To their benefit, these proteins all descended
from endogenous membrane proteins152. It is not surprising that the genesis of a
de novo designed GEVI presents problems such as a reticence to localize solely
to the membrane and sub-optimal sensitivity to changes in membrane potential.
However, in vitro biophysical characterization of the heme binding and midpoint
potential can reveal whether the current THOR probes are not energetically
favored to respond to a change in voltage. There is a plausibility that there is not
enough heme b for both HEK293T cells and rat hippocampal neurons. Rhodopsinbased GEVIs supplement media with retinal in order to ensure functionality of their
sensors85. In HEK293T cells, supplementation of the media with 5-aminolevulinic
acid and FeSO4 did not show improvement in cell health or expression patterns,
but future optimization might be needed to yield improvement in cell health (Figure
A1.5). Additional export tags or increasing the size of the transmembrane domain
of THOR could also improve membrane insertion. THORC and THORG also were
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similar in hydropathy, so having a less hydrophobic THOR variant could allow for
decreased aggregation.
As previously mentioned, mutations in the linker region could also improve
the trafficking and sensitivity of THOR. Removal of amino acids between QuasAr2
and mOrange2 in the unstructured regions improved the sensitivity of eFRET
sensor. Kost et al. improved the temporal response by 25-fold in their cpFP-based
GEVI, VSD-FR189-188, by removing amino acids in the linker region227,228. While
the water-soluble caps of THOR are structured, removal or modification of amino
acids at the N-terminus of mOrange2 should be considered for improved trafficking
and sensitivity.
A screening approach using random mutagenesis could be employed in
order to increase the bulk number of possible THOR prototypes. Co-expression of
THOR prototypes with a voltage-gated ion channel could be used in tandem with
a Fluorescent Imaging Plate Reader (FLIPR) for detecting more sensitive
variants229. Recently, a live cell system named Kuhl cells, were engineered by
adding Kir2.1, the bacterial voltage-gated sodium channel NAVROSD, and
Connexin-43 into HEK293 cells230. These novel synthetic, excitable cells, created
as a medium-throughput method for screening both voltage and calcium sensors,
also is a potential screening platform for THOR prototypes.
Once a THOR prototype becomes functional, THOR is poised to sense
neuronal electrical events at speeds seen in voltage sensitive dyes. mOrange2 as
a fluorescent reporter for THOR was the sole focus of this chapter, but as seen in
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Chapter 3, other fluorescent proteins can be employed can increase the spectral
range of THOR. Once an electron-transfer chain is successful and optimized,
future designs could incorporate the HaloTag-fluorophore combination seen in
Voltron and Positron. While THOR would technically no longer be a true GEVI if
this reporting mechanism were used, combining the theoretical speed of an
electron transfer-based GEVI with the sensitivity, brightness, and long-term
imaging capabilities seen in Voltron and Positron would make a future THOR
variant a superior GEVI. A final exploration for THOR designs is to poise the heme
midpoint potential, or any cofactor for that matter, to be sensitive in various
excitable cellular systems, such as mitochondria, skeletal muscle cells,
proliferative cells, and plant walls.
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Chapter 5: Conclusions

“All is but a woven web of guesses.”
-Xenophanes

Neurons transmit information to other neurons by utilizing voltage signaling.
Engineering probes that can image these signaling patterns with high spatial and
temporal resolution is essential for enhancing our understanding of the
mechanisms that underlie neural activity12,13. GEVIs are a non-invasive technology
for voltage imaging. A functional GEVI is comprised of two basic units: a sensing
unit and a reporting unit. While much progress has occurred since the earliest
constructed GEVIs, the fastest and most sensitive GEVIs are still outperformed by
voltage sensitive dyes.
The maquette approach to protein design initiated as a methodology to
improve our understanding of biological electron transfer using minimalistic,
functional scaffolds102. The maquettome has diversified in both structure and
function since its inception, and maquette synthesis has transformed from solidphase methods to production and cofactor incorporation in Escherichia coli115,117.
A major aim of the maquette project is for complete in vivo assembly for various
functions102,113,118,119,123. This work progresses the goals of both neuroscience
technology and the maquette approach to de novo protein design. In this thesis,
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the framework for a functional de novo designed genetically encoded voltage
indicator is presented.
Chapter 2 establishes the conditions necessary for an electron transferbased voltage sensing mechanism for a de novo designed GEVI. A mathematical
model based on theories from biological electron transfer, bioenergetics, and
membrane electrostatics revealed several rules for a functional three-heme
maquette GEVI. For efficient electron transfer, hemes should be placed 13 Å or
less for sensing to occur on the microsecond timescale. As distance controls the
rate of electron transfer between the hemes, poising each heme to proper midpoint
potential dictates the favorability of electron transfer and the initial redox
conditions. Smaller differences in midpoint potential between hemes allow for
greater favorability for electron tunneling. From these calculations, a heme placed
within the intracellular side of the membrane undergoes the greatest change in
reduced state during a typical action potential, suggesting that a reporting
mechanism should be based on its redox state. This work can also be substituted
for different cofactors that are capable of electron transfer for future maquette
GEVIs.
Chapter 3 focuses on a fluorescent reporting mechanism based on heme
redox state in a water-soluble GEVI prototype. Hemomaquettes are capable of
quenching the fluorescence of an attached fluorescent protein via FRET, which is
a common voltage reporting mechanism seen across GEVIs. The findings from
this chapter show that three different fluorescent proteins were able to report
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changes in heme redox state. A spectral variety in probes allow for visualization in
different cell types or cellular compartments, meaning that GEVIs based on heme
redox state could be imaged alongside each other. Additionally, the redox
properties of the heme can be easily modulated through the mutagenesis of
residues in the heme binding pocket, which is a necessary component for
optimizing the electron tunneling in later design stages.
While initially serving as a proof of principle, the results of Chapter 3 indicate
that these GEVI prototypes could be further developed as genetically encoded
redox indicators, GERIs. The mOrange2 and Sirius variants can report the
midpoint potential of a bis-His ligated heme within a maquette. The mOrange2based probe, termed FJORD565, expresses in HEK293T cells and neurons and
preliminary results show fluorescent responses to reductants and oxidants.
Improvements to FJORD565 and later maquette-based GERIs include expanding
the spectral and redox properties and redesigning the exterior in order to interact
with specific redox-active proteins in the cell for more targeted sensing.
Chapter 4 shows the design, expression, and initial voltage sensitivity of a
new class of de novo designed GEVIs, named THORs. THORs were designed by
introducing lipophilic patterning and export tags in the maquette featured in
Chapter 3, originally designed by Nathan Ennist118. While THOR prototypes face
aggregation issues, preliminary experiments reveal some sensitivity to voltage
changes. A directed evolution approach can be used to screen for constructs in
order to improve the monomerization, trafficking, and sensitivity of these
127

prototypes. These approaches are widely used in optimizing GEVIs and other
biosensors and can advance the development of THORs86,89,92.
Current GEVI development has focused on improving the kinetics and
sensitivity of probes based on voltage-sensitive phosphatases and rhodopsin
proteins. Over time, probes in both families have achieved submillisecond
detection of action potentials. While the range of geometries and spectral
capabilities are diverse among GEVIs, no GEVI is completely satisfactory in the
demands of an ideal GEVI148,152. This thesis serves to present an alternative
method for developing GEVIs by harnessing the power of de novo protein design.
Rather than being derived from a natural voltage-sensitive domain, the original
scaffold that THOR was born from was inspired by the reaction center in
photosystem II, and modifications were guided by one of the cytochrome proteins
involved in the electron transport chain. Neither in nature contain a voltage
sensitive domain, yet when properly reengineered, can be used to detect electrical
activity in membranes.
This thesis as a whole lays out a blueprint for the design principles in
maquette-based GEVIs and GERIs. While the focus was primarily on employing
the heme cofactor for voltage- and redox-sensing, other redox- and light-active
cofactors are capable of binding and functionalizing maquette scaffolds. This
creates endless possibilities of developing maquette-based biosensors for voltage
and redox sensing, while simultaneously realizing the goal of in vivo assembly for
protein maquettes.
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Appendix A1: Experimental Methods

“Winning the prize wasn’t half as exciting as doing the work itself.”
–Maria Goeppert-Mayer

A1.1 Cloning and Molecular Biology Techniques
A1.1.1 Gene construction of FJORD
The gene encoding the MZH3 or the Reaction Center (RC) maquette (PDB:
5VJS) was originally purchased from DNA2.0 in a pJexpress414 vector with
codons optimized for E. coli expression. The gene was designed with an Nterminal six-histidine tag and a TEV protease cleavage sequence. A sequence
encoding a GGDG loop was added between the six-histidine tag and TEV protease
cleavage sites to improve TEV cleavage efficiency. (Note: RC maquette is also
referred to as MZH3 in portions of the thesis. MZH3 is the lab name given by its
designer, Nathan Ennist. RC is used as a more systematic, functional name.)
Three different fluorescent proteins were attached to the RC maquette:
mOrange2, mTFP1, and Sirius. mOrange2-pBAD was a gift from Michael
Davidson & Nathan Shaner & Roger Tsien (Addgene plasmid #54531:
http://n2t.net/addgene:54531; RRID:Addgene_54531). mTFP1-pBAD was a gift
from Robert Campbell & Michael Davidson (Addgene plasmid #54553;
http://n2t.net/addgene54553; RRID:Addgene_54553). Sirius/pRSETB was a gift
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from Takeharu Nagai (Addgene plasmid #51956; http://n2t.net/addgene:51956;
RRID:Addgene_51956).
To construct FJORD, restriction free cloning was used to amplify each
fluorescent protein with primers synthesized by IDT and to fuse to the C-terminus
of our de novo designed protein in the PJ414 expression vector231. The primary
PCR mutagenesis was carried out using the Apex Taq RED DNA Polymerase
Master Mix (Genesee Scientific). A volume of 25 µL Taq 2x Master Mix was
combined with 1 µL of a 10 µM solution of a primer mix containing each primer,
1.5 µL of a solution containing 50 ng of the fluorescent protein DNA, and 22.5 µL
of water. The secondary PCR mutagenesis was completed using Q5® HighFidelity 2X Master Mix (New England Biolabs). A volume of 25 µL Q5® HighFidelity 2X Master Mix was combined with 180.7 ng of the product of primary PCR
mutagenesis, 55.8 ng of the plasmid containing the RC maquette, and water to
bring the total volume to 50 µL. Amounts of primary PCR product and plasmid were
determined using the RF-Cloning server232. Samples were cycled on an Eppendorf
Master Cycler Pro. Samples were digested with 0.5 µL of Dpn-1 (New England
Biolabs) for 2 hours at 37 °C. A volume of 3 µL of DNA was transformed into DH5α
cells (Genesee Scientific) and grown overnight on an LB agar ampicillin plate (100
µg/mL) at 37 °C. Single colonies were picked and cultured in LB media with
ampicillin, and DNA was extracted using a Qiagen Miniprep kit. Sequences were
verified using the DNA Sequencing Facility of the Penn Genomic Analysis Core
using a T7 promoter primer.
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Primary PCR Mutagenesis:
The plasmids containing mOrange2, mTFP1, and Sirius were subjected to
the following procedure: initial denaturation at 95 °C for 30 seconds, followed by
40 repeating cycles of denaturation at 95 °C for 30 seconds, annealing at 57.5 °C
for 30 seconds, and extension at 68 °C for 30 seconds. A final extension was done
at 68 °C for 5 minutes and ended with a hold at 4 °C.

Secondary PCR Mutagenesis:
mOrange2 attachment: Samples for the secondary PCR mutagenesis were
subjected to the following procedure: preheat the thermocycler to 98 °C, initial
denaturation at 98 °C for 3 minutes, followed by 15 cycles of denaturation at 98 °C
for 30 seconds, annealing at 72 °C for 30 seconds, and extension at 72 °C for 3
minutes. The annealing temperature decreased by 1 °C each cycle. Then, ten
cycles of denaturation at 98 °C for 30 seconds, annealing at 60 °C for 30 seconds,
and extension at 72 °C for 3 minutes. A final extension was done at 72 °C for 10
minutes and ended with a hold at 4 °C.

mTFP1 and Sirius attachment:
To express FJORD in mammalian cells, the gene encoding the RC
maquette was cloned into the pcDNA3.1(+) vector containing mOrange2, originally
purchased from GenScript, through RF cloning.
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A mitochondria localization signal derived from the cytochrome c oxidase
subunit 8A was cloned into the FJORD pcDNA3.1(+) vector from the gene
encoding the mito-tagged DsRed2 protein via RF cloning. DsRed2-Mito-7 was a
gift

from

Michael

Davidson

(Addgene

plasmid

#55838;

http://n2t.net/addgene:55838; RRID:Addgene_55838).

A1.1.2 Vector Map of FJORD

Figure A1.1: FJORD565 was cloned into the pcDNA3.1(+) vector containing mOrange2 for
mammalian expression.
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A1.1.3 Gene construction of THOR
The gene encoding for THORC, THORG, and their mini THOR analogues
were originally purchased from GenScript in a pcDNA3.1(+) vector with codons
optimized for HEK cell expression. The gene was designed with a Kozak
sequence, an N-terminal six-histidine tag, a TEV protease cleavage sequence, an
ER export tag, and three stop codons “TAATGATAA”. A sequence encoding a
GGDG loop was added between the six-histidine tag and TEV protease cleavage
sites to improve TEV cleavage efficiency. Ala-Ser was inserted between the
maquette and mOrange2 sequences as the NheI restriction site “GCTAGC”.
A Golgi export signal (GS), a membrane trafficking signal (TS), and a soma
trafficking signal (TS) were attached through restriction free cloning as detailed
above. GS and TS were cloned from a gene encoding the Kir2.1 ion channel.
pCAG-Kir2.1-T2A-tdTomato was a gift from Massimo Scanziani (Addgene plasmid
#60598; http://n2t.net/addgene:60598; RRID:Addgene_60598. Soma trafficking
signal (ST) was cloned from a gene encoding the voltage sensor, Positron. pCAGPositron-ST was a gift from Eric Schreiter (Addgene plasmid #129254;
http://n2t.net/addgene:129254; RRID:Addgene_129254).
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A1.1.4 Vector Map of THOR

Figure A1.2: Plasmid map of THORG, which is representative of all the THORs that were
cloned.
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A1.1.5 List of Primers
mOrange2
Attachment
mTFP1
Attachment
Sirius
Attachment
FJORD
Insertion into
pcDNA3.1(+)
ATG
insertion
FJORD
H110M
FJORD
H110K
FJORD
H110C
MitoTag
FJORD
Insertion
Golgi Export
Signal
Insertion
Membrane
Trafficking
Insert
Soma
Trafficking
Tag Insertion
MitoTag
THOR
Insertion
mOrange2
Attachment
(AM1)

FWD
RVS
FWD
RVS
FWD
RVS
FWD
RVS

5'-TCAGAAGCTGTGGCAGCTGGGTGTGAGCAAGGGCGAGGAG-3'
5'-GGTTATGCTAGGGGGCTCGAGTTATTACTTGTACAGCTCGTCCATG-3'
5’-GTCAGAAGCTGTGGCAGCTGGGTGTGAGCAAGGGCGAGGAG-3’
5’-GGGGTTATGCTAGGGGGCTCGAGTTACTTGTACAGCTCGTCCATGC-3’
5’-TCAGAAGCTGTGGCAGCTGGGTGTGAGCAAGGGCGAGGAG-3’
5’-GGGTTATGCTAGGGGGCTCGAGTTACTTGTACAGCTCGTCCATGC-3’
5’-TACCGAGCTCGGATCCGCCACCGGCAGCGGCGAGTTGCGC-3’
5’-CGCCTTTGCTCACGCCGCTAGCACCCAGCTGCCACAGCTT-3’

FWD
RVS
FWD
RVS
FWD
RVS
FWD
RVS
FWD
RVS

5’-TCGGATCCGCCACCATGGGCAGCGGCGAGTTG-3’
5’-CAACTCGCCGCTGCCCATGGTGGCGGATCCGA-3’
5’-CTGCGCCAGAAAATGCAACAGCTGGCC-3’
5’-GGCCAGCTGTTGCATTTTCTGGCGCAG-3’
5’-CTGCGCCAGAAAAAGCAACAGCTGGCC-3’
5’-GGCCAGCTGTTGCTTTTTCTGGCGCAG-3’
5’-CTGCGCCAGAAATGCCAACAGCTGGCC-3’
5’-GGCCAGCTGTTGGCATTTCTGGCGCAG-3’
5’-CGAGCTCGGATCCGCCACCATGTCCGTCCTGACGCCGCTG-3’
5’-CTTGGCGCAACTCGCCGCTGCCCAACGAATGGATCTTGGCG-3’

FWD
RVS

5’-CGAGCTCGGATCCGCCACCATGAGGAGCCGCTTTGTGAAG-3’
5’-CGCCATGATGGTGGTGATGATGACCCACGTTGATAAACTGAACATTGCA-3’

FWD
RVS
FWD
RVS

5’-CGGCGGTATGGATGAACTGTACAAGAAATCTAGGATCACTTCAGAAGGG-3’
5’-AATTCTTATCATTACACCTCGTTTTCATAGCAGAAAACATTGATGTCTATCTGGTCCAA3’
5’-ACATCAATGTTTTCTGCTATGAAAACGAGGTGCAAAGTCAGCCTATCCTGAACA-3’
5’-CACTGTGCTGGATATCTGCAGAATTCTTATCATTAGAATCGAGTAGCCTCGGG-3’

FWD
RVS

5’-CGAGCTCGGATCCGCCACCATGTCCGTCCTGACGCCGCTG-3’
5’-CGCCATGATGGTGGTGATGATGACCCAACGAATGGATCTTGGCG-3’

FWD
RVS

5’-CCAATTTGAGGACCTGGCGAAACAGGTGAGCAAGGGCGAGGAG-3’
5’-GGTGGTGGTGGTGCTCGAGTTACTTGTACAGCTCGTCCATGC-3’

Table A1.1: Primers used in this thesis.

A1.2 Protein expression and purification of FJORD
mOrange2, mTFP, and all FJORD variants were expressed in E. coli BL21
(DE3) (New England Biolabs). The entire expression procedure was performed at
37 °C and 220 rpm. A 125 mL starter culture with 100 mg/L ampicillin was
incubated overnight and then transferred into 2 L Terrific Broth with 100 mg/L
ampicillin. When the absorbance at 600 nm reached 0.8, the cells were induced
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with 1 mM isopropyl-thiogalactopyranoside (Lab Scientific) for FJORD and 1%
(w/v) L-arabinose (MilliporeSigma) for mOrange2 and mTFP, respectively. Cells
were pelleted after 21 hours at 6000 g and purified or stored at -20°C until further
use.
Cell pellets containing the proteins were resuspended in 300 mM NaCl, 20
mM imidazole, and 50 mM NaH2PO4 (pH 8.0) wash buffer, incubated with 1 mg/mL
lysozyme and 5 µg/ml DNase I for 30 minutes, homogenized, and microtip
sonicated (Instrument name, Company name). Lysate was centrifuged at 15,000
g for 30 minutes. FPLC purification was performed using a 5 mL His-Trap Ni-NTA
column (GE Healthcare) on an Akta Purifier 10 (GE Healthcare). The protein was
loaded onto the column and eluted with 300 mM NaCl, 300 mM imidazole, and 50
mM NaH2PO4 (pH 8.0) buffer. The His-tag was cleaved with TEV protease
overnight and the protein was separated from the cleaved His-tag by gravity
columns (Amerscham Biosciences). SDS-PAGE gel of the protein sample before
and after TEV protease cleavage were ran to confirm molecular weight of each
construct and successful his-tag removal. Purified protein was aliquoted, flash
frozen in liquid nitrogen, and stored at -80°C until further use.

A1.3 Heme binding
A stock solution of heme b was prepared in DMSO. Concentration of the
heme stock was verified through a hemochrome assay233. Sub-stoichiometric
aliquots of heme b were added to FJORD in a phosphate-buffered saline of 137
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mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4, and 1.8 mM KH2PO4, pH 8.0. For general
heme-protein assembly, heme b was added to in slight excess, and excess heme
was removed with a PD-10 desalting column. Binding titrations were performed
over a range of protein concentrations, from 200 nM to 1 µM.

A1.4 Spectroscopic and biophysical characterizations
A1.4.1 Spectroscopic characterization
UV/Vis

absorbance

spectra

were
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a

Cary-50

spectrophotometer (Varian) at room temperature. Fluorescence spectra were
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Figure A1.3: Absorbance, excitation, and emission spectra of mOrange2 (left), Sirius (middle),
and mTFP1 (right.)

A1.4.2 Redox Titration
Initial redox experiments on FJORD constructs were carried out in a
phosphate-buffered saline of 137 mM NaCl, 2.7 mM KCl, 10 mM NaH2PO4, and
1.8 mM KH2PO4, pH 8.0. Samples were stirred and purged with vanadyl sulfate
scrubbed argon starting 1 h before the experiment234. Molar equivalent additions
of sodium dithionite in 30 mM KOH were added for the heme b to be fully reduced.
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After UV-Vis and fluorescence spectra were collected, the sample was oxidized
using a molar equivalent of ferricyanide or exposure to air.
To ensure additions of sodium dithionite did not alter the pH of the solution,
pH of 3 mL of phosphate-buffered saline was measured as 190 μM additions of
sodium dithionite in 20 mM KOH were added (Figure A3). The pH of the
phosphate-buffered saline did not alter greatly in amounts that were used in this
work.

A1.4.3 Spectroelectrochemistry
Redox midpoint potentials of protein-bound heme b were measured in a 1
mL cuvette equipped with Ag/AgCl and platinum electrodes (MI-800/411,
Microelectrodes Inc.).
Electrode-solution-heme redox mediation was facilitated by redox
mediators: 25 μM 2,3,5,6-tetramethyl-p-phenylenediamine (DAD), 25 μM 2hydroxy-1.4-naphthoquinone (HNQ), 20 μM phenazine methosulfate (PMS), 20
μM phenazine ethosulfate (PES), 20 μM phenazine (PHE), 20 μM anthraquinone2- sulfonate (AQS), 50 μM duroquinone (DQ), and 10 μM pyocyanine (PC). Stock
solutions of all the mediators except PC were made in DMSO. PC wa prepared in
water. After equilibrium at each potential, the heme b optical spectrum was
recorded and the course of the reduction of heme b was followed by the increase
in the sharp α-band absorption at 559 nm relative to a 575 nm reference
wavelength.
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Data were fitted using the Nernst equation with n-values of 1.0 for hemes:
𝐸! = 𝐸" +

$.$&'
(

[*+]

log [-./]

Eqn. A1.1

where Eh is the solution redox potential vs. standard hydrogen electrode, Em is the
midpoint potential of the heme, and [ox]/[red] is the ratio of concentrations of
oxidized to reduced heme.

A1.4.4 Spectrofluoroelectrochemistry
To confirm that both fluorescence and absorbance can be used for
measurements of heme b redox midpoint potentials, the absorption and
fluorescence spectra were collected simultaneously as a function of the solution
redox potential using a custom-made assembly of a bipotentiostat, fluorimeter, and
spectrophotometer, seen in Figure A1.4. Samples of 400 μL were prepared in 15
mM NaCl and 10 mM sodium phosphate, pH 7 in a specialized cuvette, with a
reference electrode (Ag/AgCl), a platinum counterelectrode. UV/Vis absorbance
spectra were collected with an Ocean Optics DH-2000 Deuterium-Halogen light
source, which emitted and collected through a fiber optic cable.
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Figure A1.4: Schematic of the spectrofluoroelectrochemical setup. To monitor the spectral and
fluorescent changes of the probes, a Y-shaped fiber optic allowed for light to be collected both
by the UV/Vis spectrophotometer and the fluorimeter. A) Potentiostat B) Excitation source,
fluorimeter C) Source of UV/Vis spectrophotometer D) Detector of UV/Vis spectrophotometer
E) Detector, fluorimeter F) Spectral response of potentiostat G) Spectral response of UV/Vis
spectrophotometer H) Spectral response of fluorimeter I) Reference electrode (Ag/AgCl) J)
Platinum counterelectrode K) Platinum rod in contact with the platinum foil electrode dipped into
the solution L) Platinum foil counter electrode.

A1.4.5 Chronoamperometry
The electrochemical technique for chronoamperometry was carried out in
the specialized cuvette described in A1.4.4, where a square-wave potential was
applied over time. A quiet time of 300 s at -250 mV was first applied, followed by
alternating steps at 0 mV and -500 mV. Fluorescence spectra was collected, and
redox mediators were used in order to speed redox equilibration.
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A1.4.6 Pyocyanine Preparation
For electrochemical experiments, pyocyanine was prepared from
phenazine methosulfate using the method described in Cheluvappa 2014235.

A1.5 Protein Sequences and Localization Tags
mOrange2
MVSKGEENNMAIIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPYEGFQTAKLKV
TKGGPLPFAWDILSPHFTYGSKAYVKHPADIPDYFKLSFPEGFKWERVMNYED
GGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPE
DGALKGKIKMRLKLKDGGHYTSEVKTTYKAKKPVQLPGAYIVDIKLDITSHNEDY
TIVEQYERAEGRHSTGGMDELYK
mTFP1
MVSKGEETTMGVIKPDMKIKLKMEGNVNGHAFVIEGEGEGKPYDGTNTINLEVK
EGAPLPFSYDILTTAFAYGNRAFTKYPDDIPNYFKQSFPEGYSWERTMTFEDKG
IVKVKSDISMEEDSFIYEIHLKGENFPPNGPVMQKKTTGWDASTERMYVRDGVL
KGDVKHKLLLEGGGHHRVDFKTIYRAKKAVKLPDYHFVDHRIEILNHDKDYNKV
TVYESAVARNSTDGMDELYK
Sirius
MVSKGEELFTGVVPILVELDGDVNGHRFSVSGEGEGDATYGKLTLKLICTTGKL
PVPWPTLVTTLQFGVLCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNY
KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNGISSNVYITADKQKNGIK
AHFKIRHNIEDGGVQLADHYQQNTPIGDGPVLLPDNHYLSVQSKLSKDPNEKRD
HMVLLESVTAAGITLGMDELYK
MZH3
MGKGGHHHHHHGGDGENLYFQGSGELRQEHQQLAQEFQQLLQEIQQLGREL
LKGELQGIKQLREASEKARNPEKKSVLQKILEDEEKHIELLETLQQTGQEAQQLL
QELQQTGQELWQLGGSGGPELRQKHQQLAQKIQQLLQKHQQLGAKILEDEEK
HIELLETILGGSGGDELRELLKGELQGIKQYRELQQLGQKAQQLVQKLQQTGQK
LWQLG
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MZH3 portion of FJORD565
GSGELRQEHQQLAQEFQQLLQEIQQLGRELLKGELQGIKQLREASEKARNPEK
KSVLQKILEDEEKHIELLETLQQTGQEAQQLLQELQQTGQELWQLGGSGGPEL
RQKHQQLAQKIQQLLQKHQQLGAKILEDEEKHIELLETILGGSGGDELRELLKGE
LQGIKQYRELQQLGQKAQQLVQKLQQTGQKLWQLG
mitoFJORD without fluorescent protein
GSVLTPLLLRGLTGSARRLPVPRAKIHSLSGELRQEHQQLAQEFQQLLQEIQQL
GRELLKGELQGIKQLREASEKARNPEKKSVLQKILEDEEKHIELLETLQQTGQEA
QQLLQELQQTGQELWQLGGSGGPELRQKHQQLAQKIQQLLQKHQQLGAKILE
DEEKHIELLETILGGSGGDELRELLKGELQGIKQYRELQQLGQKAQQLVQKLQQ
TGQKLWQLG
THORC
GHHHHHHGGDGSPELRQEHQQLAQEFQQLWLLGFLLGLLLVILIILGLLLAREA
SEKARNPEKKSVLQKFFALHFLLPFIILGLVLIHLILLQLLQELQQTGQELWQLGG
SGGPELRQKHQQLAQKIQQVWLVGVIILLLLLAVAFLGYVLLETILGGSGGDELR
ELRYIHANGASLFFILIYLHIARLQLVQKLQQTGQKLWQLGASGVSKGEENNMAII
KEFMRFKVRMEGSVNGHEFEIEGEGEGRPYEGFQTAKLKVTKGGPLPFAWDIL
SPHFTYGSKAYVKHPADIPDYFKLSFPEGFKWERVMNYEDGGVVTVTQDSSLQ
DGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGKIKMRLK
LKDGGHYTSEVKTTYKAKKPVQLPGAYIVDIKLDITSHNEDYTIVEQYERAEGRH
STGGMDELYKFCYENEV

THORG
GHHHHHHGGDGSPELRQEHQQLAQEFQQLLLFGFLLGLLLAILIITGLLWLREA
SEKARNPEKKSVLQKLLVLHFLLPFLYLGLALLHLIAWQLLQELQQTGQELWQL
GGSGGPELRQKHQQLAQKIQQLLLVGVILGLLIAAVAFLGYVWLETILGGSGGD
ELREIRYIHANGASLLFILAYLHIGRWQLVQKLQQTGQKLWQLGASGVSKGEEN
NMAIIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPYEGFQTAKLKVTKGGPLPF
AWDILSPHFTYGSKAYVKHPADIPDYFKLSFPEGFKWERVMNYEDGGVVTVTQ
DSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASSERMYPEDGALKGKI
KMRLKLKDGGHYTSEVKTTYKAKKPVQLPGAYIVDIKLDITSHNEDYTIVEQYER
AEGRHSTGGMDELYKFCYENEV
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mitoTHORG
GRSRFVKKDGHCNVQFINVHHHHHHGGDGSPELRQEHQQLAQEFQQLLLFGF
LLGLLLAILIITGLLWLREASEKARNPEKKSVLQKLLVLHFLLPFLYLGLALLHLIAW
QLLQELQQTGQELWQLGGSGGPELRQKHQQLAQKIQQLLLVGVILGLLIAAVAF
LGYVWLETILGGSGGDELREIRYIHANGASLLFILAYLHIGRWQLVQKLQQTGQK
LWQLGASGVSKGEENNMAIIKEFMRFKVRMEGSVNGHEFEIEGEGEGRPYEG
FQTAKLKVTKGGPLPFAWDILSPHFTYGSKAYVKHPADIPDYFKLSFPEGFKWE
RVMNYEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEAS
SERMYPEDGALKGKIKMRLKLKDGGHYTSEVKTTYKAKKPVQLPGAYIVDIKLDI
TSHNEDYTIVEQYERAEGRHSTGGMDELYKDYGGALSAVGRELLFCYENEV
mini THORC
GHHHHHHGGDGSPQELWLLGFLLGLLLVILIILGLLLAQLGGSGGILLRYIHANGA
SLFFILIYLHIARLQEGGSGGQKVWLVGVIILLLLLAVAFLGYVLLLLGGSGGLLFF
ALHFLLPFIILGLVLIHLILLQKGASGVSKGEENNMAIIKEFMRFKVRMEGSVNGH
EFEIEGEGEGRPYEGFQTAKLKVTKGGPLPFAWDILSPHFTYGSKAYVKHPADI
PDYFKLSFPEGFKWERVMNYEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSD
GPVMQKKTMGWEASSERMYPEDGALKGKIKMRLKLKDGGHYTSEVKTTYKAK
KPVQLPGAYIVDIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKFCYENEV
mini THORG
GHHHHHHGGDGSPQELLLFGFLLGLLLAILIITGLLWLQLGGSGGILIRYIHANGA
SLLFILAYLHIGRWQEGGSGGQKLLLVGVILGLLIAAVAFLGYVWLLLGGSGGLL
LLVLHFLLPFLYLGLALLHLIAWQKGASGVSKGEENNMAIIKEFMRFKVRMEGSV
NGHEFEIEGEGEGRPYEGFQTAKLKVTKGGPLPFAWDILSPHFTYGSKAYVKH
PADIPDYFKLSFPEGFKWERVMNYEDGGVVTVTQDSSLQDGEFIYKVKLRGTN
FPSDGPVMQKKTMGWEASSERMYPEDGALKGKIKMRLKLKDGGHYTSEVKTT
YKAKKPVQLPGAYIVDIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYKFCYE
NEV
ER export signal – FCYENEV
Golgi export signal – RSRFVKKDGHCNVQFINV
Membrane trafficking signal – DYGGALSAVGRELL
Soma trafficking signal
QSQPILNTKEMAPQSKPPEELEMSSMPSPVAPLPARTEGVIDMRSMSSIDSFIS
CATDFPEATRF
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Mitochondrial localization signal – SVLTPLLLRGLTGSARRLPVPRAKIHSL
A1.6 Mammalian Cell Techniques and Imaging
A1.6.1 HEK Cell Methods
HEK 293T cells were cultured in complete DMEM (DMEM supplemented
with 10% (v/v) FBS and 1% (v/v) P/S). HEK 293T cells were kept in 37 ºC in
humidified air containing 5% CO2. Cells were transfected using lipofectamine and
imaged 24 hours post transfection and imaged on an automated Leica DMI6000B
fluorescence microscope.

Figure A1.5: THORG and
THORG-ST were supplemented
with 5-aminolevulinic acid and
FeSO4 as seen in Ref. [X] to see
whether membrane trafficking
and cell health would improve.
Preliminary experiments do not
show an improvement. Some
membrane localization occurs
but HEK293T cells seem
unhealthy.

A1.6.2 Cultured Primary Neuron Methods
Rat hippocampal neurons were cultured in Neurobasal A medium
supplemented with B-27 and Glutamax. Rat hippocampal neurons were plated in
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a glass-bottom imaging dish (growth diameter = 20 mm). Cells were plated at
approximately 500k per growth area and transfected with approximately 2 μg DNA
at DIV5. Cells were imaged either on a LSM710 inverted confocal system or a
Zeus LSM 880 upright microscope between DIV7 and DIV14 as indicated using
the 40x water immersion lens.
Neurons were fixed using 4% paraformaldehyde/4% sucrose in PBS (10
mins, room temperature), washed 3x for 10 minutes with PBS. Cells were
permeated with 0.2% PBS-Triton for 10 minutes. Cells were blocked at room
temperature for 2 hours in blocking buffer (10% normal donkey serum in PBS).
Cells were stained with mouse TuJ-1 (3 hours, room temperature, diluted in
blocking buffer), washed 3x for 10 minutes with PBS (room temperature).
Secondary staining was carried out with AlexaFluor488 (1:2000) and Hoechst
(1:2500) for 2 hours at room temperature. Cells were then washed 3x for 10
minutes at room temperature.

Figure A1.6: Mouse hippocampal neurons DIV10 expressing THORG-ST were stained to show
localization of THORG-ST (red) remained in the soma. Green is stained for microtubules and
blue is Hoechst stain.

145

A1.6.3 Potassium depolarization assay
For potassium depolarization assays, neurons were in a 2 mL solution of
Hank’s Buffered Saline Solution (HBSS), with a K+ concentration of 4 mM. After 50
s, 1 mL was removed and replaced with 1 mL of a high potassium buffer, with a
[K+] of 134 mM, increasing the total extracellular ion concentration to 69 mM. Cells
were imaged on a LSM710 inverted confocal system.
The change in fluorescence for each neuron and neuronal process was
measured through its integrated density over time, where:

Eqn A1.2
using the image analysis software, Fiji.
A1.7 Dictionary
jawn
/jôn/
noun
noun: jawn; plural noun: jawns
1. (chiefly in eastern Pennsylvania) used to refer to a thing, place, person, or
event that one need not or cannot give a specific name to.
Definition from Oxford Languages.

146

BIBLIOGRAPHY
1.
2.
3.
4.
5.
6.

7.

8.

9.
10.
11.
12.
13.
14.
15.

16.

17.

18.

19.

Galvani, L. De viribus electricitatis in motu musculari commentarius. Comment.
Bononiensi Sci. Artium Inst. Atque Acad. 7, 363–418 (1791).
Golgi, C. Sulla sostanza grigia del cervello. Gazetta Medica Ital. 33, 244–246
(1873).
Ramón y Cajal, S. La rétine des vertébrés. Cellule 9, 121–255 (1892).
Curtis, H. J. & Cole, K. S. Membrane Resting and Action Potentials from the
Squid Giant Axon. J. Cell. Comp. Physiol. 19, 135–144 (1942).
Kandel, E., Schwartz, J., Jessel, T., Siegelbaum, S. & Hudspeth, A. Principles of
Neural Science. (McGraw-Hill, Health Professionals Division, 2012).
Hodgkin, A. L. & Huxley, A. F. Currents Carried By Sodium and Potassium Ions
Through the Membrane of the Giant Axon of Loligo. J. Physiol. 116, 449–472
(1952).
Hodgkin, A. L. & Huxley, A. F. A Quantitative Description of Membrane Current
and its Application to Conduction and Excitation in Nerve. J. Physiol. 117, 500–
544 (1952).
Chen, J. L., Andermann, M. L., Keck, T., Xu, N.-L. & Ziv, Y. Imaging Neuronal
Populations in Behaving Rodents: Paradigms for Studying Neural Circuits
Underlying Behavior in the Mammalian Cortex. J. Neurosci. 33, 17631–17640
(2013).
Hodgkin, A. L. & Huxley, A. F. Action Potentials Recorded from Inside a Nerve
Fibre. Nature 144, 710–711 (1939).
Guan, B., Chen, X. & Zhang, H. in (ed. Gamper, N.) 79–89 (Humana Press,
2013). doi:10.1007/978-1-62703-351-0_6
Nowotny, T. & Levi, R. Encyclopedia of Computational Neuroscience. Encycl.
Comput. Neurosci. 1–5 (2020). doi:10.1007/978-1-4614-7320-6
Alivisatos, A. P. et al. Nanotools for neuroscience and brain activity mapping. ACS
Nano 7, 1850–1866 (2013).
Peterka, D. S., Takahashi, H. & Yuste, R. Imaging Voltage in Neurons. Neuron
69, 9–21 (2011).
Yuste, R. & Denk, W. Neuronal Integration. Nature 375, 145–156 (1995).
Helmchen, F., Imoto, K. & Sakmann, B. Ca2+ buffering and action potentialevoked Ca2+ signaling in dendrites of pyramidal neurons. Biophys. J. 70, 1069–
1081 (1996).
Smetters, D., Majewska, A. & Yuste, R. Detecting action potentials in neuronal
populations with calcium imaging. Methods A Companion to Methods Enzymol.
18, 215–221 (1999).
Brown, B. Y. J. E., Brown, P. K., Pinto, L. R., Lafayette, W. & Hole, W. Detection
of Light-Induced Changes of Intracellular Ionized Calcium Concentrationin
Limulus Ventral Photoreceptors using Arsenazo III. J. Physiol. 267, 299–320
(1977).
Tsien, R. Y. New Calcium Indicators and Buffers with High Selectivity Against
Magnesium and Protons: Design, Synthesis, and Properties of Prototype
Structures. Biochemistry 19, 2396–2404 (1980).
Minta, A., Kao, J. P. Y. & Tsien, R. Y. Fluorescent indicators for cytosolic calcium
based on rhodamine and fluorescein chromophores. J. Biol. Chem. 264, 8171–
147

20.
21.

22.
23.

24.

25.
26.
27.
28.
29.
30.
31.
32.
33.
34.

35.
36.
37.
38.
39.

40.

8178 (1989).
Shimomura, O., Johnson, F. H. & Saiga, Y. Extraction, purification and properties
of aequorin, a bioluminescent. J. Cell. Comp. Physiol. 59, 223–239 (1962).
Ashley, C. C. & Ridgway, E. B. Simultaneous Recording of Membrane Potential,
Calcium Transient and Tension in Single Muscle Fibres. Nature 219, 1169–1172
(1968).
Miyawaki, A. et al. Fluorescent indicators for Ca2+ based on green fluorescent
proteins and calmodulin. Nature 388, 882–887 (1997).
Baird, G. S., Zacharias, D. A. & Tsien, R. Y. Circular permutation and receptor
insertion within green fluorescent proteins. Proc. Natl. Acad. Sci. U. S. A. 96,
11241–11246 (1999).
Nagai, T., Sawano, A., Eun Sun Park & Miyawaki, A. Circularly permuted green
fluorescent proteins engineered to sense Ca2+. Proc. Natl. Acad. Sci. U. S. A. 98,
3197–3202 (2001).
Nakai, J., Ohkura, M. & Imoto, K. A high signal-to-noise ca2+ probe composed of
a single green fluorescent protein. Nat. Biotechnol. 19, 137–141 (2001).
Tian, L. et al. Imaging neural activity in worms, flies and mice with improved
GCaMP calcium indicators. Nat. Methods 6, 875–881 (2009).
Akerboom, J. et al. Optimization of a GCaMP calcium indicator for neural activity
imaging. J. Neurosci. 32, 13819–13840 (2012).
Walker, A. S., Burrone, J. & Meyer, M. P. Functional imaging in the zebrafish
retinotectal system using RGECO. Front. Neural Circuits 7, 1–10 (2013).
Carandini, M. et al. Imaging the Awake Visual Cortex with a Genetically Encoded
Voltage Indicator. J. Neurosci. 35, (2015).
Dana, H. et al. Sensitive red protein calcium indicators for imaging neural activity.
Elife 5, 1–24 (2016).
Dana, H. et al. High-performance calcium sensors for imaging activity in neuronal
populations and microcompartments. Nat. Methods 16, 649–657 (2019).
Patriarchi, T. et al. Ultrafast neuronal imaging of dopamine dynamics with
designed genetically encoded sensors. Science (80-. ). 360, (2018).
Patriarchi, T. et al. An expanded palette of dopamine sensors for multiplex
imaging in vivo. Nat. Methods 17, 1147–1155 (2020).
Sun, F. et al. A Genetically Encoded Fluorescent Sensor Enables Rapid and
Specific Detection of Dopamine in Flies, Fish, and Mice. Cell 174, 481–496.e19
(2018).
Marvin, J. S. et al. An optimized fluorescent probe for visualizing glutamate
neurotransmission. Nat. Methods 10, 162–170 (2013).
Marvin, J. S. et al. Stability, affinity, and chromatic variants of the glutamate
sensor iGluSnFR. Nat. Methods 15, 936–939 (2018).
Marvin, J. S. et al. A genetically encoded fluorescent sensor for in vivo imaging of
GABA. Nat. Methods 16, 763–770 (2019).
Chemla, S. & Chavane, F. Voltage-sensitive dye imaging: Technique review and
models. J. Physiol. Paris 104, 40–50 (2010).
Salzberg, B., Davila, H. V. & Cohen, L. B. Optical Recording of Impulses in
Individual Neurones of an Invertebrate Central Nervous System. Nature 246, 508–
509 (1973).
Salzberg, B. M., Grinvald, A., Cohen, L. B., Davila, H. V. & Ross, W. Optical
148

41.
42.
43.
44.
45.
46.

47.

48.
49.

50.

51.

52.

53.
54.

55.
56.

57.
58.

Recording of Neuronal Activity in an Invertebrate Central Nervous System:
Simultaneous Monitoring of Several Neurons. Nature 268, 140–142 (1977).
Ghosh, S. N., Trambarulo, R. & Gordy, W. Electric Dipole Moments of Several
Molecules from the Stark Effect. J. Chem. Phys. 21, 308 (1953).
Platt, J. R. Electrochromism, a possible change of color producible in dyes by an
electric field. J. Chem. Phys. 34, 862–863 (1961).
Angel, J. R. P. & Sandars, P. G. H. The hyperfine structure Stark effect. Proc.
Roy. Soc. A 305, 125–138 (1968).
Hochstrasser, R. M. Electric-Field Effects on Oriented Molecules and MolecularCrystals. Acc. Chem. Res. 6, 263–269 (1973).
Bastard, G., Mendez, E. E., Chang, L. L. & Esaki, L. Variational calculations on a
quantum well in an electric field. Phys. Rev. B 28, 3241–3245 (1983).
Grinvald, A., Hildesheim, R., Farber, I. C. & Anglister, L. Improved fluorescent
probes for the measurement of rapid changes in membrane potential. Biophys. J.
39, 301–8 (1982).
Loew, L. M., Cohen, L. B., Salzberg, B. M., Obaid, A. L. & Bezanilla, F. Chargeshift probes of membrane potential. Characterization of aminostyrylpyridinium
dyes on the squid giant axon. Biophys. J. 47, 71–77 (1985).
Fromherz, P. & Lambacher, a. Spectra of voltage-sensitive fluorescence of styryldye in neuron membrane. Biochim. Biophys. Acta 1068, 149–56 (1991).
Fromherz, P. & Schenk, O. Voltage-sensitive fluorescence of amphiphilic
hemicynanie dyes in a black lipid membrane of gycerol monooleate. Biochim.
Biophys. Acta 1191, 299–308 (1994).
Hübener, G., Lambacher, A. & Fromherz, P. Anellated Hemicyanine Dyes with
Large Symmetrical Solvatochromism of Absorption and Fluorescence. J. Phys.
Chem. B 107, 7896–7902 (2003).
Kuhn, B. & Fromherz, P. Anellated Hemicyanine Dyes in a Neuron
Membrane: Molecular Stark Effect and Optical Voltage Recording. J. Phys.
Chem. B 107, 7903–7913 (2003).
Kuhn, B., Fromherz, P. & Denk, W. High sensitivity of Stark-shift voltage-sensing
dyes by one- or two-photon excitation near the red spectral edge. Biophys. J. 87,
631–9 (2004).
Frey, W. et al. Plasma membrane voltage changes during nanosecond pulsed
electric field exposure. Biophys. J. 90, 3608–3615 (2006).
Rohr, S. & Salzberg, B. M. Multiple site optical recording of transmembrane
voltage (MSORTV) in patterned growth heart cell cultures: assessing electrical
behavior, with microsecond resolution, on a cellular and subcellular scale.
Biophys. J. 67, 1301–1315 (1994).
Cohen, L. & Salzberg, B. in Reviews of Physiology, Biochemistry and
Pharmacology, Volume 83 35–88 (Springer Berlin Heidelberg, 1978).
Miller, E. W. et al. Optically monitoring voltage in neurons by photo-induced
electron transfer through molecular wires. Proc. Natl. Acad. Sci. U. S. A. 109,
2114–9 (2012).
Woodford, C. R. et al. Improved PeT molecules for optically sensing voltage in
neurons. J. Am. Chem. Soc. 137, 1817–1824 (2015).
Grenier, V., Walker, A. S. & Miller, E. W. A Small-Molecule Photoactivatable
Optical Sensor of Transmembrane Potential. J. Am. Chem. Soc. 137, 10894–
149

59.
60.

61.
62.

63.

64.

65.
66.

67.

68.

69.
70.
71.
72.
73.
74.

75.

76.
77.

10897 (2015).
Siegel, M. S. & Isacoff, E. Y. A genetically encoded optical probe of membrane
voltage. Neuron 19, 735–741 (1997).
Guerrero, G., Siegel, M. S., Roska, B., Loots, E. & Isacoff, E. Y. Tuning FlaSh:
redesign of the dynamics, voltage range, and color of the genetically encoded
optical sensor of membrane potential. Biophys. J. 83, 3607–3618 (2002).
Ataka, K. & Pieribone, V. A. A genetically targetable fluorescent probe of channel
gating with rapid kinetics. Biophys. J. 82, 509–516 (2002).
Sakai, R., Repunte-canonigo, V., Raj, C. D. & Kno, T. Design and characterization
of a DNA-encoded , voltage-sensitive fluorescent protein. Neuroscience 13,
2314–2318 (2001).
Baker, B. J. et al. Three fluorescent protein voltage sensors exhibit low plasma
membrane expression in mammalian cells. J. Neurosci. Methods 161, 32–38
(2007).
Murata, Y., Iwasaki, H., Sasaki, M., Inaba, K. & Okamura, Y. Phosphoinositide
phosphatase activity coupled to an intrinsic voltage sensor. Nature 435, 1239–
1243 (2005).
Dimitrov, D. et al. Engineering and characterization of an enhanced fluorescent
protein voltage sensor. PLoS One 2, 2–6 (2007).
Lundby, A., Mutoh, H., Dimitrov, D., Akemann, W. & Kn??pfel, T. Engineering of a
genetically encodable fluorescent voltage sensor exploiting fast Ci-VSP voltagesensing movements. PLoS One 3, 1–5 (2008).
Tsutsui, H., Karasawa, S., Okamura, Y. & Miyawaki, A. Improving membrane
voltage measurements using FRET with new fluorescent proteins. Nat. Methods
5, 683–685 (2008).
Baker, B. J. et al. Genetically encoded fluorescent voltage sensors using the
voltage-sensing domain of Nematostella and Danio phosphatases exhibit fast
kinetics. J. Neurosci. Methods 208, 190–196 (2012).
Akemann, W. et al. Imaging neural circuit dynamics with a voltage-sensitive
fluorescent protein. J. Neurophysiol. 108, 2323–37 (2012).
Monakhov, M. V. et al. Bright near-infrared genetically encoded voltage indicator
for all-optical electrophysiology. bioRxiv 1–15 (2019). doi:10.1101/536359
Perron, A., Mutoh, H., Launey, T. & Kn??pfel, T. Red-Shifted Voltage-Sensitive
Fluorescent Proteins. Chem. Biol. 16, 1268–1277 (2009).
Jin, L. et al. Single Action Potentials and Subthreshold Electrical Events Imaged in
Neurons with a Fluorescent Protein Voltage Probe. Neuron 75, 779–785 (2012).
Kwon, T., Sakamoto, M., Peterka, D. S. & Yuste, R. Attenuation of Synaptic
Potentials in Dendritic Spines. Cell Rep. 20, 1100–1110 (2017).
Barnett, L., Platisa, J., Popovic, M., Pieribone, V. A. & Hughes, T. A Fluorescent,
Genetically-Encoded Voltage Probe Capable of Resolving Action Potentials. PLoS
One 7, 3–9 (2012).
Abdelfattah, A. S. et al. A Bright and Fast Red Fluorescent Protein Voltage
Indicator That Reports Neuronal Activity in Organotypic Brain Slices. J. Neurosci.
36, 2458–2472 (2016).
St-Pierre, F. et al. High-fidelity optical reporting of neuronal electrical activity with
an ultrafast fluorescent voltage sensor. Nat. Neurosci. 17, (2014).
Yang, H. H. H. et al. Subcellular Imaging of Voltage and Calcium Signals Reveals
150

78.
79.
80.
81.

82.

83.
84.

85.
86.
87.

88.
89.
90.
91.
92.
93.

94.
95.
96.

97.

Neural Processing In Vivo. Cell 166, 245–257 (2016).
Chamberland, S. et al. Fast two-photon imaging of subcellular voltage dynamics
in neuronal tissue with genetically encoded indicators. Elife 6, 1–35 (2017).
Kralj, J. M., Hochbaum, D. R., Douglass, A. D. & Cohen, A. E. Electrical Spiking in
Escherichia coli. Science (80-. ). 333, 345–348 (2011).
Chow, B. Y. et al. High-performance genetically targetable optical neural silencing
by light-driven proton pumps. Nature 463, 98–102 (2010).
Kralj, J. M., Douglass, A. D., Hochbaum, D. R., Maclaurin, D. & Cohen, A. E.
Optical recording of action potentials in mammalian neurons using a microbial
rhodopsin. Nat. Methods 9, 90–95 (2011).
Maclaurin, D., Venkatachalam, V., Lee, H. & Cohen, A. E. Mechanism of voltagesensitive fluorescence in a microbial rhodopsin. Proc. Natl. Acad. Sci. U. S. A.
110, 5939–44 (2013).
Gong, Y., Li, J. Z. & Schnitzer, M. J. Enhanced Archaerhodopsin Fluorescent
Protein Voltage Indicators. PLoS One 8, (2013).
Flytzanis, N. C. et al. Archaerhodopsin variants with enhanced voltage-sensitive
fluorescence in mammalian and Caenorhabditis elegans neurons. Nat. Commun.
5, (2014).
Hochbaum, D. R. et al. All-optical electrophysiology in mammalian neurons using
engineered microbial rhodopsins. Nat. Methods 11, 825–833 (2014).
Zou, P. et al. Bright and fast multicoloured voltage reporters via electrochromic
FRET. Nat. Commun. 5, (2014).
Gong, Y., Wagner, M. J., Zhong Li, J. & Schnitzer, M. J. Imaging neural spiking in
brain tissue using FRET-opsin protein voltage sensors. Nat. Commun. 5, 3674
(2014).
Gong, Y. et al. High-speed recording of neural spikes in awake mice and flies with
a fluorescent voltage sensor. Science (80-. ). 350, 1361–1366 (2015).
Kannan, M. et al. Fast, in vivo voltage imaging using a red fluorescent indicator.
Nat. Methods 15, 1108–1116 (2018).
Herwig, L. et al. Directed Evolution of a Bright Near-Infrared Fluorescent
Rhodopsin Using a Synthetic Chromophore. Cell Chem. Biol. 24, 415–425 (2017).
Abdelfattah, A. S. et al. Bright and photostable chemigenetic indicators for
extended in vivo voltage imaging. Science (80-. ). 365, 699–704 (2019).
Abdelfattah, A. S. et al. A general approach to engineer positive-going eFRET
voltage indicators. Nat. Commun. 11, (2020).
Bando, Y., Sakamoto, M., Kim, S., Ayzenshtat, I. & Yuste, R. Comparative
Evaluation of Genetically Encoded Voltage Indicators. Cell Rep. 26, 802–813.e4
(2019).
Kolakowski, L. F. GCRDb: a G-protein-coupled receptor database. Receptors
Channels 2, 1—7 (1994).
Foord, S. M. et al. International Union of Pharmacology. XLVI. G Protein-Coupled
Receptor List. Pharmacol. Rev. 57, 279–288 (2005).
Holger Römpler; Claudia Stäubert; Doreen Thor; Angela Schulz; Michael
Hofreiter; Torsten Schöneberg; Molecular Inerventions. Mol. Inerventions 7, 17–
25 (2007).
Insel, P. A., Tang, C.-M., Hahntow, I. & Michel, M. C. Impact of GPCRs in clinical
medicine: Monogenic diseases, genetic variants and drug targets. Biochim.
151

98.
99.
100.
101.

102.
103.
104.
105.

106.

107.

108.
109.
110.
111.
112.
113.

114.
115.
116.
117.

Biophys. Acta - Biomembr. 1768, 994–1005 (2007).
Darwin, C. R. The Expression of the Emotions in Man and Animals. (John Murray,
1872).
Muller, H. J. The relation of recombination to mutational advance. Mutat. Res.
Mol. Mech. Mutagen. 1, 2–9 (1964).
Gibney, B. R., Rabanal, F., Skalicky, J. J., Wand, A. J. & Dutton, P. L. Iterative
protein redesign. J. Am. Chem. Soc. 121, 4952–4960 (1999).
Discher, B. M., Koder, R. L., Moser, C. C. & Dutton, P. L. Hydrophilic to
amphiphilic design in redox protein maquettes. Curr. Opin. Chem. Biol. 7, 741–
748 (2003).
Ennist, N. M. et al. Maquette strategy for creation of light- and redox-active
proteins. Photosynth. Bioenerg. 1–34 (2017). doi:10.1142/9789813230309_0001
Regan, L. & Degrado, W. F. Characterization of a Helical Protein Designed from
First Principles. Science (80-. ). 241, 976–978 (1988).
McLachlan, A. D. & Stewart, M. Tropomyosin coiled-coil interactions: Evidence for
an unstaggered structure. J. Mol. Biol. 98, 293–304 (1975).
Discher, B. M. et al. Design of amphiphilic protein maquettes: Controlling
assembly, membrane insertion, and cofactor interactions. Biochemistry 44,
12329–12343 (2005).
Noy, D., Discher, B. M., Rubtsov, I. V., Hochstrasser, R. M. & Dutton, P. L. Design
of amphiphilic protein maquettes: Enhancing maquette functionality through
binding of extremely hydrophobic cofactors to lipophilic domains. Biochemistry 44,
12344–12354 (2005).
Goparaju, G. et al. First principles design of a core bioenergetic transmembrane
electron-transfer protein. Biochim. Biophys. Acta - Bioenerg. 1857, 503–512
(2016).
Pace, C. N. & Scholtz, J. M. A Helix Propensity Scale Based on Experimental
Studies of Peptides and Proteins. Biophys. J. 75, 422–427 (1998).
Wimley, W. C. & White, S. H. Experimentally determined hydrophobicity scale for
proteins at membrane interfaces. Nat. Struct. Biol. 3, 842–848 (1996).
Farid, T. a et al. Elementary tetrahelical protein design for diverse oxidoreductase
functions. Nat. Chem. Biol. 9, 826–33 (2013).
Curnow, P. et al. Small-residue packing motifs modulate the structure and
function of a minimal de novo membrane protein. Sci. Rep. 10, 1–11 (2020).
Lichtenstein, B. R. et al. Engineering oxidoreductases: maquette proteins
designed from scratch. Biochem. Soc. Trans. 40, 561–6 (2012).
Solomon, L. A., Kodali, G., Moser, C. C. & Dutton, P. L. Engineering the Assembly
of Heme Cofactors in Man-Made Proteins. J. Am. Chem. Soc. 136, 3192–3199
(2014).
Kodali, G. et al. Design and engineering of water-soluble light-harvesting protein
maquettes. Chem. Sci. 8, 316–324 (2016).
Robertson, D. E. et al. Design and synthesis of multi-haem proteins. Nature 368,
425–432 (1994).
Koder, R. L. et al. Design and engineering of an O2 transport protein. Nature 458,
305–309 (2009).
Anderson, J. L. R. et al. Constructing a man-made c-type cytochrome maquette in
vivo: electron transfer, oxygen transport and conversion to a photoactive light
152

harvesting maquette. Chem. Sci. 5, 507–514 (2014).
118. Ennist, N. M. Design, Structure, and Action of an Artificial Photosynthetic Reaction
Center. (University of Pennslyvania, 2017).
119. Moser, C. C. et al. De Novo Construction of Redox Active Proteins. Peptide,
Protein and Enzyme Design (Elsevier Inc., 2016).
doi:10.1016/bs.mie.2016.05.048
120. Fry, B. A., Solomon, L. A., Leslie Dutton, P. & Moser, C. C. Design and
engineering of a man-made diffusive electron-transport protein. Biochim. Biophys.
Acta - Bioenerg. 1857, 513–521 (2016).
121. Mancini, J. A. et al. De novo synthetic biliprotein design, assembly and excitation
energy transfer. J. R. Soc. Interface 15, (2018).
122. Sheehan, M. M. et al. Rational Construction of Compact de Novo-Designed
Biliverdin-Binding Proteins. Biochemistry 57, 6752–6756 (2018).
123. Mancini, J. A. et al. Multi-step excitation energy transfer engineered in genetic
fusions of natural and synthetic light-harvesting proteins. J. R. Soc. Interface 14,
(2017).
124. Bialas, C. et al. Engineering an Artificial Flavoprotein Magnetosensor. J. Am.
Chem. Soc. 138, 16584–16587 (2016).
125. Zollitsch, T. M. et al. Magnetically Sensitive Radical Photochemistry of Nonnatural Flavoproteins. J. Am. Chem. Soc. 140, 8705–8713 (2018).
126. Bialas, C. et al. Ultrafast flavin/tryptophan radical pair kinetics in a magnetically
sensitive artificial protein. Phys. Chem. Chem. Phys. 21, 13453–13461 (2019).
127. Lichtenstein, B. R. et al. Designing Light-Activated Charge-Separating Proteins
with a Naphthoquinone Amino Acid. Angew. Chemie 127, 13830–13833 (2015).
128. Ai, H. W., Henderson, J. N., Remington, S. J. & Campbell, R. E. Directed
evolution of a monomeric, bright and photostable version of Clavularia cyan
fluorescent protein: Structural characterization and applications in fluorescence
imaging. Biochem. J. 400, 531–540 (2006).
129. Shaner, N. C. et al. Improving the photostability of bright monomeric orange and
red fluorescent proteins. Nat. Methods 5, 545–551 (2008).
130. Shaner, N. C. et al. Evaluating and improving the photostability of fluorescent
proteins. Proc. SPIE 7191, 719105-719105–11 (2009).
131. Marcus, R. A. On the Theory of Oxidation-Reduction Reactions Involving Electron
Transfer. Journal 24, 966–978 (1956).
132. Bertini, I., Gray, H. B., Valentine, J. S. & Stiefel, E. I. Biological Inorganic
Chemistry: Structure and Reactivity. (University Science Books, 2007).
133. Metzger, R. M. Unimolecular electronics. J. Mater. Chem. 18, 4364–4396 (2008).
134. Beratan, D. N., Onuchic, J. N. & Hopfield, J. J. Electron tunneling through
covalent and noncovalent pathways in proteins. J. Chem. Phys. 86, 4488–4498
(1987).
135. Beratan, D. N., Onuchic, J. N., Winkler, J. R. & Gray, H. B. Electron-tunneling
pathways in proteins. Science (80-. ). 258, 1740+ (1992).
136. Langen, R. et al. Electron tunneling in proteins: coupling through a beta strand.
Science (80-. ). 268, 1733–1735 (1995).
137. Moser, C. C., Keske, J. M., Warncke, K., Farid, R. S. & Dutton, P. L. Nature of
Biological Electron-Transfer. Nature 355, 796–802 (1992).
138. Moser, C. C., Page, C. C., Farid, R. & Dutton, P. L. Biological electron transfer. J.
153

Bioenerg. Biomembr. 27, 263–274 (1995).
139. Page, C. C., Moser, C. C., Chen, X. & Dutton, P. L. Natural engineering principles
of electron tunnelling in biological oxidation–reduction. Nature 402, 47–52 (1999).
140. Page, C. C., Moser, C. C. & Dutton, P. L. Mechanism for electron transfer within
and between proteins. Curr. Opin. Chem. Biol. 7, 551–556 (2003).
141. DeVault, D. Quantum-mechanical tunnelling in biological systems. (Cambridge
University Press, 1984).
142. Takamiya, K. & Dutton, P. L. The Influence of Transmembrane Potentials of the
Redox Equilibrium Between Cytochrome C2 and the Reaction Center in
Rhodopseudomonas Sphaeroides Chromatophores. FEBS Lett. 80, 279–284
(1977).
143. Olivotto, M., Arcangeli, A., Carla, M. & Wanke, E. Electric fields at the plasma
membrane level: a neglected element in the mechanisms of cell signalling.
BioEssays 18, 495–504 (1996).
144. Lyklema, J. Fundamentals of Interface and Colloid Science: Soft Colloids.
(Academic Press, 2005).
145. Ohshima, H. & Ohki, S. Donnan potential and surface potential of a charged
membrane. Biophys. J. 47, 673–678 (1985).
146. Veech, R. L., Kashiwaya, Y. & King, M. T. The resting membrane potential of cells
are measures of electrical work, not of ionic currents. Integr. Physiol. Behav. Sci.
30, 283–307 (1995).
147. Shomer, I., Novacky, A. J., Pike, S. M., Yermiyahu, U. & Kinraide, T. B. Electrical
Potentials of Plant Cell Walls in Response to the Ionic Environment. Plant Physiol.
133, 411–422 (2003).
148. Lin, M. Z. & Schnitzer, M. J. Genetically encoded indicators of neuronal activity.
Nat. Neurosci. 19, 1142–1153 (2016).
149. Huang, S. S., Gibney, B. R., Stayrook, S. E., Leslie Dutton, P. & Lewis, M. X-ray
structure of a maquette scaffold. J. Mol. Biol. 326, 1219–1225 (2003).
150. Kim, N., Ripple, M. O. & Springett, R. Measurement of the mitochondrial
membrane potential and pH gradient from the redox poise of the hemes of the bc
1 complex. Biophys. J. 102, 1194–1203 (2012).
151. Jaud, S. et al. Insertion of short transmembrane helices by the Sec61 translocon.
Proc. Natl. Acad. Sci. U. S. A. 106, 11588–11593 (2009).
152. Xu, Y., Zou, P. & Cohen, A. E. Voltage imaging with genetically encoded
indicators. Curr. Opin. Chem. Biol. 39, 1–10 (2017).
153. Storace, D. et al. Toward Better Genetically Encoded Sensors of Membrane
Potential. Trends Neurosci. 39, 277–289 (2016).
154. Kannan, M., Vasan, G. & Pieribone, V. A. Optimizing strategies for developing
genetically encoded voltage indicators. Front. Cell. Neurosci. 13, 1–17 (2019).
155. Peng, L., Xu, Y. & Zou, P. Genetically-encoded voltage indicators. Chinese Chem.
Lett. 28, 1925–1928 (2017).
156. Yang, H. H. & St-Pierre, F. Genetically Encoded Voltage Indicators: Opportunities
and Challenges. J. Neurosci. 36, 9977–9989 (2016).
157. Tome-Stangl, L., Schaetzel, C., Tenzer, S., Bernhard, F. & Schneider, D. The
soluble loop BC region guides, but not dictates, the assembly of the
transmembrane cytochrome b6. PLoS One 12, 1–20 (2017).
158. Pintscher, S. et al. Tuning of Hemes b equilibrium redox potential is not required
154

for cross-membrane electron transfer. J. Biol. Chem. 291, 6872–6881 (2016).
159. Shinde, S., Cordova, J. M., Woodrum, B. W. & Ghirlanda, G. Modulation of
function in a minimalist heme-binding membrane protein. J. Biol. Inorg. Chem. 17,
557–564 (2012).
160. Patti, J. & Isacoff, E. Y. Measuring Membrane Voltage with Fluorescent Proteins.
Cold Spring Harb. Protoc. 8, 606–613 (2013).
161. Abdul Kadir, L., Stacey, M. & Barrett-Jolley, R. Emerging Roles of the Membrane
Potential: Action Beyond the Action Potential. Front. Physiol. 9, 1661 (2018).
162. Neher, E. & Sakmann, B. Single-channel currents recorded from membrane of
denervated frog muscle fibres. Nature 260, 799–802 (1976).
163. Sundelacruz, S., Levin, M. & Kaplan, D. L. Membrane potential controls
adipogenic and osteogenic differentiation of mesenchymal stem cells. PLoS One
3, e3737 (2008).
164. Shi, R. & Borgens, R. B. Three-dimensional gradients of voltage during
development of the nervous system as invisible coordinates for the establishment
of embryonic pattern. Dev. Dyn. an Off. Publ. Am. Assoc. Anat. 202, 101–114
(1995).
165. Pai, V. P. et al. Endogenous gradients of resting potential instructively pattern
embryonic neural tissue via Notch signaling and regulation of proliferation. J.
Neurosci. 35, 4366–4385 (2015).
166. Bhavsar, M. B. et al. Membrane potential (V(mem)) measurements during
mesenchymal stem cell (MSC) proliferation and osteogenic differentiation. PeerJ
7, e6341 (2019).
167. Shifman, J. M., Gibney, B. R., Sharp, R. E. & Dutton, P. L. Heme Redox Potential
Control in de Novo Designed Four-α-Helix Bundle Proteins. Biochemistry 39,
14813–14821 (2000).
168. Kauffman, G. B. & Adloff, J. The 2008 Nobel Prize in Chemistry : Osamu
Shimomura , Martin Chalfie , and Roger Y . Tsien : the Green Fluorescent Protein.
Chief Exec. 4171, 70–78 (2009).
169. Shaner, N. C. et al. Improved monomeric red, orange and yellow fluorescent
proteins derived from Discosoma sp. red fluorescent protein. Nat. Biotechnol. 22,
1567–72 (2004).
170. Zhao, Y. et al. An Expanded Palette of Genetically. Cell 557, 1888–1891 (2011).
171. Tomosugi, W. et al. An ultramarine fluorescent protein with increased
photostability and pH insensitivity. Nat. Methods 6, 351–353 (2009).
172. Margoliash, E. & Schejter, A. in (eds. Anfinsen, C. B., Anson, M. L., Edsall, J. T. &
Richards, F. M. B. T.-A. in P. C.) 21, 113–286 (Academic Press, 1966).
173. Tezcan, F. A., Winkler, J. R. & Gray, H. B. Effects of Ligation and Folding on
Reduction Potentials of Heme Proteins. J. Am. Chem. Soc. 120, 13383–13388
(1998).
174. Zhong, F. & Pletneva, E. V. Ligation and Reactivity of Methionine-Oxidized
Cytochrome c. Inorg. Chem. 57, 5754–5766 (2018).
175. Lushington, G. H. et al. Comparison of Thioethers and Sulfoxides as Axial
Ligands for N-Acetylmicroperoxidase-8: Implications for Oxidation of Methionine80 in Cytochrome c. Inorg. Chem. 42, 7550–7559 (2003).
176. Perdoncin, G. & Scorrano, G. Protonation Equilibria in Water at Several
Temperatures of Alcohols, Ethers, Acetone, Dimethyl Sulfide, and Dimethyl
155

Sulfoxide. J. Am. Chem. Soc. 99, 6983–6986 (1977).
177. McMillin, D. R. & Morris, M. C. Further perspectives on the charge transfer
transitions of blue copper proteins and the ligand moieties in stellacyanin. Proc.
Natl. Acad. Sci. 78, 6567–6570 (1981).
178. Rodkey, F. L., O’Neal, J. D., Collison, H. A. & Uddin, D. E. Relative Affinity of
Hemoglobin S and Hemoglobin A for Carbon Monoxide and Oxygen. Clin. Chem.
20, 83–84 (1974).
179. Schieber, M. & Chandel, N. S. ROS function in redox signaling and oxidative
stress. Curr. Biol. 24, R453–R462 (2014).
180. Jeong, E. M. et al. Real-Time Monitoring of Glutathione in Living Cells Reveals
that High Glutathione Levels Are Required to Maintain Stem Cell Function. Stem
Cell Reports 10, 600–614 (2018).
181. Chance, B., Sies, H. & Boveris, A. Hydroperoxide metabolism in mammalian
organs. Physiol. Rev. 59, 527–605 (1979).
182. Lennicke, C., Rahn, J., Lichtenfels, R., Wessjohann, L. A. & Seliger, B. Hydrogen
peroxide - Production, fate and role in redox signaling of tumor cells. Cell
Commun. Signal. 13, 1–19 (2015).
183. Cai, S. Q. & Sesti, F. Oxidation of a potassium channel causes progressive
sensory function loss during aging. Nat. Neurosci. 12, 611–617 (2009).
184. Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of
senescence. Genes Dev. 24, 2463–2479 (2010).
185. Genova, M. L. & Lenaz, G. The Interplay Between Respiratory Supercomplexes
and ROS in Aging. Antioxid. Redox Signal. 23, (2015).
186. Filomeni, G. & Ciriolo, M. R. Redox Control of Apoptosis: An Update. Antioxid.
Redox Signal. 8, 2187–2192 (2006).
187. Hansen, J. M., Go, Y. M. & Jones, D. P. Nuclear and mitochondrial
compartmentation of oxidative stress and redox signaling. Annu. Rev. Pharmacol.
Toxicol. 46, 215–234 (2006).
188. Go, Y.-M. & Jones, D. P. Redox compartmentalization in eukaryotic cells. Crit.
Care 1780, 1273–1290 (2009).
189. Bilan, D. S. & Belousov, V. V. New tools for redox biology: From imaging to
manipulation. Free Radic. Biol. Med. 109, 167–188 (2017).
190. Fan, Y., Chen, Z. & Ai, H. W. Monitoring Redox dynamics in living cells with a
redox-sensitive red fluorescent protein. Anal. Chem. 87, 2802–2810 (2015).
191. Østergaard, H., Henriksen, A., Hansen, F. G. & Winther, J. R. Shedding light on
disulfide bond formation: engineering a redox switch in green fluorescent protein.
EMBO J. 20, (2001).
192. Banach-Latapy, A. et al. Redox-sensitive YFP sensors for monitoring dynamic
compartment-specific glutathione redox state. Free Radic. Biol. Med. 65, 436–445
(2013).
193. Banach-Latapy, A., Dardalhon, M. & Huang, M.-E. in The Nucleus. Methods in
Molecular Biology (Humana Press, 2015). doi:https://doi.org/10.1007/978-1-49391680-1_13
194. Hanson, G. T. et al. Investigating Mitochondrial Redox Potential with Redoxsensitive Green Fluorescent Protein Indicators*. J. Biol. Chem. 279, 13044–13053
(2004).
195. Dooley, C. T. et al. Imaging Dynamic Redox Changes in Mammalian Cells with
156

Green Fluorescent Protein Indicators*. J. Biol. Chem. 279, 22284–22293 (2004).
196. Gutscher, M. et al. Real-time imaging of the intracellular glutathione redox
potential. Nat. Methods 5, 553–559 (2008).
197. Fan, Y., Makar, M., Wang, M. X. & Ai, H. W. Monitoring thioredoxin redox with a
genetically encoded red fluorescent biosensor. Nat. Chem. Biol. 13, 1045–1052
(2017).
198. Belousov, V. V. et al. Genetically encoded fluorescent indicator for intracellular
hydrogen peroxide. Nat. Methods 3, 281–286 (2006).
199. Markvicheva, K. N. et al. A genetically encoded sensor for H2O2 with expanded
dynamic range. Bioorg. Med. Chem. 19, 1079–1084 (2011).
200. Ermakova, Y. G. et al. Red fluorescent genetically encoded indicator for
intracellular hydrogen peroxide. Nat. Commun. 5, (2014).
201. Albrecht, S. C., Barata, A. G., Großhans, J., Teleman, A. A. & Dick, T. P. In Vivo
Mapping of Hydrogen Peroxide and Oxidized Glutathione Reveals Chemical and
Regional Specificity of Redox Homeostasis. Cell Metab. 14, 819–829 (2011).
202. Back, P. et al. Exploring real-time in vivo redox biology of developing and aging
Caenorhabditis elegans. Free Radic. Biol. Med. 52, 850–859 (2012).
203. Knoefler, D. et al. Quantitative In Vivo Redox Sensors Uncover Oxidative Stress
as an Early Event in Life. Mol. Cell 47, 767–776 (2012).
204. Gauron, C. et al. Hydrogen peroxide (H2O2) controls axon pathfinding during
zebrafish development. Dev. Biol. 414, 133–141 (2016).
205. Han, P. et al. Hydrogen peroxide primes heart regeneration with a derepression
mechanism. Cell Res. 24, 1091–1107 (2014).
206. Hung, Y. P., Albeck, J. G., Tantama, M. & Yellen, G. Imaging Cytosolic NADHNAD+ Redox State with a Genetically Encoded Fluorescent Biosensor. Cell
Metab. 14, 545–554 (2011).
207. Hosseinzadeh, P. & Lu, Y. Design and fine-tuning redox potentials of
metalloproteins involved in electron transfer in bioenergetics. Biochim. Biophys.
Acta - Bioenerg. 1857, 557–581 (2016).
208. Pletnev, S. et al. Orange fluorescent proteins: Structural studies of LSSmOrange,
PSmOrange and PSmOrange2. PLoS One 9, 1–12 (2014).
209. Shu, X., Shaner, N. C., Yarbrough, C. A., Tsien, R. Y. & Remington, S. J. Novel
chromophores and buried charges control color in mFruits. Biochemistry 45,
9639–9647 (2006).
210. Stradyn, Y. P., Kadysh, V. P. & Giller, S. A. Polarography of heterocyclic
compounds - I. Miscellaneous data on the polarographic behavior of heterocycles
and electrochemical reduction of heteroaromatic compounds (review). Chem.
Heterocycl. Compd. 9, 1435–1448 (1973).
211. Rodriguez, E. A. et al. A far-red fluorescent protein evolved from a cyanobacterial
phycobiliprotein. 13, (2016).
212. Saribaş, A. S., Ding, H., Dutton, P. L. & Daldal, F. Substitutions at position 146 of
cytochrome b affect drastically the properties of heme bL and the Qo site of
Rhodobacter capsulatus cytochrome bc1 complex. Biochim. Biophys. Acta Bioenerg. 1319, 99–108 (1997).
213. Fry, B. A. Recreating bioenergetic elements in protein maquettes. (University of
Pennsylvania, 2016).
214. Iwata, S. et al. Complete structure of the 11-subunit bovine mitochondrial
157

cytochrome bc1 complex. Science (80-. ). 281, 64–71 (1998).
215. Bender, G. M. et al. De Novo Design of a Single-Chain Diphenylporphyrin
Metalloprotein. J. Am. Chem. Soc. 129, 10732–10740 (2007).
216. Aurora, R. & Rose, G. D. Helix capping. Protein Sci. 7, 21–38 (1998).
217. Williamson, M. P. The structure and function of proline-rich regions in proteins.
Biochem. J. 297, 249–260 (1994).
218. Betz, S. F. & DeGrado, W. F. Controlling topology and native-like behavior of de
novo-designed peptides: Design and characterization of antiparallel four-stranded
coiled coils. Biochemistry 35, 6955–6962 (1996).
219. Betz, S. F., Liebman, P. A. & DeGrado, W. F. De novo design of native proteins:
Characterization of proteins intended to fold into antiparallel, rop-like, four-helix
bundles. Biochemistry 36, 2450–2458 (1997).
220. Munson, M., O’Brien, R., Sturtevant, J. M. & Regan, L. Redesigning the
hydrophobic core of a four-helix-bundle protein. 2015–2022 (1994).
221. Willis, M. A., Bishop, B., Regan, L. & Brunger, A. T. Dramatic Structural and
Thermodynamic Consequences of Repacking a Protein’s Hydrophobic Core.
Structure 8, 1319–1328 (2000).
222. Kyte, J. & Doolittle, R. F. A simple method for displaying the hydropathic character
of a protein. J. Mol. Biol. 157, 105–132 (1982).
223. Hessa, T. et al. Recognition of transmembrane helices by the endoplasmic
reticulum translocon. Nature 433, 377–381 (2005).
224. Zhao, G. & London, E. An amino acid ‘transmembrane tendency’ scale that
approaches the theoretical limit to accuracy for prediction of transmembrane
helices: Relationship to biological hydrophobicity. Protein Sci. 15, 1987–2001
(2006).
225. Gradinaru, V. et al. Molecular and Cellular Approaches for Diversifying and
Extending Optogenetics. Cell 141, 154–165 (2010).
226. Chertkova, A. O. et al. Robust and Bright Genetically Encoded Fluorescent
Markers for Highlighting Structures and Compartments in Mammalian Cells.
bioRxiv (2020). doi:10.1101/160374
227. Kost, L. A. et al. Insertion of the voltage-sensitive domain into circularly permuted
red fluorescent protein as a design for genetically encoded voltage sensor. PLoS
One 12, 1–13 (2017).
228. Kost, L. A. et al. Red fluorescent genetically encoded voltage indicators with
millisecond responsiveness. Sensors (Switzerland) 19, 1–12 (2019).
229. Fairless, R. et al. Membrane Potential Measurements of Isolated Neurons Using a
Voltage-Sensitive Dye. PLoS One 8, (2013).
230. Thomas, M. & Hughes, T. E. Optically activated, customizable, excitable cells.
PLoS One 15, e0229051 (2021).
231. van den Ent, F. & Löwe, J. RF cloning: A restriction-free method for inserting
target genes into plasmids. J. Biochem. Biophys. Methods 67, 67–74 (2006).
232. Bond, S. R. & Naus, C. C. RF-Cloning.org: an online tool for the design of
restriction-free cloning projects. Nucleic Acids Res. 40, W209–W213 (2012).
233. Farid, T. A. Engineering an Artificial, Multifunctional Oxidoreductase Protein
Maquette. (University of Pennsylvania, 2012).
234. Englander, S. W., Calhoun, D. B. & Englander, J. J. Biochemistry without oxygen.
Anal. Biochem. 161, 300–306 (1987).
158

235. Cheluvappa, R. Standardized chemical synthesis of Pseudomonas aeruginosa
pyocyanin. MethodsX 1, 67–73 (2014).

159

